Cytochrome P-450 Substrates

DrugDrug NameDrug Indication
DB00188BortezomibFor treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
DB00201CaffeineFor management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.
DB00261AnagrelideFor the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
DB00268RopiniroleFor the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome [FDA label].
DB00277TheophyllineFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
DB00281LidocaineLidocaine is an anesthetic of the amide group indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks [F4349, L5930].
DB00286Conjugated estrogensThe conjugated estrogens are indicated for several different conditions including: - Treatment of moderate to severe vasomotor symptoms due to menopause. - Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. - Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - Palliative treatment of breast cancer in appropriately selected patients with metastatic disease. - Palliative treatment of androgen-dependent carcinoma of the prostate. - Preventive therapy of postmenopausal osteoporosis.[A38238]
DB00296RopivacaineUsed in obstetric anesthesia and regional anesthesia for surgery.
DB00315ZolmitriptanFor the acute treatment of adult migraine with or without auras.
DB00321AmitriptylineThis drug in indicated for the following conditions [FDA label]: Major depressive disorder in adults Management of neuropathic pain in adults Prophylactic treatment of chronic tension-type headache (CTTH) in adults Prophylactic treatment of migraine in adults Treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis [FDA label] Off-label uses: irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation, fibromyalgia, and insomnia
DB00334OlanzapineOlanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label] As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014] Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label] Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936] Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]
DB00363ClozapineFor use in patients with treatment-resistant schizophrenia.
DB00365GrepafloxacinFor treatment of adults with mild to moderate infections caused by susceptible strains of Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
DB00370MirtazapineThis drug is indicated for the treatment of major depressive disorder and its associated symptoms.[FDA label] Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.[A177811,A177946]
DB00379MexiletineFor the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
DB00382TacrineFor the palliative treatment of mild to moderate dementia of the Alzheimer's type.
DB00458ImipramineFor the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label]. May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
DB00476Duloxetine**Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
DB00499FlutamideFor the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
DB00502HaloperidolHaloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette’s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also indicated in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.[F4645]
DB00540NortriptylinePrimarily indicated for the relief of symptoms of depression.
DB00544FluorouracilFor the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
DB00571PropranololPropranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
DB00655EstroneFor management of perimenopausal and postmenopausal symptoms.
DB00661VerapamilFor the treatment of hypertension, angina, and cluster headache prophylaxis.
DB00682Warfarin**Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
DB00697TizanidineTizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471].
DB00740RiluzoleFor the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
DB00744ZileutonFor the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
DB00783EstradiolEstradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of post-menopausal osteoarthritis. It is also used for the treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
DB00851DacarbazineFor the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
DB00904OndansetronIn the adult patient population: i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and - the prevention and treatment of postoperative nausea and vomiting ii) intravenously administered ondansetron injection formulations are indicated for: - the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and - the prevention and treatment of postoperative nausea and vomiting In the pediatric (4-18 years of age) patient population: i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting, ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger, iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting In the geriatric (>65 years of age) patient population: i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population
DB00924CyclobenzaprineCyclobenzaprine is indicated as a short-term (2-3 weeks) adjunct therapy, along with rest and physical therapy, for relief of muscle spasm associated with acute, painful musculoskeletal conditions. It has not been found effective in the treatment of spasticity originating from cerebral or spinal cord disease, or spasticity in children with cerebral palsy.[L8408,L8411] Cyclobenzaprine is also occasionally used off-label for reducing pain and sleep disturbances in patients with fibromyalgia.[A184946]
DB00980RamelteonFor the treatment of insomnia characterized by difficulty with sleep onset.
DB00998FrovatriptanFor the acute treatment of migraine attacks with or without aura in adults.
DB01002LevobupivacaineFor the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management
DB01012CinacalcetFor the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
DB01100PimozideUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
DB01182PropafenoneUsed to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
DB01242ClomipramineMay be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
DB01367RasagilineFor the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
DB00356ChlorzoxazoneFor the relief of discomfort associated with acute painful musculoskeletal conditions.
DB00477ChlorpromazineFor the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
DB00532MephenytoinFor the treatment of refractory partial epilepsy.
DB00586DiclofenacDiclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.
DB00972AzelastineIntranasal azelastine is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 5 years and older and for the symptomatic treatment of vasomotor rhinitis in patients 12 years and older.[L8240] Ophthalmic azelastine solution is indicated for the treatment of itchy eyes associated with allergic conjunctivitis.[L8270]
DB01418AcenocoumarolFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
DB01424AminophenazoneFormerly widely used as an antipyretic and analgesic in rheumatism, neuritis, and common colds. Currently used to measure total body water.
DB00377PalonosetronFor the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
DB01065MelatoninUsed orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders.
DB00619ImatinibFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
DB00468QuinineFor the treatment of malaria and leg cramps
DB01142DoxepinOral doxepin is approved for the following indications: - Treatment of depression and/or anxiety.[A177163] - Treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders.[T249] - Treatment of psychotic depressive disorders with associated anxiety.[T249] - Treatment of involutional depression.[T249] - Treatment of manic-depressive disorder.[T249] - Treatment of insomnia characterized by difficulties with sleep maintenance.[A177163] Topical doxepin is also approved for short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis, pruritus or lichen simplex chronicus.[T249] Off-label, doxepin is used topically for the management of neuropathic pain.[A177172] Depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities. This condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environment.[L5980] Anxiety is a normal reaction of the body towards a normal danger. When the anxious state is exacerbated or appears on situations without danger, it is defined as an anxiety disorder. This disorders can appear in different forms such as phobias, panic, obsessive-compulsive disorder and post-traumatic stress disorder.[L5983] Insomnia is a sleep disorder that directly affects the quality of life of the individual. It is characterized by the complication either to fall asleep or to stay asleep. This condition can be occasional or chronic.[L5986] Pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch. It can be localized or generalized and it can appear in an acute or chronic manner.[L5989] Neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptors.[L5992]
DB00564CarbamazepineCarbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia.[L1335] In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures.[A180301,L1335] Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder.[L1335] Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.[A180415,A180421]
DB00425ZolpidemThis drug is indicated for the short-term treatment of insomnia in adults characterized by difficulties with sleep initiation [FDA label].
DB00472FluoxetineFluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.[L7664]
DB01435AntipyrineAntipyrine is an analgesic often used to test effects of other drugs on liver enzymes. In combination with benzocaine in otic solutions, antipyrine is indicated for the symptomatic relief of acute otitis media arising from various etiologies.
DB00857TerbinafineTerbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]
DB00568CinnarizineFor the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.
DB04841FlunarizineUsed in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
DB00788NaproxenNaproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.[L6582][L6583][A178975] Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.[A178975]
DB03783PhenacetinUsed principally as an analgesic.
DB01223AminophyllineFor the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
DB06216AsenapineUsed for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.
DB00195BetaxololFor the management of hypertension.
DB04574Estrone sulfateEstropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
DB00629GuanabenzFor management of High blood pressure
DB01623ThiothixeneFor the management of schizophrenia.
DB00831TrifluoperazineFor the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
DB00420PromazineUsed as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
DB01136CarvedilolCarvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.[L7889,L7892]
DB01645GenisteinCurrently Genistein is being studied in clinical trials as a treatment for prostate cancer.
DB02709ResveratrolBeing investigated for the treatment of Herpes labialis infections (cold sores).
DB00518AlbendazoleFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
DB01558BromazepamFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
DB01151DesipramineFor relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.
DB01191DexfenfluramineFor the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
DB01184DomperidoneFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
DB00898EthanolFor therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.
DB00773EtoposideFor use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
DB01283LumiracoxibFor the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
DB00772MalathionFor patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.
DB00934MaprotilineFor treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.
DB00333MethadoneMethadone is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate. It's recommended that use is reserved for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.[F4688] Methadone is also indicated for detoxification treatment of opioid addiction (heroin or other morphine-like drugs), and for maintenance substitution treatment for opioid dependence in adults in conjunction with appropriate social and medical services.[F4685,F4691]
DB01028MethoxyfluraneFor use in the induction and maintenance of general anesthesia
DB06148MianserinFor the treatment of depression.
DB00806PentoxifyllineFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
DB00850PerphenazineFor use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
DB01037SelegilineMonotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
DB01412Theobrominetheobromine is used as a vasodilator, a diuretic, and heart stimulant. And similar to caffeine, it may be useful in management of fatigue and orthostatic hypotension.
DB06264TolperisoneInvestigated for use/treatment in neurologic disorders, spinal cord injuries, muscle spasm, back pain, and multiple sclerosis.
DB00246ZiprasidoneIn it's oral form, ziprasidone is approved for the treatment of Schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342]
DB00530ErlotinibErlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label]. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label]. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label]
DB01166CilostazolIndicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
DB06210EltrombopagThrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
DB00575ClonidineClonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications.[L7237,L7240] A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient.[L7243] An extended release tablet of clonidine is indicated for the treatment of ADHD either alone or in combination with other medications.[L7246] Clonidine is also used for the diagnosis of pheochromocytoma,[A180565] treatment of nicotine dependance,[A180568] and opiate withdrawal.[A180571]
DB06510MuraglitazarInvestigated for use/treatment in diabetes mellitus type 2.
DB06235VadimezanInvestigated for use/treatment in solid tumors, lung cancer, ovarian cancer, and prostate cancer.
DB00461Nabumetone**Indicated** for:[label] 1) Symptomatic relief in rheumatoid arthritis. 2) Symptomatic relief in osteoarthritis.
DB06589PazopanibTreatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
DB08867UlipristalAs the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is indicated for treatment of the signs and symptoms of uterine fibroids in adult women.
DB04871LorcaserinFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
DB06605ApixabanApixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].
DB06626AxitinibUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB09570IxazomibIxazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
DB06769BendamustineBendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
DB12332RucaparibIndicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.
DB11737IcotinibIcotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
DB12161DeutetrabenazineIndicated for the treatment of chorea associated with Huntington’s disease [FDA Label].
DB09118StiripentolIndicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.
DB12026VoxilaprevirVosevi (Voxilaprevir/[DB08934]/[DB11613]) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing [DB08934] without an NS5A inhibitor [L935].
DB13874EnasidenibIndicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
DB13952Estradiol acetateFemring is indicated for the treatment of vasomotor and urogenital symptoms associated with menopause. Use of Femring (estradiol acetate) has been shown to improve symptoms caused by atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).
DB13953Estradiol benzoateEstradiol benzoate is not currently available in any FDA or Health Canada approved products.
DB13954Estradiol cypionateDepo-Estradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism.
DB13955Estradiol dienanthateEstradiol dienanthate is not currently available in any FDA or Health Canada approved products.
DB13956Estradiol valerateEstradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.
DB09225ZotepineZotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108] It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857] Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]
DB04948LofexidineLofexidine is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment. It is the first non-opioid medication for the symptomatic management of opioid discontinuation.[L2801] Opioid withdrawal syndrome is a debilitating manifestation of opioid dependence.[A33085] This condition is extremely unpleasant lasting several days with some of the main features being abdominal pain, nausea, diarrhea, mydriasis, lacrimation, and piloerection. These symptoms are often observed after abrupt reductions in the opioid dose and can be resolved by re-administration of the opioid.[A33088]
DB09071TasimelteonTasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
DB04951PirfenidoneFor the treatment of idiopathic pulmonary fibrosis (IPF).
DB09290RamosetronFor the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.
DB00316AcetaminophenIn general, acetaminophen is used for the treatment of mild to moderate pain and reduction of fever [F4124]. It is available over the counter in various forms, the most common being oral forms. Acetaminophen _injection_ is indicated for [FDA label]: • Management of mild to moderate pain • Management of moderate to severe pain with adjunctive opioid analgesics • Reduction of fever Because of its low risk of causing allergic reactions, this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies, including bronchial asthmatics [F4124]. Specific dosing guidelines should be followed when administering acetaminophen to children [L5780].
DB00758ClopidogrelClopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
DB00176FluvoxamineIndicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
DB09256TegafurIndicated for the treatment of cancer usually in combination with other biochemically modulating drugs. Indicated in adults for the treatment of advanced gastric cancer when given in combination with [DB00515] [L933]. Indicated for the first-line treatment of metastatic colorectal cancer with [DB03419] and calcium folinate [L934].
DB01118AmiodaroneIntravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
DB12945DihydralazineNot Available
DB11450PimobendanNot Available
DB00863RanitidineThis drug is used alone or with concomitant antacids for the following conditions [FDA label]: **Duodenal ulcer** Treatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose) **Pathological hypersecretion of gastric acid** Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion **Gastric ulcer** Short term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose) **Other conditions**: Treatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing [FDA label]
DB08883PerampanelUsed in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
DB08496(R)-warfarinNot Available
DB119196-O-benzylguanineNot Available
DB141328-chlorotheophyllineWhen used in combination with [DB01075] as the antiemetic [DB00985], 8-chlorotheophylline is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
DB04076HypoxanthineNot Available
DB12406LisofyllineNot Available
DB01303OxtriphyllineUsed to treat the symptoms of asthma, bronchitis, COPD, and emphysema.
DB02134XanthineNot Available
DB01405TemafloxacinFor the treatment of lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections.
DB13573AcefyllineNot Available
DB00787AcyclovirAn acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older.[L7303] Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox.[L7315] An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutaneous herpes simplex in immunocompromised patients.[L7318] An acyclovir cream with hydrocortisone is indicated to treat recurrent herpes labialis, and shortening lesion healing time in patients 6 years and older.[L7321] An acyclovir buccal tablet is indicated for the treatment of recurrent herpes labialis.[L7324] An acyclovir ophthalmic ointment is indicated to treat acute herpetic keratitis.[L7327]
DB13203BamifyllineNot Available
DB14018BromotheophyllineBromotheophylline is used as a diuretic and also, in combination with [DB00316], it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.[L2737]
DB13812BufyllineNot Available
DB12926CafedrineNot Available
DB09273DoxofyllineIndicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component.
DB00442EntecavirFor the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
DB13592EtamiphyllineNot Available
DB01482FenethyllineNot Available
DB12531LobucavirNot Available
DB02568PeldesineNot Available
DB00642PemetrexedUsed in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
DB00299PenciclovirUsed to treat recurrent cold sores on the lips and face from various herpesvirus invections.
DB13634PentifyllineNot Available
DB06479PropentofyllineInvestigated for use/treatment in alzheimer's disease.
DB13449ProxyphyllineNot Available
DB12927TheodrenalineNot Available
DB09288PropacetamolPropacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapy.[L1511]
DB00184NicotineFor the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
DB00262CarmustineFor the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
DB00978LomefloxacinFor the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.
DB01094HesperetinFor lowering cholesterol and, possibly, otherwise favorably affecting lipids. In vitro research also suggests the possibility that hesperetin might have some anticancer effects and that it might have some anti-aromatase activity, as well as activity again.
DB01097LeflunomideFor the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
DB00533RofecoxibFor the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.
DB00730ThiabendazoleFor the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.
DB01115NifedipineFor the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
DB01087PrimaquineFor the treatment of malaria.
DB01628EtoricoxibFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
DB01058PraziquantelFor the treatment of infections due to all species of schistosoma.
DB00384TriamtereneTriamterene is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.[Label] Triamterene in combination with hydrochlorothiazide is indicated for the managment of hypertension or treatment of edema in patients who develop hypokalemia following hydrochlorothiazide monotherapy, and in patients who require thiazide diuretic and in whom the development of hypokalemia cannot be risked.[L6169] Triamterene allows the maintenance of potassium balance when given in combination with loop diuretics and thiazides.[T28]
DB01254DasatinibFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DB06770Benzyl alcoholUlesfia (benzyl alcohol) lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia Lotion does not have ovicidal activity.
DB06774CapsaicinThe capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.
DB11967Binimetinib On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335].
DB00993AzathioprineFor use in rheumatoid arthritis, preventing renal transplant rejection, Crohn's disease, and colitis.
DB016678-azaguanineNot Available
DB043569-DeazaguanineNot Available
DB024899-MethylguanineNot Available
DB00280DisopyramideFor the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
DB00969AlosetronOnly for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.
DB00398SorafenibSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
DB06594AgomelatineAgomelatine is indicated to treat major depressive episodes in adults.
DB01056TocainideFor the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
DB12245TriclabendazoleThis drug is indicated for the treatment of fascioliasis in patients aged 6 years old and above.[FDA label,L5452]
DB06292DapagliflozinDapagliflozin is indicated to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise[Label,A6757,A6758].
DB05676ApremilastApremilast is indicated for the treating of active psoriatic arthritis in adults, for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment. In addition, apremilast is now indicated for the treatment of oral ulcers associated with Behcet's disease in adults.[L7501]
DB00715ParoxetineParoxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
DB00675TamoxifenTamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.[L7802]
DB11757IstradefyllineIstradefylline is indicated in adjunct to levodopa and carbidopa in the treatment of Parkinson's disease.[L8237]
DB00625EfavirenzFor use in combination treatment of HIV infection (AIDS)
DB01233MetoclopramideMetoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis, in addition to the treatment of gastroesophageal reflux disease (GERD) in patients who have failed to respond to traditional therapy.[L8414] In the intravenous injection form, it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery. Intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine. In some cases, the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract, and metoclopramide is used to facilitate emptying in these cases, allowing for adequate diagnostic visualization.[L8417] Some off-label uses of metoclopramide include the management of radiation-induced nausea and vomiting, gastric bezoars, intractable hiccups, and migraine pain.[A184961,A184964,A184967,A40105]
DB00455LoratadineLoratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.[A176435][A176438][L8486]
DB05708GTS-21Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
DB04889BicifadineFor the treatment of pain.
DB09068VortioxetineVortioxetine is indicated for the treatment of major depressive disorder (MDD).
DB00983FormoterolFor use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD.
DB01006LetrozoleFor the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
DB01159HalothaneFor the induction and maintenance of general anesthesia
DB01181IfosfamideUsed as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
DB00313Valproic acid**Indicated** for:[Label] 1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures. 2) Adjunctive therapy in the management of multiple seizure types that include absence seizures. 3) Prophylaxis of migraine headaches. 4) Acute management of mania associated with bipolar disorder. **Off-label** uses include: 1) Maintenance therapy for bipolar disorder.[A177919] 2) Treatment for acute bipolar depression.[A177928,A177931,A177934] 3) Emergency treatment of status epilepticus.[A177955]
DB00238NevirapineFor use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
DB00471MontelukastMontelukast is indicated for: (a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304]; (b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and (c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307]. Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331] Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328] Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]
DB00604CisaprideFor the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.
DB06470ClomethiazoleInvestigated for use/treatment in strokes.
DB00531CyclophosphamideCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
DB01544FlunitrazepamFor short-term treatment of severe insomnias, that are not responsive to other hypnotics.
DB01236SevofluraneUsed for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
DB00495ZidovudineUsed in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
DB00690FlurazepamFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
DB00755TretinoinFor the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.
DB01274ArformoterolA bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
DB09327Tegafur-uracilTegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate.[L934] Colorectal cancer is the third most diagnosed cancer and 30% of the cases can present the metastatic state.[A32077]
DB11586AsunaprevirAsunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
DB09274ArtesunateFor the treatment of severe malaria caused by *Plasmodium falciparum* in adults and children [L891]
DB00916MetronidazoleMetronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis[L7432], certain types of amebiasis, and various anaerobic infections.[A181057] The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections.[L3754] It is also used off-label in the treatment of Crohn's disease and rosacea, as a prophylactic agent after surgery[A181039], and in the treatment of Helicobacter pylori infection.[A181045] It has also been studied in the prevention of preterm births and to treat periodontal disease.[A1391,A181078]
DB04977PlitidepsinIntended for the treatment of various forms of cancer.
DB01156BupropionBupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. When used in combination with [naltrexone] as the marketed product ContraveⓇ, bupropion is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Bupropion is also used off-label as a first-line treatment in patients with ADHD and comorbid bipolar disorder when used as an adjunct to mood stabilizers.[F4624]
DB00454MeperidineUsed to control moderate to severe pain.
DB00818PropofolUsed for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.
DB01221KetamineKetamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label] Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874]
DB09167DosulepinIndicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required.
DB13411LofepramineNot Available
DB13384MelitracenNot Available
DB00726TrimipramineFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
DB00503RitonavirIndicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
DB00836LoperamideFor the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.
DB01074PerhexilineFor the management of severe angina pectoris.
DB00193TramadolTramadol is approved for the management of moderate to severe pain in adults.[F4676,F4679] Tramadol is also used off-label in the treatment of premature ejaculation.[A173986]
DB01104SertralineSertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]
DB00849MethylphenobarbitalFor the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.
DB00762IrinotecanFor the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
DB01069PromethazineFor the treatment of allergic disorders, and nausea/vomiting.
DB06739SeratrodastNot Available
DB00514DextromethorphanFor treatment and relief of dry cough.
DB00865BenzphetamineFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
DB06697ArtemetherArtemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
DB00835BrompheniramineFor the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.
DB00349ClobazamFor treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
DB01559ClotiazepamFor the treatment of anxiety disorders.
DB00751EpinastineFor the prevention of itching associated with allergic conjunctivitis.
DB01466EthylmorphineEthylmorphine is an analgesic used for pain relief.
DB00753IsofluraneFor induction and maintenance of general anesthesia.
DB06738KetobemidoneFor the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
DB06710MethyltestosteroneMethyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.
DB04930PermethrinFor the treatment of infestation with Sarcoptes scabiei (scabies).
DB00231TemazepamTemazepam is specifically indicated only for the short-term management of insomnia [FDA Label], [L5539]. Furthermore, such management is generally predominantly associated with the symptomatic relief of transient and short-term insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings [F3718]. In particular, the official prescribing information for temazepam typically specifies that the instructions issued for dispensed prescriptions of the medication should indicate specifically that patients are only expected to use the therapy for short periods of time - usually 7-10 days in general [FDA Label, F3718]. Subsequently, treatment with temazepam should usually not exceed 7 to 10 consecutive days and nor should it be prescribed in quantities exceeding a one-month supply [F3718]. Some regional prescribing information also notes that temazepam may be used for premedication prior to minor surgery or other related procedures [L5539].
DB00624TestosteroneTestosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
DB04975BanoxantroneFor the treatment of various forms of cancer.
DB06209PrasugrelIndicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
DB04938OspemifeneOspemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
DB06176RomidepsinFor the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
DB11613VelpatasvirVelpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label].
DB05541BrivaracetamUsed as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
DB13943Testosterone cypionateTestosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153]
DB13944Testosterone enanthateTestosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Some of the treated conditions are 1) primary hypogonadism, defined as testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; 2) hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or due to a pituitary-hypothalamic injury from tumors, trauma or radiation, in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy; 3) to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder. If the conditions 1 and 2 occur prior to puberty, the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after puberty.[FDA label] In females, testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.[FDA label] Testosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism [F1941]. The use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with late-onset hypogonadism and males less than 18 years old have not yet been established [F1941]. Moreover, subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies, considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death [F1941].
DB13946Testosterone undecanoateTestosterone undecanoate is indicated for replacement therapy in adult males with conditions that are linked with an absence or deficiency in endogenous testosterone production. [F4247][FDA Label]
DB13132ArtemisininNot Available
DB11823EsketamineThis drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label]. Note: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label].
DB00956HydrocodoneHydrocodone is indicated for the management of acute pain, sometimes in combination with [acetaminophen] or [ibuprofen], as well as the symptomatic treatment of the common cold and allergic rhinitis in combination with decongestants, antihistamines, and expectorants.[label,L7991]
DB00381AmlodipineAmlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions [FDA label]: • Hypertension • Coronary artery disease • Chronic stable angina • Vasospastic angina (Prinzmetal’s or Variant angina) • Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
DB00829DiazepamIn general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression [F3160]. Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens [F3160]. Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome" [F3160]. Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery [L5188]. In the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication [L5188].
DB04856DexloxiglumideFor the treatment of Irritable Bowel Syndrome (IBS) and Gastroesophageal Reflux Disease (GERD).
DB00264MetoprololMetoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141] Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141] All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]
DB00285VenlafaxineVenlafaxine is indicated in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), and panic disorder with or without agoraphobia. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232]. It is also considered a second-line option for management of obsessive-compulsive disorder (OCD) [A177226, A177235].
DB00289AtomoxetineAtomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
DB00318CodeineCodeine sulfate is a form of this drug that is commonly used. It is available in tablet form [FDA label] and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate [FDA label]. The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above [L5521], [L5524].
DB00373Timolol Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742]
DB00497OxycodoneOxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
DB00679ThioridazineFor the treatment of schizophrenia and generalized anxiety disorder.
DB00734RisperidoneRisperidone is indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with Bipolar I Disorder, and irritability associated with autistic disorder.[L4697,L4700] Risperidone has additional indications through Health Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[F4700] Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression,[A177226]
DB01195FlecainideIn New Zealand and America, flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmias.[L8878] In the United States, it is also indicated to prevent paroxysmal atrial fibrillation and flutter.[A186886,L5056]
DB01238AripiprazoleAripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].
DB06608TafenoquineTafenoquine is used for the treatment and prevention of relapse of Vivax malaria in patients 16 years and older. Tafenoquine is not indicated to treat acute vivax malaria.[A35671] Malaria is a disease that remains to occur in many tropical countries. Vivax malaria, caused by _Plasmodium vivax_, is known to be less virulent and seldom causes death. However, it causes a substantive illness-related burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months. This dormant form produces ongoing relapses.[A35671]
DB12930OpipramolNot Available
DB00344ProtriptylineFor the treatment of depression.
DB00396Progesterone**Gelatinized capsules** The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label]. **Vaginal gel** Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898]. **Vaginal insert** This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901]. **Injection (intramuscular)** This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907]. **Tablets, contraceptive** The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904].
DB11979ElagolixElagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis [FDA Label].
DB01193AcebutololFor the management of hypertension and ventricular premature beats in adults.
DB00866AlprenololFor the treatment of hypertension, angina, and arrhythmia
DB11785AnisodamineNot Available
DB09204ArotinololArtinolol was introduced to be used as an antihypertensive agent since 1986.[T88] It has been studied for other functions like tremor control for patients with Parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart rate.[L1168]
DB00335Atenolol**Indicated** for:[label] 1) Management of hypertension alone and in combination with other antihypertensives. 2) Management of angina pectoris associated with coronary atherosclerosis. 3) Management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmHg. **Off-label** uses include: 1) Secondary prevention of myocardial infarction.[A178156] 2) Management of heart failure.[A178153] 3) Management of atrial fibrillation.[A178141] 4) Management of supraventricular tachycardia.[A178162] 5) Management of ventricular arrythmias such as congenital long-QT and arrhythmogenic right ventricular cardiomyopathy.[A178168] 6) Management of symptomatic thyrotoxicosis in combination with [methimazole].[A178147] 7) Prophylaxis of migraine headaches.[A178171] 8) Management of alcohol withdrawal.[A178174,A178177]
DB09013BefunololUsed in the management of open angle glaucoma. PMID: 12480285.
DB01295BevantololFor the treatment of angina pectoris and hypertension.
DB08807BopindololFor the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
DB12752BucindololNot Available
DB06726BufuralolNot Available
DB08808BupranololUsed to manage hypertension and tachycardia. Also used to treat glaucoma.
DB00521CarteololFor the treatment of intraocular hypertension and chronic open-angle glaucoma
DB04846CeliprololCeliprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.
DB13508CloranololNot Available
DB13757EpanololNot Available
DB13443EsatenololNot Available
DB00187EsmololFor the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
DB08952IndenololNot Available
DB12212LandiololNot Available
DB09351LevobetaxololUsed in the treatment of open-angle glaucoma and ocular hypertension [FDA Label].
DB01210LevobunololFor lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
DB13530MepindololNot Available
DB01214MetipranololIndicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
DB01203NadololNadolol is indicated to treat angina pectoris and hypertension.[L7922] Another product formulated with [bendroflumethiazide] is indicated to treat hypertension.[L7925]
DB04861NebivololNebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]
DB01580OxprenololUsed in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
DB01359PenbutololPenbutolol is indicated in the treatment of mild to moderate arterial hypertension. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.
DB00960PindololFor the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
DB01297PractololUsed in the emergency treatment of cardiac arrhythmias.
DB00489SotalolSotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.[Label] There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.[Label,L6373,L6376]
DB11770TalinololNot Available
DB13775TertatololNot Available
DB01267PaliperidoneFor the treatment of schizophrenia.
DB04884DapoxetineFor the treatment of premature ejaculation.
DB00215CitalopramFor the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].
DB01175EscitalopramEscitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
DB08918LevomilnacipranLevomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
DB01149NefazodoneFor the treatment of depression.
DB00656TrazodoneTrazodone is indicated for the treatment of major depressive disorder (MDD).[L3484] It has been used off-label for adjunct therapy in alcohol dependence, and off-label to treat anxiety and insomnia.[L3484] It may also be used off-label to treat symptoms of dementia, Alzheimer’s disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors.[A31634]
DB02703Fusidic acidFor the treatment of bacterial infections.
DB00674GalantamineFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
DB09183DasabuvirDasabuvir, in combination with [DB09296], [DB09297], and [DB00503] (as Viekira Pak) is indicated for the treatment of patients with HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] including those with compensated cirrhosis [FDA Label].
DB00921BuprenorphineBuprenorphine is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Buprenorphine is also used in combination with [naloxone] in a fixed-dose combination product for the treatment of severe opioid dependence.[F4715,F4718]
DB00490BuspironeIndicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.[L4478]
DB01244BepridilFor the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
DB01095FluvastatinTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
DB14185Aripiprazole lauroxilAripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
DB01624ZuclopenthixolUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
DB06702FesoterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB11642PitolisantPitolisant is indicated for the treatment of narcolepsy with or without cataplexy [L1471] and excessive daytime sleepiness in narcolepsy in adult patients.[L8063]
DB09128BrexpiprazoleAs an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
DB09039EliglustatEliglustat is indicated for the long-term treatment of type 1 Gaucher disease in adult patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.[label]
DB00182AmphetamineAmphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271] On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274] Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]
DB00185CevimelineFor the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
DB00433ProchlorperazineIndicated for the symptomatic treatment of severe nausea and vomiting.[label] Indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.[label,L6634] Off-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.[L6637]
DB00496DarifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
DB00699NicergolineFor the treatment of senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration.
DB00757DolasetronFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
DB00805MinaprineFor the treatment of depression
DB00843DonepezilDonepezil is indicated for the management of mild to moderate Alzheimer’s Disease at doses of 5 mg or 10 mg.[L7916] It is also indicated for the management of moderate to severe Alzheimer’s Disease in a higher dose of 10 mg or 23 mg administered once daily.[L7916] Off-label uses include the management of vascular dementia, Parkinson's Disease-associated dementia, and Lewy body dementia, among others.[A182333,T668] When combined with memantine, the extended-release form of donepezil is indicated to treat the symptoms of moderate to severe dementia.[L7937]
DB00914PhenforminFor the reatment of type II diabetes mellitus.
DB00918AlmotriptanFor the treatment of acute migraine headache in adults
DB01035ProcainamideFor the treatment of life-threatening ventricular arrhythmias.
DB01036TolterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB01114ChlorpheniramineFor the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
DB01228EncainideEncainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
DB01171MoclobemideFor the treatment of major depressive disorder and bipolar disorder [A31901].
DB01409TiotropiumTiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD.[L7084] A combination tiotropium and [olodaterol] metered inhalation spray is indicated for maintenance of COPD.[L7087] A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old.[L7090] A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.[L7093]
DB01075DiphenhydramineDiphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea [L5263, L5266, L5269, F3379, A174541]. Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for: i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated [F3352]; ii) the active treatment of motion sickness [F3352]; and iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents [F3352].
DB04840DebrisoquineFor the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
DB00317GefitinibFor the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
DB00342TerfenadineFor the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
DB00343Diltiazem**Oral** Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.[label] Indicated for use to improve exercise tolerance in patients with chronic stable angina.[label] Indicated for the management of variant angina (Prinzmetal's angina).[L6298] **Intravenous** Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.[L6292] Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.[L6292] **Off-label** Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension,[L6289] idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.[L6298]
DB00705DelavirdineFor the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
DB00933MesoridazineUsed in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses.
DB01071MequitazineFor the treatment of Hay fever, urticaria (hives) and allergic rhinitis
DB01192OxymorphoneFor the treatment of moderate-to-severe pain.
DB01403MethotrimeprazineFor the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
DB01551DihydrocodeineDihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
DB06144SertindoleUsed in the treatment of schizophrenia.
DB04905TesmilifeneIntended for the treatment of various forms of cancer.
DB05271RotigotineFor use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
DB00589LisurideFor the management of Parkinson's Disease
DB05109TrabectedinIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
DB014724-MethoxyamphetamineNot Available
DB06727SparteineNot Available
DB00208TiclopidineUsed in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
DB00543AmoxapineFor the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation.
DB00608ChloroquineFor the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
DB04946IloperidoneTreatment of acute schizophrenia.
DB01577MetamfetamineFor the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.
DB01621PipotiazineFor the maintenance treatment of chronic non-agitated schizophrenic patients.
DB00706TamsulosinTamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.[Label] Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.[A178339,L6259]
DB04844TetrabenazineTreatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
DB00932TipranavirFor combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
DB04855DronedaroneDronedarone is indicated for the management of atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF to reduce the risk of hospitalization.[L9007]
DB00216EletriptanFor the acute treatment of migraine with or without aura in adults.
DB00203SildenafilSildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications: (1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and (2) treatment of pulmonary hypertension, where: a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850]; b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].
DB00701AmprenavirFor the treatment of HIV-1 infection in combination with other antiretroviral agents.
DB01429AprindineNot Available
DB00637AstemizoleAstemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
DB00245BenzatropineBenztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also be used for the control of extrapyramidal disorders due to neuroleptic drugs.[T203] The extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia.[A175120] Parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to Parkinson's disease such as tremors, slow movement, and stiffness. The parkinsonism includes a large number of disorders and some of them have not been clearly defined.[L5509]
DB00297BupivacaineFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
DB00590DoxazosinDoxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]
DB01177IdarubicinFor the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
DB00731NateglinideFor the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.
DB00738PentamidineFor the treatment of pneumonia due to Pneumocystis carinii.
DB00592PiperazineUsed as alternative treatment for ascariasis caused by Ascaris lumbricoides (roundworm) and enterobiasis (oxyuriasis) caused by Enterobius vermicularis (pinworm). It is also used to treat partial intestinal obstruction by the common roundworm, a condition primarily occurring in children.
DB01224QuetiapineQuetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546] Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]
DB00409RemoxiprideRemoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.
DB00641SimvastatinSimvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658] This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658] Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB01079TegaserodTegaserod is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) [F4223, F4229]. The safety and effectiveness of tegaserod in men with IBS-C have not been established [F4223, F4229].
DB01392YohimbineIndicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
DB06684VilazodoneVilazodone is approved for treatment of major depressive disorder[Label,A38477,A177622].
DB06506RepinotanInvestigated for use/treatment in strokes, cerebral ischemia, and depression.
DB04920ClevidipineFor the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.
DB06735EnclomipheneNot Available
DB06204TapentadolThe immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy.
DB08893MirabegronMirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DB08901PonatinibPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
DB06203AlogliptinIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09048NetupitantNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.
DB09076UmeclidiniumIndicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
DB06016CariprazineCariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder.
DB06678EsmirtazapineInvestigated for use/treatment in insomnia and sleep disorders.
DB09555Dexchlorpheniramine maleateDexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis, vasomotor rhiniti, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, and dermographism.
DB06217VernakalantIndicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for non-surgery patients that lasts for less than 7 days of duration and post-cardiac surgery patients with atrial fibrillation lasting less than 3 days of duration.
DB11915ValbenazineFor the treatment of tardive dyskinesia in adults [FDA Label].
DB08922PerospironeFor the treatment of schizophrenia and acute cases of bipolar mania.
DB11614RupatadineFor the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.
DB12070LetermovirFor use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label].
DB11130OpiumOpium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain. Opium and its alkaloid-derivatives can also be used as tranquilizers, antitussives and in the treatment of diarrhea.[T138] The direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine, as well as the use of a tincture of opium for severe diarrhea can be seen in medical practice.[T139] Illegal use of opium has been registered to be for both recreational and medicinal purposes.[A32182]
DB09053IbrutinibIbrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.[FDA label] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.[L1929] Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.[FDA label] CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.[L1931] Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.[FDA label] CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.[A32305] Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).[FDA label] WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.[L1934]
DB13293IpecacIpecac is indicated as an emetic agent for the induction of vomiting in poisoning victims who ingested systemic poison in order to prevent absorption of the chemicals through the gastrointestinal tract. In low doses, ipecac was also used as an expectorant.[L2753] Reports have suggested that ipecac was vastly used in patients with eating disorders to produce vomiting.[T49]
DB04829Lysergic acid diethylamideNot Available
DB11718EncorafenibUsed in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335].
DB09195LorpiprazoleIn 2016, lorpiprazole was classified in the "Chemical structure-related drug-like criteria of global approved drugs" as an antipsychotic and anxiolytic.[L1167] An antipsychotic is a medication used to treat a state of delusion, hallucination, paranoia or disordered thought. On the other hand, an anxiolytic is a medication used for the treatment of severe, chronic or debilitating anxiety. The anxiety state can be defined as an unpleasant state of tension, apprehension or uneasiness.[T77]
DB00647DextropropoxypheneFor the relief of mild to moderate pain.
DB00964ApraclonidineFor prevention or reduction of intraoperative and postoperative increases in intraocular pressure (IOP) before and after ocular laser surgery when used prophylactically. Also used as a short-term adjunctive therapy in patients with open-angle glaucoma who are on maximally tolerated medical therapy requiring additional IOP reduction.
DB01454MidomafetamineClinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
DB11963DacomitinibDacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812] Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201]
DB11855RevefenacinRevefenacin is indicated as an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).[L4820] COPD is a growing disease being the third leading cause of death in the US. This disease is characterized by not fully reversible airflow limitation.[L4821]
DB01255LisdexamfetamineFor the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246]. This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
DB00243RanolazineRanolazine is approved as a second-line agent in the management of chronic stable angina pectoris that is refractory to conventional anti-ischemic therapy.[A174913] Ranolazine has also been used off-label for the treatment of some arrhythmias such as ventricular tachycardia, however, this use does not have a lot of supporting evidence.[A174940] The use of ranolazine has been researched in the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control.[A174898]
DB01576DextroamphetamineDextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)[Label].
DB00737MeclizineIndicated for the symptomatic treatment of nausea, vomiting, and dizziness associated with motion sickness,[L6772] and management of vertigo due to various causes, including radiation sickness, Meniere’s syndrome, labyrinthitis and other vestibular disturbances.[L6766]
DB13679DexchlorpheniramineNot Available
DB01591SolifenacinSolifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]
DB00908QuinidineFor the treatment of ventricular pre-excitation and cardiac dysrhythmias
DB00482CelecoxibCelecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA).[L7646] Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.[L7586,L7646] It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea. In addition, celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposis.[L7646]
DB09173ButyrfentanylButyrfentanyl was investigated as a potential opioid analgesic but is no longer used for this purpose.[A182060] It is more often being used as a recreational drug.[A182060]
DB00211MidodrineFor the treatment of symptomatic orthostatic hypotension (OH).
DB00598LabetalolLabetalol injections are indicated to control blood pressure in severe hypertension.[L7727] Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.[L7730]
DB01096OxamniquineFor treatment of Schistosomiasis caused by Schistosoma mansoni
DB01410CiclesonideFor the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
DB09061CannabidiolWhen used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications: 1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [L886]; Due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications: 1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; 2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain [L886].
DB04957AzimilideInvestigated for use/treatment in arrhythmia and atrial fibrillation.
DB140105-methoxy-N,N-dimethyltryptamineNot Available
DB14011NabiximolsIn Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. Sativex has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit. Patients should be advised of the conditional nature of the authorizations with conditions.
DB00228EnfluraneUsed for the induction and maintenance of general anaesthesia during surgery and cesarean section and also used for analgesia during vaginal delivery.
DB06728AnilineNot Available
DB00593EthosuximideFor the treatment of petit mal epilepsy.
DB06712NilvadipineFor the management of vasospastic angina, chronic stable angina and hypertension.
DB00347TrimethadioneUsed in the control of absence (petit mal) seizures that are refractory to treatment with other medications.
DB14046DichlorobenzeneNot Available
DB00949FelbamateFor use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
DB02701NicotinamideNot Available
DB00549ZafirlukastFor the prophylaxis and chronic treatment of asthma.
DB00678LosartanLosartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]
DB01029IrbesartanIrbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.[L7456] A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.[L7459]
DB01050IbuprofenIbuprofen is the most commonly used and prescribed NSAID. It is very common over the counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096] The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097] Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labor.[A39092] As ibuprofen is a widely used medication, the main therapeutic indications are: * Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100] * Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176] * Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177] * Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651] * Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901] * Minor pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] * Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer's disease, Parkinson disease, and breast cancer.[A39092]
DB01067GlipizideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[label]
DB00214TorasemideTorasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.[FDA label] Edema is considered when swelling is observed due to the trap of fluid in the body tissue. It is mainly located in feet, ankles and legs but it can also be extended to other parts such as face, hands and abdomen or even the whole body.[L5251] As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.[FDA label] Hypertension is defined by the presence of high blood pressure. This is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteries.[L5254]
DB00252PhenytoinFor the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
DB00412RosiglitazoneRosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB01016GlyburideGlyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.[L8120,L8123]
DB00554PiroxicamFor treatment of osteoarthritis and rheumatoid arthritis.
DB00946PhenprocoumonUsed for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
DB14055(S)-WarfarinNot Available
DB13136FluindioneNot Available
DB12474LynestrenolNot Available
DB06414EtravirineIndicated as an adjunct therapy in the treatment of adult HIV-1 infections resistant to therapy with other NNRTIs and antiretroviral agents.
DB00582VoriconazoleFor the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00812PhenylbutazoneFor the treatment of backache and ankylosing spondylitis
DB00672ChlorpropamideFor treatment of NIDDM in conjunction with diet and exercise.
DB00839TolazamideFor use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
DB01120GliclazideFor the treatment of NIDDM in conjunction with diet and exercise.
DB00222GlimepirideGlimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy. It may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone [F4540].
DB00414AcetohexamideUsed in the management of diabetes mellitus type 2 (adult-onset).
DB01251GliquidoneUsed in the treatment of diabetes mellitus type 2.
DB01289GlisoxepideFor the treatment of diabetes mellitus type 2.
DB08962GlibornurideNot Available
DB13406CarbutamideNot Available
DB13675MetahexamideNot Available
DB01320FosphenytoinFor the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.
DB08899EnzalutamideEnzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
DB00448LansoprazoleLansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]
DB00338OmeprazoleOmeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes: • Treatment of active duodenal ulcer in adults • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults • Treatment of active benign gastric ulcer in adults • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older • Pathologic hypersecretory conditions in adults
DB00404AlprazolamAlprazolam is indicated for the management of anxiety disorder, anxiety associated with depression, panic disorder, and panic disorder with agoraphobia.[Label] Alprazolam may also be prescribed off label for insomnia, premenstrual syndrome, and depression.[A177973]
DB01098RosuvastatinThe FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.[F4649] The Health Canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate. It is also indicated for the prevention of major cardiovascular events (including risk of myocardial infarction, nonfatal stroke, and coronary artery revascularization) in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.[F4652] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00307BexaroteneUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
DB00559BosentanUsed in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
DB06218LacosamideLacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
DB00794PrimidonePrimidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures [L4645, FDA Label]. In addition, it has also been studied and utilized as an effective management of essential tremor [A39414, A39415, L4645].
DB00250DapsoneFor the treatment and management of leprosy and dermatitis herpetiformis.
DB00327HydromorphoneHydromorphone is indicated for the management of moderate to severe acute pain and severe chronic pain. Due to its addictive potential and overdose risk, hydromorphone is only prescribed when other first-line treatments have failed.[A176468] The WHO has proposed a three-step ladder for the management of pain in which it is suggested to start with a non-opioid medication followed by addition of weak opioids to the non-opioid treatment for moderate pain and finishing in the use of strong opioids such as hydromorphone along with the existing regimen for cases of severe pain.[A176471] Off-label, hydromorphone can be administered for the suppression of refractory cough.[A176468]
DB00469TenoxicamFor the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.
DB00470DronabinolFor the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
DB00580ValdecoxibFor the treatment of osteoarthritis and dysmenorrhoea
DB00617ParamethadioneUsed for the control of absence (petit mal) seizures that are refractory to treatment with other medications.
DB00712FlurbiprofenFlurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
DB00749EtodolacFor acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.
DB00784Mefenamic acidFor the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
DB00814MeloxicamFor symptomatic treatment of arthritis and osteoarthritis.
DB00870SuprofenUsed as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery.
DB01015SulfamethoxazoleFor the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections.
DB00796Candesartan cilexetilMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
DB01072AtazanavirUsed in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
DB04557Arachidonic AcidNot Available
DB01174PhenobarbitalFor the treatment of all types of seizures except absence seizures.
DB01357MestranolMestranol was used as one of the first oral contraceptives.
DB01355HexobarbitalFor the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
DB00177ValsartanValsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate.[F4703,F4706]
DB01041ThalidomideFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
DB06652VicrivirocInvestigated for use/treatment in HIV infection and viral infection.
DB06725LornoxicamFor the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.
DB00440TrimethoprimFor the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.
DB01198ZopicloneFor the short-term treatment of insomnia.
DB06268SitaxentanInvestigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.
DB00328IndomethacinOral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778] Intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[F4600]
DB00936Salicylic acidKey additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.
DB01009KetoprofenFor symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
DB04725LicofeloneFor the management of osteoarthritis.
DB06737ZaltoprofenNot Available
DB06736AceclofenacAceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
DB00945Acetylsalicylic acid**Pain, fever, and inflammation** Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label]. **Other indications** ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label]. For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label]. For the prevention of thromboembolism after hip replacement surgery [FDA label]. For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label]. Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. **Important note regarding use of the extended-release formulation [F4405]** In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].
DB00869DorzolamideFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
DB01132PioglitazonePioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
DB01131ProguanilFor the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world.
DB01589QuazepamUsed to treat insomnia.
DB00197TroglitazoneFor the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
DB06370IndisulamInvestigated for use/treatment in lung cancer.
DB06803NiclosamideFor the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis.
DB01154ThiamylalUsed for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.
DB08828VismodegibVismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
DB00374TreprostinilFor use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
DB08860PitavastatinPitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). It is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.[F4667] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB08875CabozantinibFor the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DB09080OlodaterolOlodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
DB08439ParecoxibUsed for short term perioperative pain control.
DB11560LesinuradFor use, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
DB03756DoconexentUsed as a high-docosahexaenoic acid (DHA) oral supplement.
DB13919CandesartanNot Available
DB13941PiperaquineFor the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB11638].
DB13746BioallethrinBioallethrin was used for lice and scabies infestation. Other pyrethroids are now used in place of bioallethrin.
DB14009Medical CannabisNot Available
DB04898XimelagatranFor the treatment of acute deep vein thrombosis.
DB01124TolbutamideFor treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.
DB04665CoumarinNot Available
DB07615TranilastFor the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
DB00304DesogestrelOral desogestrel is used in combination with [ethinylestradiol] as a contraceptive agent for the prevention of pregnancy.[FDA label] Desogestrel is part of the combined oral contraceptives that contain a mix of estrogen and progestin which inhibit ovulation.[L5698]
DB12371SiponimodThis drug is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults [FDA label].
DB12147ErdafitinibErdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor [FDA Label][A177109, A177112, A177115] that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has: i) susceptible FGFR3 or FGFR2 genetic alterations and has [FDA Label], ii) progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [FDA Label]. The selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible FGFR genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic like the FDA approved therascreen FGFR RGQ RT-PCR Kit as developed by QIAGEN [FDA Label]. This above indication is approved under accelerated approval by the US FDA based on tumor response rate [FDA Label]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [FDA Label].
DB09213DexibuprofenFor more information, refer to [ibuprofen].
DB00465KetorolacKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. [A176131] It is indicated for short term management of acute pain that requires the caliber of pain management offered by opioids. [L6526] Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. [L6520] Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days).[L6526] A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.[A176131]
DB08502CapravirineInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
DB00213Pantoprazole **Pantoprazole Injection**: **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis** Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label] **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome** Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label] **Pantoprazole delayed-release oral suspension**: **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)** Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202] **Maintenance of healing of erosive esophagitis** Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202] **Pathological hypersecretory conditions including Zollinger-Ellison syndrome** Indicated for the long-term treatment of the above conditions.[F3202]
DB00395CarisoprodolCarisoprodol is indicated for the relief of discomfort related to acute, painful musculoskeletal conditions [FDA label]. **Important limitations of use** [FDA label]: • Should only be used for acute treatment periods up to two or three weeks • Adequate evidence of effectiveness for more prolonged use has not been established • Not recommended in pediatric patients less than 16 years of age
DB00736EsomeprazoleEsomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.
DB13762DexrabeprazoleNot Available
DB01129RabeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB01483BarbitalNot Available
DB00474MethohexitalMethohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
DB00312PentobarbitalFor the short-term treatment of insomnia.
DB00599ThiopentalFor use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.
DB05246MethsuximideFor the control of absence (petit mal) seizures that are refractory to other drugs.
DB01259LapatinibIndicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
DB00909ZonisamideFor use as adjunctive treatment of partial seizures in adults with epilepsy.
DB01323St. John's WortNot Available
DB12130LorlatinibLorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) [L4848] indicated for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on a) the prior use of crizotinib and at least one other ALK inhibitor for metastatic disease, or b) the prior use of alectinib as the first ALK inhibitor therapy for metastatic disease, or c) the prior use of certinib as the first ALK inhibitor therapy for metastatic disease [L848, FDA Label].
DB09166EtizolamIndicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.
DB05351DexlansoprazoleDexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
DB12500FedratinibFedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk.[L8090]
DB00439CerivastatinUsed as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
DB00912RepaglinideAs an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB01229PaclitaxelUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
DB00613AmodiaquineFor treatment of acute malarial attacks in non-immune subjects.
DB12781BalaglitazoneNot Available
DB09201CiglitazoneNot Available
DB09198LobeglitazoneLobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
DB09199NetoglitazoneNot Available
DB09200RivoglitazoneNot Available
DB09296OmbitasvirWhen used in combination with [DB09297] and [DB00503] (as the fixed dose product Technivie), Ombitasvir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis [L866]. When used in combination with [DB09297], [DB00503], and [DB09183] (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with [DB00811], for the treatment of HCV genotype 1a [FDA Label]
DB01076AtorvastatinAtorvastatin is approved for the treatment of several types of dyslipidemias including: - Primary hyperlipidemia and mixed dyslipidemia in adults. - Hypertriglyceridemia. - Primary dysbetalipoproteinemia. - Homozygous familial hypercholesterolemia. - Heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397] Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397] Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors, and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397] Atorvastatin can also be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00255DiethylstilbestrolUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
DB00977EthinylestradiolFor treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
DB01261SitagliptinSitagliptin is indicated for the management of glycemic control in type 2 diabetes mellitus along with diet and exercise[Label].
DB00402EszopicloneEszopiclone is indicated for the treatment of insomnia.[L6769]
DB06772CabazitaxelFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
DB01218HalofantrineFor treatment of Severe malaria
DB00295MorphineMorphine is used for the management of chronic moderate-to-severe pain.[A176050] Opioids, including morphine, can manage pain effectively when used for a short amount of time. The use of opioids for longer periods needs to be monitored as they can develop a physical dependence, addiction disorder and drug abuse.[L5728]
DB00359SulfadiazineFor the treatment of rheumatic fever and meningococcal meningitis
DB00799TazaroteneUsed to treat psoriasis, acne and sun damaged skin (photodamage).
DB05229BeraprostFor the treatment of pulmonary hypertension.
DB08912DabrafenibTafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test [FDA label]. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib [FDA label]. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2712].
DB00688Mycophenolate mofetilMycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal, hepatic, or cardiac transplants. It should be used with cyclosporine and corticosteroids.[L7363] Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy.[A180814] Other off-label uses of this drug include lupus-associated nephritis and dermatitis in children.[A180817]
DB11362SelexipagSelexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
DB08931RiociguatRiociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).
DB06670OdanacatibInvestigated for use/treatment in osteoporosis [A19388].
DB12267BrigatinibThe anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]
DB11901ApalutamideIndicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC) [FDA Label].
DB00622NicardipineUsed for the management of patients with chronic stable angina and for the treatment of hypertension.
DB11978GlasdegibGlasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy.[L5080] Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adults.[L4832]
DB00227LovastatinLovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.[F4661] Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.[F4661,F4664] Lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.[F4661] Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls with Heterozygous Familial Hypercholesterolemia (HeFH) who are at least one year post-menarche, 10 to 17 years of age, with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than 189 mg/dL or LDL-C remains greater than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient. Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed. Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00224IndinavirIndinavir is an antiretroviral drug for the treatment of HIV infection.
DB00401NisoldipineFor the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
DB00541VincristineTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
DB00683Midazolam**Intravenous** Indicated for promoting preoperative sedation, anxiolysis, anesthesia induction, or amnesia.[F2434] **Intramuscular** Indicated for the treatment of status epilepticus in adults.[FDA label] **Nasal** Indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.[L6559]
DB00802AlfentanilFor the management of postoperative pain and the maintenance of general anesthesia.
DB00820TadalafilUsed for the treatment of erectile dysfunction.
DB00862VardenafilUsed for the treatment of erectile dysfunction
DB00864TacrolimusFor use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was given FDA approval in 1994 for use in liver transplantation. Since then, this indication has expanded to kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB00897TriazolamFor the short-term treatment of insomnia.
DB00976TelithromycinFor the treatment of Pneumococcal infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia.
DB01023FelodipineFor the treatment of mild to moderate essential hypertension.
DB01054NitrendipineFor the treatment of mild to moderate hypertension
DB01211ClarithromycinAn alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
DB01232SaquinavirFor the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
DB00199Erythromycin Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria.[L7261] The indications for erythromycin have been summarized by body system below: **Respiratory infections** Mild to moderate upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with erythromycin.[L7261] Mild to moderate lower-respiratory tract infections due to susceptible strains of Streptococcus pneumoniae or Streptococcus pyogenes may also be treated. Erythromycin treats listeriosis caused by Listeria monocytogenes may also be treated with erythromycin.[L7261] Erythromycin is indicated to treat pertussis (whooping cough) caused by Bordetella pertussis. It is effective in eliminating the causative organism from the nasopharynx of infected individuals, rendering them noninfectious. Clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacteria.[L7261] Respiratory tract infections due to Mycoplasma pneumoniae may also be treated with erythromycin.[L7261] Despite the fact that no controlled clinical efficacy studies have been conducted to this date, in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in Legionnaires’ Disease.[L7261] Finally, erythromycin is indicated to treat diphtheria and other infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers.[L7261] In addition to the prevention of diphtheria, erythromycin can be used to prevent rheumatic fever in penicillin intolerant patients.[L7261] **Skin infections** Mild to moderate skin or skin structure infections caused by Streptococcus pyogenes or Staphylococcus aureus may be treated with erythromycin, however, resistant staphylococcal organisms may emerge.[L7261] Erythromycin can also be used to treat erythrasma, an infectious condition caused by Corynebacterium minutissimum.[L7261] **Gastrointestinal infections** Intestinal amebiasis caused by Entamoeba histolytica can be treated with oral erythromycin. Extraenteric amebiasis warrants treatment with other antimicrobial drugs.[L7261] **Genital infections/STIs** Erythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by N. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin.[L7261] Syphilis, caused by Treponema pallidum, can be treated with erythromycin. It serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. Erythromycin can also be used in the primary stage of primary syphilis.[L7261] Another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. It is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by Chlamydia trachomatis.[L7261] Erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. Finally, erythromycin is indicated to treat nongonococcal urethritis due to Ureaplasma urealyticum.[L7261]
DB00091CyclosporineCyclosporine is officially approved for different conditions listed below: * Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. For this indication, it can be used concomitantly with azathioprine and corticosteroids. * Treatment of patients with severe active, rheumatoid arthritis when the patient no longer responds to methotrexate. * Concomitantly with methotrexate for the treatment of patients with severe active rheumatoid arthritis when patients do not respond to methotrexate treatment alone. * Treatment of adult nonimmunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[FDA label] * Its ophthalmic solution is indicated to increase tear production in patients with keratoconjunctivitis sicca in patients from 4 years old.[L5158] * Prevention of graft rejection following bone marrow transplantation and in the treatment of graft-versus-host disease (GVHD). * Treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases such as minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis in adults and children.[F3091] Away from all this approved and reviewed indications, cyclosporine is commonly used on dermatology for the treatment of various inflammatory skin conditions such as atopic dermatitis, blistering disorders, and connective tissue diseases.[A174085]
DB00207AzithromycinAzithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label]. Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. **Adults**: Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage. Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_. Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. **Pediatric Patients** Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.
DB05521TelaprevirTelaprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB08873BoceprevirBoceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB11633Isavuconazole- Indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [FDA Label]. - Indicated for patients 18 years of age and older for the treatment of invasive mucormycosis [FDA Label], including patients where treatment amphotericin B is inappropriate [L1482].
DB00220NelfinavirUsed in combination with other antiviral drugs in the treatment of HIV in both adults and children.
DB01319FosamprenavirIndicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
DB06290SimeprevirIndicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis. Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
DB06287TemsirolimusFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
DB06237AvanafilTreatment of erectile dysfunction in males.
DB00872ConivaptanFor the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
DB01264DarunavirDarunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.
DB11742EbastineNot Available
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB08827LomitapideUsed in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
DB09049NaloxegolIndicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
DB01222BudesonideThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
DB00700EplerenoneFor improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
DB08815LurasidoneTreatment of schizophrenia.
DB04835MaravirocFor treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
DB08816TicagrelorTicagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with ST elevation.
DB06212TolvaptanTreatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
DB00673AprepitantFor the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
DB01394ColchicineColchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of 4 years of age and older. It is important to note that this medication is not a pain reliever to be used for other painful conditions. Consider analgesics for this purpose.[L8138] Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.[A183932,A183935]
DB08864RilpivirineRilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031]
DB06228RivaroxabanRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
DB00247MethysergideFor the treatment of vascular headache
DB09289TianeptineUsed primarily in the treatment of major depressive disorder and anxiety [A31969]. It is currently being studied for fibromyalgia pain treatment [L1426].
DB01200BromocriptineFor the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
DB00248CabergolineFor the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
DB11273DihydroergocornineTo know more about the approved indications please visit [DB01049]
DB13345DihydroergocristineDihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.[L2649] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].
DB13385DihydroergocryptineNot Available
DB00320DihydroergotamineFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
DB01049Ergoloid mesylateIt was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.[A32926] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[L2637] To know more about the individual components of the ergoloid mixture, please visit [DB13345] and [DB11274]
DB01253ErgometrineUsed to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
DB00696ErgotamineFor use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
DB00353MethylergometrineFor the prevention and control of excessive bleeding following vaginal childbirth
DB01186PergolideIndicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
DB13399TergurideNot Available
DB00620TriamcinoloneTriamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum.[L8246] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8246] Triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L8249,L8258] A triamcinolone acetonide 10mg/mL or 40mg/mL injection is indicated intra-articularly for acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L8252,L8255] The same 10mg/mL injection is indicated by the intralesional route for the treatment of alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon.[L8252] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8252] The 40mg/mL injection is indicated intramuscularly for controlling severe allergic conditions such as asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis, serum sickness, and transfusion reactions; treatment of bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, Stevens-Johnson syndrome, congenital adrenal hyperplasia, hypercalcemia in cancer, nonsuppurative thyroiditis, autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, secondary thrombocytopenia, trichinosis, tuberculous meningitis, acute exacerbations of multiple sclerosis or cerebral edema, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, berylliosis, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis, dermatomyositis, polymyositis, and systemic lupus erythematosus; adjunct treatment of adrenocortical insufficiency, regional enteritis, ulcerative colitis, fulminating or disseminated pulmonary tuberculosis, acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis; palliative management of leukemia and lymphoma; induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosus.[L8255] A triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions.[L8261] The intravitreal injection is also used for visualization during vitrectomy.[L8261] An extended release suspension is indicated intra-articularly for management of pain in osteoarthritis of the knee.[L8264]
DB01601LopinavirIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
DB00444TeniposideTeniposide is used for the treatment of refractory acute lymphoblastic leukaemia
DB00346AlfuzosinFor the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
DB12010FostamatinibFostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].
DB06267UdenafilInvestigated for use/treatment in erectile dysfunction and hypertension.
DB00635PrednisoneFor the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
DB13867FluticasoneFluticasone's 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxis[FDA Label][F4364]as well as inflammatory and pruritic dermatoses[F4355]. A [DB00588] nasal spray is indicated for managing nonallergic rhinitis[F4358] while the [DB08906] nasal spray is indicated for treating season and perennial allergic rhinitis[F4361,A177130].
DB09236LacidipineIndicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors [L1126].
DB01431AllylestrenolAllylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.
DB00443BetamethasoneNot Available
DB01380Cortisone acetateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
DB11921DeflazacortDeflazacort is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients 2 years of age and older.[FDA label]
DB09123DienogestIndicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.
DB01234DexamethasoneInjection: for the treatment of endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
DB11487Dexamethasone isonicotinateNot Available
DB01395DrospirenoneDrospirenone, in combination with ethinyl estradiol, is indicated as an oral contraceptive for the prevention of pregnancy. In addition to its use for contraceptive effects, this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorder.[L7973,L7976] The drug has approved indications for combination with estrogens for the treatment of menopause-associated symptoms, such as vasomotor symptoms and vulvovaginal atrophy. Drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been post-menopausal for at least a year and are not candidates for other therapies.[L7997,L8075] It can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraception.[L8078] When used for the treatment of acne vulgaris, drospirenone-containing contraceptives should only be used in women ≥14 years of age who have experienced menarche, desire oral contraception, and do not have any contraindications to oral contraceptives.[L7976] Off-label uses for this drug include the treatment of menstrual irregularities, dysmenorrhea, hirsutism, and endometriosis.[A2439,A182576]
DB00294EtonogestrelEtonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990] Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698]
DB00180FlunisolideFor the maintenance treatment of asthma as a prophylactic therapy.
DB08971FluocortoloneNot Available
DB00324FluorometholoneFor the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
DB08906Fluticasone furoateFluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
DB00588Fluticasone propionateFluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. A fluticasone propionate nasal spray is indicated for managing nonallergic rhinitis[F4358].
DB00741HydrocortisoneFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14538Hydrocortisone aceponateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14539Hydrocortisone acetateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14540Hydrocortisone butyrateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14541Hydrocortisone cypionateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14542Hydrocortisone phosphateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14543Hydrocortisone probutateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14544Hydrocortisone valerateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB06789Hydroxyprogesterone caproateHydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth. (1)
DB00367Levonorgestrel**Emergency contraception** Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age.[L7760] This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse.[A181976,L7760] It has shown a lower efficacy when it is used off label within 96 hours.[T659] **Long-term contraception or nonemergency contraception** In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol.[L7766] It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years.[L7778,L7781,L7787] Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child.[L7778] A subdermal implant is also available for the prevention of pregnancy for up to 5 years.[L7823] **Hormone therapy and off-label uses** Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.[L7805]Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.[T659]
DB00451LevothyroxineLevothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
DB00603Medroxyprogesterone acetateMedroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology.[L8657] Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.[L8660] Subcutaneous MPA is indicated to prevent pregnancy and manage pain associated with endometriosis.[L8663] Intramuscular MPA is indicated to prevent pregnancy,[L8666] and at higher concentrations for palliative treatment of endometrial or renal carcinoma.[L8669]
DB00959MethylprednisoloneAdjunctive therapy for short-term administration in rheumatoid arthritis.
DB00717NorethisteroneFor the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
DB00957NorgestimateFor the prevention of pregnancy
DB09389NorgestrelNorgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
DB01384ParamethasoneFor the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone.
DB01708PrasteroneDHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids). DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.
DB00860PrednisoloneFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
DB034104-hydroxycoumarinNot Available
DB13275ClorindioneNot Available
DB13347DiphenadioneNot Available
DB08794Ethyl biscoumacetateNot Available
DB09230AzelnidipineFor the treatment of hypertension.
DB09227BarnidipineIndicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.
DB13488BencyclaneNot Available
DB09231BenidipineBenidipine is a potent and long-lasting drug indicated for the treatment of cardiovascular diseases such as hypertension, renoparenchymal hypertension and angina pectoris.[A31950]
DB11960CarboxyamidotriazoleNot Available
DB13835CaroverineNot Available
DB09232CilnidipineCilnidipine is indicated for the management of hypertension for end-organ protection.[L1436] It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnidipine has been increasingly used in patients with chronic kidney disease Hypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel.[L1438]
DB04838CyclandelateUsed in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps.
DB09234DarodipineNot Available
DB14068DexniguldipineNot Available
DB14063DexverapamilNot Available
DB06446DotarizineInvestigated for use/treatment in migraine and cluster headaches.
DB09235EfonidipineFor the treatment of hypertension.
DB14064EmopamilNot Available
DB08992EperisoneNot Available
DB08980FendilineNot Available
DB13961Fish oilUnder FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label, F36]. Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].
DB04842FluspirileneUsed for the treatment of schizophrenia.
DB12923GallopamilNot Available
DB00270IsradipineFor the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.
DB00555LamotrigineIndicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [FDA Label]. Indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[FDA Label]. Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy [FDA Label].
DB00528LercanidipineFor the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
DB13766LidoflazineNot Available
DB14065LomerizineNot Available
DB09238ManidipineFor the treatment of hypertension.
DB00825LevomentholUsed to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.
DB01388MibefradilFor the treatment of angina and high blood pressure.
DB12092NaftopidilNot Available
DB09240NiludipineNot Available
DB04743NimesulideFor the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
DB00393NimodipineFor use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
DB06152NylidrinNylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis [L2285]. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor)[A32531].
DB09239NiguldipineNot Available
DB13500OtiloniumNot Available
DB13791PenfluridolNot Available
DB09090PinaveriumPinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.
DB04825PrenylamineNot Available
DB13725TerodilineNot Available
DB12093TetrahydropalmatineNot Available
DB14066TetrandrineNot Available
DB09216Tolfenamic acidIn the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[L1293]
DB09089TrimebutineIndicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery.
DB05885SeletracetamInvestigated for use/treatment in epilepsy.
DB12131VinpocetineNot Available
DB13950WIN 55212-2Not Available
DB06283ZiconotideNot Available
DB00602IvermectinFor the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite Onchocerca volvulus. Can be used to treat scabies caused by Sarcoptes scabiei.
DB04845IxabepiloneInvestigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
DB01045RifampicinFor the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
DB00615RifabutinFor the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
DB01201RifapentineFor the treatment of pulmonary tuberculosis.
DB01220RifaximinRifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
DB08896RegorafenibRegorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
DB09083IvabradineIvabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more[FDA Label].
DB08881VemurafenibVemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
DB08865CrizotinibCrizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
DB06636IsavuconazoniumIndicated in the treatment of invasive aspergillosis and invasive mucormycosis.
DB00204DofetilideFor the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
DB00234ReboxetineFor the treatment of clinical depression.
DB00309VindesineFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
DB00361Vinorelbine Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998]. Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011]. For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011]. For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011]. For the treatment of recurrent ovarian cancer [L2011]. For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011]. For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].
DB00539ToremifeneFor the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
DB00570VinblastineFor treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
DB00584EnalaprilIndicated for the management of essential or renovascular hypertension [L6586] as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.[label] Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.[label] Indicated for the management of asymptomatic left ventricular dysfunction in patients with an ejection fraction of ≤ to 35 percent to decrease the rate of development of overt heart failure and the incidence of hospitalization for heart failure.[label]
DB00636ClofibrateFor Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.
DB00643MebendazoleFor the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
DB00745ModafinilTo improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
DB00778RoxithromycinUsed to treat respiratory tract, urinary and soft tissue infections.
DB00813FentanylFentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.[Label] These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia.[Label] Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.[Label] Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.[L6598,L6601,L6604,L6607,L922,L6610]
DB00834MifepristoneFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
DB00889GranisetronFor the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
DB00906TiagabineFor the treatment of partial seizures
DB00907CocaineFor the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
DB00910ParicalcitolFor treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
DB00911TinidazoleFor the treatment of trichomoniasis caused by T. vaginalis in both female and male patients. Also for the treatment of giardiasis caused by G. duodenalis in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by E. histolytica in both adults and pediatric patients older than three years of age.
DB00938SalmeterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB00962ZaleplonFor the treatment of short-term treatment of insomnia in adults.
DB00990ExemestaneFor the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
DB00997DoxorubicinDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
DB01008BusulfanFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
DB01020Isosorbide mononitrateFor the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.
DB01026KetoconazoleFor the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
DB01062OxybutyninOxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms.[L8648] On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.[T689]
DB01068ClonazepamClonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures [FDA Label] [F3787]. Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides [FDA Label] [F3787]. Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V [FDA Label]. Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements [L5572, F3796]. Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy [F3796].
DB01105SibutramineFor the treatment of obesity.
DB01126DutasterideIndicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].[label]
DB01167ItraconazoleFor the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
DB01190ClindamycinFor the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
DB01215EstazolamFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
DB01216FinasterideIndicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.
DB01227LevacetylmethadolFor the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.
DB01256RetapamulinFor use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01263PosaconazoleFor prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
DB06155RimonabantFor use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.
DB06685LaquinimodInvestigated for use/treatment in multiple sclerosis.
DB01110MiconazoleFor topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.
DB01248DocetaxelFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
DB06403AmbrisentanAmbrisentan is indicated for treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in patients with WHO functional class II or III symptoms. In the United States of America, ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
DB00612BisoprololBisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]
DB00136CalcitriolUsed to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB00475ChlordiazepoxideFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
DB00628Clorazepic acidFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
DB01219DantroleneFor use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
DB01396DigitoxinFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
DB01018GuanfacineFor use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
DB00358MefloquineFor the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
DB04868NilotinibFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
DB06207SilodosinTreatment for symptomatic relief of benign prostatic hyperplasia
DB06145SpiramycinMacrolide antibiotic for treatment of various infections.
DB00759TetracyclineUsed to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.
DB06335SaxagliptinTreatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
DB00708SufentanilThe indications for this drug are as follows: 1. As an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated. 2. As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated. 3. For epidural administration as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery 4. The sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. [FDA label]
DB01128BicalutamideFor treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
DB01138SulfinpyrazoneFor the treatment of gout and gouty arthritis.
DB00546AdinazolamFor the treatment of anxiety and status epilepticus.
DB03701VanoxerineNot Available
DB00169CholecalciferolCholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia [F4027, F4042]. Concurrently, as one of the most commonly utilized forms of vitamin D, cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others [A176041, A176044, F4051].
DB01173OrphenadrineIndicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.
DB06700DesvenlafaxineDesvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
DB06708LumefantrineLumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
DB06742AmbroxolAmbroxol is indicated for secretolytic therapy in bronchoplmonary diseaes with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
DB00278ArgatrobanArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
DB01393BezafibrateFor the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
DB01194BrinzolamideFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DB00748CarbinoxamineFor symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
DB00567CephalexinCephalexin is indicated for the treatment of certain infections caused by susceptible bacteria.[Label,L6550,L6553] These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.[Label,L6550,L6553]
DB00845ClofazimineFor the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
DB00987CytarabineFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
DB00694DaunorubicinFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
DB00822DisulfiramFor the treatment and management of chronic alcoholism
DB01196EstramustineFor the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
DB00426FamciclovirFor the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
DB01039FenofibrateFenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]
DB00947FulvestrantFor the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
DB05381HistamineHistamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function.
DB00724ImiquimodFor the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
DB01103QuinacrineFor the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
DB04833MethaqualoneFor the treatment of insomnia, and as a sedative and muscle relaxant.
DB01595NitrazepamUsed to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
DB00768OlopatadineOlopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution.[L6781] In nasal spray, olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older.[L6784]
DB01588PrazepamFor the treatment of anxiety disorders.
DB01349TasosartanTasosartan is infrequently in the treatment of hypertension and heart failure.
DB04572ThiotepaThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
DB13179TroleandomycinFor the treatment of bacterial infection.
DB04828ZomepiracZomepirac was indicated for the management of mild to severe pain.
DB01587KetazolamKetazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
DB00808IndapamideFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
DB08820IvacaftorWhen used as monotherapy as the product Kalydeco, ivacaftor is indicated for the management of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D.[L768,L6838] When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are shown to be homozygous for the F508del mutation in the CFTR gene. When used in combination with [Tezacaftor] in the product Symdeko, it is used to manage CF in patients 12 years and older who have at least one mutation in the CFTR gene or patients aged 12 or older who are shown to be homozygous for the F508del mutation.[L6814]
DB05039IndacaterolFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
DB06777Chenodeoxycholic acidChenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.
DB06762PinacidilNot Available
DB00337PimecrolimusFor treatment of mild to moderate atopic dermatitis.
DB08870Brentuximab vedotinSeattle Genetics Announced FDA Approval of ADCETRIS® (Brentuximab Vedotin) in combination with chemotherapy for adults with previously untreated stage III or IV Classical Hodgkin Lymphoma in March 2018 [L1737, L1739]. Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates [FDA label], [L1737]. Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [FDA label].
DB05294VandetanibVandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
DB08877RuxolitinibTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
DB05812AbirateroneUsed in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
DB08895TofacitinibFor the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB08903BedaquilineBedaquiline is indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
DB08907CanagliflozinThis drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus [FDA label]. Another indication for canagliflozin is the prevention of major cardiovascular events (myocardial infarction, stroke, or death due to a cardiovascular cause) in patients with type 2 diabetes, as well as hospitalization for heart failure in patients with type 2 diabetes[L5897,[L8917]. In addition to the above, canagliflozin can be used to lower the risk of end-stage kidney disease and major increases in serum creatinine and cardiovascular death for patients with a combination of type 2 diabetes mellitus, diabetic nephropathy, and albuminuria.[L8917] It is important to note that this drug is **not** indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis [FDA label].
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB08833Taurochenodeoxycholic acidTaurochenodeoxycholic acid is likely indicated as a choleretic and cholagogue. It is also being investigated for its role in inflammation and cancer therapy.
DB08932MacitentanMacitentan is indicated for patients with pulmonary arterial hypertension.
DB09074OlaparibOlaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: (I) Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy [FDA Label]. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib [FDA Label]. [II] Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment [FDA Label]. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib [FDA Label].
DB09073PalbociclibPalbociclib is indicated in combination with [letrozole] as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with [fulvestrant] in patients with disease progression with prior endocrine therapy.[A176783] In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted to letrozole, as initial endocrine-based therapy in postmenopausal women or in man.[FDA label] The breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue. This growth can spread into other parts of the body which is called metastasis. According to the location of the cancer cells, it can be categorized in ductal carcinoma and lobular carcinoma. However, other types of breast cancer include inflammatory breast cancer, Paget disease of the breast, triple negative breast cancer non-Hodgkin lymphoma and soft tissue sarcoma.[L5870] In males, breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinoma.[L5873]
DB09082VilanterolVilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta and in combination with umeclidinium bromide as Anoro Ellipta. Approved by the FDA in 2013, use of Breo Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
DB09026AliskirenFor the treatment of hypertension, to lower blood pressure.
DB09101ElvitegravirElvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
DB09291RolapitantThis drug is indicated in adults in combination with other antiemetics for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.
DB04908FlibanserinFor the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
DB09102DaclatasvirIndicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.
DB09143SonidegibSonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2)
DB06603PanobinostatPanobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
DB09297ParitaprevirWhen used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie, paritaprevir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the Health Canada-approved, commercially available product Holkira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without cirrhosis.
DB09317Synthetic Conjugated Estrogens, AFor the treatment of moderate to severe vasomotor symptoms due to menopause and for treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
DB09318Synthetic Conjugated Estrogens, BFor the treatment of moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe vaginal dryness, pain with intercourse, and symptoms of vulvar and vaginal atrophy due to menopause.
DB11581VenetoclaxA BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label].
DB09381Esterified estrogensEsterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the body. It is also indicated for the treatment of symptoms of breast cancer in both men and women. In men it can be used for the treatment of advanced prostate cancer. It is also indicated for the treatment of menopausal symptoms.
DB06654SafinamideSafinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease
DB11575GrazoprevirGrazoprevir is indicated in combination with [DB11574] (as the fixed dose combination product Zepatier) with or without [DB00811] for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
DB09262ImidafenacinUsed in the treatment of overactive bladder [FDA Label].
DB11828NeratinibFor use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
DB06595MidostaurinInvestigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
DB11574ElbasvirElbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].
DB12483CopanlisibIndicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
DB12001Abemaciclib* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
DB11817BaricitinibIndicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.
DB13074MacimorelinIndicated for the diagnosis of adult growth hormone deficiency (AGHD) [FDA Label].
DB09223BlonanserinUsed for the treatment of schizophrenia [L1097].
DB01420Testosterone propionateTestosterone propionate is often used for muscle mass building. The original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropause.[L1161] Nowadays testosterone propionate is indicated for its use in heifers in order to stimulate maximal growth.[L1160]
DB11799BictegravirBictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine [L1219, L1220].
DB11712TezacaftorTezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis (CF) in patients aged 12 years or older with two copies of the _F508del_ gene mutation or at least one mutation in the CFTR gene that is responsive to this drug.[L6814]
DB11251TocopherolTocopherol can be used as a dietary supplement for patients with a deficit of vitamin E; this is mainly prescribed in the alpha form.[A32443] Vitamin E deficiency is rare, and it is primarily found in premature babies of very low birth weight, patients with fat malabsorption or patients with abetalipoproteinemia.[L2120] Tocopherol, due to its antioxidant properties, is studied for its use in prevention or treatment in different complex diseases such as cancer,[A32436] atherosclerosis, cardiovascular diseases,[A32442] and age-related macular degeneration.[A32444]
DB14003alpha-Tocopherol acetateThe primary health-related use for which alpha-tocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin E deficiency. At the same time, vitamin E deficiency is generally quite rare but may occur in premature babies of very low birth weight (< 1500 grams), individuals with fat-malabsorption disorders (as fat is required for the digestive tract to absorb vitamin E), or individuals with abetalipoproteinemia - a rare, inherited disorder that causes poor absorption of dietary fat - who require extremely large doses of supplemental vitamin E daily (around 100 mg/kg or 5-10 g/day) [L2120]. In all such cases, alpha-tocopherol is largely the preferred form of vitamin E to be administered. Elsewhere, vitamin E's chemical profile as a fat-soluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin E possesses like cardiovascular diseases, diabetes, ocular conditions, immune illnesses, cancer, and more [T166]. None of these ongoing studies have yet to elucidate any formally significant evidence, however [T166].
DB12278PropiverineIndicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) [L2315]. Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury [A32581].
DB11641VinflunineFor use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy [L2381].
DB11635TocofersolanTocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age [L2371].
DB11637DelamanidIndicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability [L1407].
DB14019FosnetupitantIndicated in combination palonosetron (as the drug Akynzeo) and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy [FDA label]. The following are indications listed on the EMA label [F29]: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy [F29]. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy [F29].
DB11274Dihydro-alpha-ergocryptineAlpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease[A32980] as well as for its use in migraine prophylaxis,[A32983] treatment of low blood pressure and peripheral vascular disorder. To know more about the ergoloid mesylate mixture and its uses please visit [DB01049].
DB13456MidecamycinMidecamycin was used for the treatment of infections in the oral cavity, upper and lower respiratory tracts and skin and soft tissue infections. The alone use of midecamycin was mainly used in Europe or Japan.[T207]
DB14583Segesterone acetateSegesterone acetate in combination with ethinyl estradiol is indicated for use by females of reproductive potential to prevent pregnancy as a combination hormonal contraceptive (CHC). It induces contraception for thirteen 28-day cycles (1 year) following vaginal administration. The vaginal system must remain in place continuously for 3 weeks (21 days) followed by a 1-week (7-day) vaginal system-free interval. The use in females with a body mass index of >29 kg/m^2 has not been adequately evaluated [FDA Label].
DB09065CobicistatCobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
DB00563MethotrexateMethotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150] Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]
DB08882LinagliptinLinagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].
DB05239CobimetinibFor the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.
DB09330OsimertinibOsimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.
DB09063CeritinibCeritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB11730RibociclibKisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
DB09079NintedanibIn the US, nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF)[L8453] and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.[L8462] In the EU, nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic, locally advanced, or locally recurrent non-small cell lung cancer of adenocarcinoma histology who have already tried first-line therapy.[L8459]
DB01656RoflumilastRoflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
DB09034SuvorexantSuvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
DB09030VorapaxarVorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB01411PranlukastUsed as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
DB12329EravacyclineThis drug is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older [FDA label].
DB06717FosaprepitantFor the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
DB06419CethromycinInvestigated for use/treatment in bacterial infection, pediatric indications, and pneumonia.
DB12301DoravirineDoravirine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history [FDA Label].
DB11952DuvelisibDuvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.[L4586] The CLL is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells. In leukemia, there is an overproduction of cells that are abnormal and do not mature into blood cells and thus, they just crowd out normal cells and impair their normal function. In lymphocyte leukemia, the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes. The CLL is the type of lymphocytic leukemia that develops slowly over months or years.[L4587] The SLL is a very similar disease to the CLL and these terms are usually referred interchangeably. The only difference between these two diseases is that in CLL the cells are found mostly in the blood and bone marrow while in SLL, the cells are mainly found in the lymph nodes.[L4588] As well, duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. This approval is still under the status of continued approval and it is restrained to confirmatory trials.[L4586] The follicular lymphoma is a B-cell lymphoma that clusters in the lymph nodes or other tissues.[L4589]
DB14568IvosidenibIvosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test [FDA Label].
DB126293,5-diiodothyropropionic acidNot Available
DB014565-androstenedioneNot Available
DB00240AlclometasoneFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB04630AldosteroneNot Available
DB00288AmcinonideFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB01536AndrostenedioneNot Available
DB00394Beclomethasone dipropionateIndicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.[L6871] Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.[L6880] Indicated for topical use to manage corticosteroid-responsive dermatoses, such as psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (infantile eczema, allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, anogenital and senile pruritus.[L6886]
DB11750ClobetasolNot Available
DB01013Clobetasol propionateFor short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
DB13158ClobetasoneIn dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.
DB04652CorticosteroneNot Available
DB01285CorticotropinFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB04839Cyproterone acetateFor the palliative treatment of patients with advanced prostatic carcinoma.
DB11636NomegestrolNot Available
DB13981Nomegestrol acetateNot Available
DB01260DesonideFor the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
DB06780Desoxycorticosterone acetateNot Available
DB01134Desoxycorticosterone pivalateExamined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
DB09095DifluocortoloneDifluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis. All these disorders present as a common characteristic the occurrence of symptoms as itching, swelling, redness and scaling.[L1083]
DB06781DifluprednateFor the treatment of inflammation and pain associated with ocular surgery.
DB00378DydrogesteroneUsed to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.
DB03515EquileninNot Available
DB02187EquilinFor the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)
DB13866EtynodiolNot Available
DB00823Ethynodiol diacetateFor the prevention of pregnancy in women who elect to use this product as a method of contraception.
DB00687FludrocortisoneFludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.[L8971]
DB00663FlumethasoneFor the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions
DB00591Fluocinolone acetonideFluocinolone acetonide has been used extensively in different medical areas. -In dermatology, it is extensively used for the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis.[F1955] -It has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalp.[L4682] -In ear drops, it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older.[L4683] -As an intravitreal implant, it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure.[L4684] -Fluocinolone acetonide was announced on October 15, 2018 to be FDA approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.[L4685] -Some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of first-degree hemorrhoids.[A39532]
DB01047FluocinonideA topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB08970FluprednideneNot Available
DB09378FluprednisoloneNot Available
DB00846FlurandrenolideFor relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions
DB06730GestodeneNot Available
DB06786HalcinonideIndicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB05212HE3286For the treatment of rheumatoid arthritis and type 2 diabetes.
DB14545Hydrocortisone succinateNot Available
DB14570HydroxyprogesteroneNot Available
DB00007LeuprolideFor treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
DB01583LiotrixMay be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy.
DB14596Loteprednol etabonateA number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label].
DB09124MedrogestoneMedrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.[T76]
DB00253MedrysoneFor the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.
DB00351Megestrol acetateFor the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
DB11529MelengestrolNot Available
DB09383MeprednisoneNot Available
DB00764MometasoneThe inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
DB14512Mometasone furoateThere are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 years[FDA Label]. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years[F4292]. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years[F4295].
DB06713NorelgestrominNorelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
DB09371NorethynodrelNot Available
DB01130PrednicarbateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB13208PrednylideneNot Available
DB02789PregnenoloneNot Available
DB13602PromegestoneNot Available
DB00896RimexoloneFor the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
DB01108TrilostaneUsed in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
DB01117AtovaquoneFor the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.
DB11619GestrinoneEndometriosis with or without accompanying sterility. Treatment is limited to a single course of 6 months duration per lifetime [L1699, L1700].
DB13528ChlormadinoneNot Available
DB13685QuingestanolNot Available
DB13857DemegestoneNot Available
DB08838AgmatineAgmatine is being studied experimentally for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma, and neuropathic pain), and psychiatric conditions (depression, anxiety, schizophrenia, and cognition). As an investigational drug, agamatine is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy.
DB01241GemfibrozilGemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
DB08953IndalpineNot Available
DB04896MilnacipranMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above [F3925]. While milnacipran may be used for the treatment of major depressive disorder (MDD), it is only recommended in adult patients who are 18 years old or above [F3922] due to an increased risk for suicidal ideation, thinking, and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. Some regional prescribing information notes that the use of the medication is specifically for the short-term symptomatic relief of MDD [F3919]. Nevertheless, it is important to note that the regulatory approval of and/or indications listed here for milnacipran may or may not exist and/or vary greatly between regions and nations [F3928, F3934].
DB09229AranidipineAranidipine has been used for many years to treat angina pectoris and hypertension.[A31895]
DB00339PyrazinamideFor the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
DB09078LenvatinibLenvatinib is indicated for the treatment of following conditions. - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DB06201RufinamideAdjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
DB00186LorazepamLorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
DB125159-aminocamptothecinNot Available
DB12952MethylprednisoneNot Available
DB14723LarotrectinibLarotrectinib is a tyrosine kinase inhibitor that is currently indicated for the treatment of adult and pediatric patients with solid tumors that either a) have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, b) are metastatic or where surgical resection is likely to result in severe morbidity, and c) have no satisfactory alternative treatments or that have progressed following treatment [FDA Label]. At the moment, these uses of larotrectinib are only approved under the auspices of an accelerated approval by the US FDA based on overall response rate and duration of response and continuation of support for these indications may be contingent upon the verification and description of continued clinical benefit in confirmatory trials [FDA Label].
DB12141GilteritinibGilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay.[L4830] Acute myeloid leukemia is cancer that impacts the blood and bone marrow with a rapid progression. This condition produces low numbers of normal blood cells and the requirement of continuous need for transfusions.[L4832]
DB12537BenzodiazepineNot Available
DB09017BrotizolamBrotizolam is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.
DB11094Vitamin DVitamin D is indicated for use in the treatment of hypoparathyroidism, refractory rickets (also known as vitamin D resistant rickets), and familial hypophosphatemia [FDA Label].
DB054827-ethyl-10-hydroxycamptothecinInvestigated for use/treatment in colorectal cancer.
DB00273TopiramateTopiramate is indicated for the following conditions: - Monotherapy for partial onset or primary generalized tonic-clonic seizures in patients over 2 years of age. - Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for adult and pediatric patients. - Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients over 2 years of age. - Prophylaxis of migraine headache in adults.[FDA label] A seizure is an abnormal, unregulated electrical discharge occurring in the brain's cortical gray matter. This electrical response produces a transient interruption in the normal brain function which in order produces altered awareness, abnormal sensations, focal involuntary movements or convulsions. The type of seizure can be classified according to the type of onset followed by a type of seizure.[L5548] A migraine headache is a [ulsating or throbbing pain that can be presented in one of both sides of the head and it can be worsened by external stimuli such as physical activity, light, sounds, and odors.[L5551] Topiramate has been commonly investigated and used off-label for weight reduction in patients with obesity or diabetes.[A175240]
DB06480PrucalopridePrucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.[L4882] CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following: -Straining during more than 25% of the bowel movements. -Lumpy or hard stools in 25% of the bowel movements. -Sensation of incomplete evacuation in more than 25% of all bowel movements. -Sensation of anorectal blockage or obstruction in more than 25% of the bowel movements. -Manual maneuvers required in more than 25% of the bowel movements. -Fewer than 3 bowel movements per week.[L4883]
DB00254DoxycyclineDoxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry [FDA label]. The following are some of the major infections that may be treated with doxycycline [FDA label]: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible [FDA label].
DB00191PhenterminePhentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia.[FDA label] Exogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants. This condition commonly causes an increase in fat storage. It is an epidemic condition in the United States where over two-thirds of adults are overweight or obese and one in three Americans is obese. In the world, the incidence of obesity has nearly doubled.[A174391]
DB09299Tenofovir alafenamideTenofovir alafenamide is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease.[L6241] In combination with [emtricitabine] and other antiretrovirals, it is indicated for the treatment of HIV-1 infection in patients with a weight higher than 35 kg. When combined with antiretrovirals other than protease inhibitors that require a CYP3A inhibitor, it can be used in pediatric patients weighing between 25 and 35 kg.[L4388] In the combination product with emtricitabine and [bictegravir], tenofovir alafenamide is considered as a complete regimen for the treatment of HIV-1 infection in treatment-naive patients or in patients virologically suppressed for at least 3 months with no history of treatment failure.[L6277] Additionally, the combination product including [elvitegravir], [cobicistat], emtricitabine and tenofovir alafenamide and the combination product including emtricitabine, [rilpivirine] and tenofovir alafenamide can be used in the treatment of HIV-1 infection in patients older than 12 years with no previous antiretroviral therapy history or who are virologically suppressed for at least 6 months with no history of treatment failure.[L6280] The combination product including [darunavir], cobicistat, emtricitabine, and tenofovir alafenamide is indicated for the treatment of HIV-1 infection in adults without prior antiretroviral therapy or in patients virologically suppressed for 6 months and no reported resistance to darunavir or tenofovir.[L6283] Tenofovir alafenamid is also combined with [emtricitabine] for the prevention of HIV-1 infections in high risk adolescents and adults excluding those who have receptive vaginal sex.[L9010]
DB14126TenofovirTenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.[A178330] To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
DB12015AlpelisibAlpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer.[Label] This cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA­ mutated.[Label] The cancer must be detected by an FDA-approved test following progression on or after an endocrine-based regimen.[Label]
DB11942SelinexorSelinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone.[label] Patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
DB00257Clotrimazole**Topical preparations** Clotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]: Tinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_ Candidiasis due to _Candida albicans_ Tinea versicolor due to _Malassezia furfur_ Diaper rash infected by _Candida albicans_ In some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121]. **Oral preparations** The oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label]. It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].
DB00163Vitamin EVitamin E supplementation is indicated for treatment of vitamin E deficiency which can occur in cystic fibrosis, cholestasis and severe liver disease, abetalipoproteinemia or simply poor diet[A176104,L3063].
DB00982IsotretinoinIsotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.[Label,L6579]
DB00989RivastigmineFor the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
DB06282LevocetirizineLevocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]
DB12978PexidartinibPexidartinib is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.[L7883]
DB00905BimatoprostBimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.[L6877] Bimatoprost is also indicated to treat eyelash hypotrichosis.[L6910]
DB05154PretomanidPretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrug-resistant (MDR), extensively drug-resistant (XDR), and treatment-intolerant forms of pulmonary tuberculosis (TB).[L8048] It is important to note that the following conditions are not approved indications for pretomanid therapy, according to the FDA[L8048]: Drug-sensitive (DS) tuberculosis, latent tuberculosis caused by M.tuberculosis, extra-pulmonary tuberculosis caused by M.tuberculosis, and multidrug-resistant TB that is not treatment-intolerant or nonresponsive to conventional TB therapy.
DB01611HydroxychloroquineHydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by _P. falciparum_, _P. malariae_, _P. ovale_, or _P. vivax_), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.[L8072]
DB11986EntrectinibEntrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults.[L8081] Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available.
DB00752TranylcypromineFor the treatment of major depressive episode without melancholia.
DB12825LefamulinLefamulin is indicated to treat adults diagnosed with community-acquired bacterial pneumonia (CABP) that is caused by susceptible bacteria. Its use should be reserved for confirmed susceptible organisms or a high probability of infection with susceptible organisms. The list of susceptible bacteria includes Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible), Legionella pneumophila, Haemophilus influenza, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.[L8093]
DB00301FlucloxacillinUsed to treat bacterial infection by susceptible microorganisms.
DB15489MexazolamMexazolam is indicated for the treatment of anxiety with or without psychoneurotic conditions.[A184910]
DB04886Calanolide AFor use in combination treatment of HIV infection (AIDS).
DB04934RifalazilInvestigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease.
DB12240Polatuzumab vedotinThis medication is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapies.[Label]
DB09237LevamlodipineFor the treatment of hypertension and angina [L1483].
DB14637Fluprednisolone acetateNot Available
DB13997Baloxavir marboxilFor the treatment of influenza A and B virus infection [L1473, L1475], [FDA label] in patients 12 and older who have been symptomatic for no more than 48 hours. Clinical trials of this drug did not include subjects 65 years of age and older to determine whether they respond in a different way than younger subjects [FDA label].
DB11761TenapanorTenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults.[L8558] It is also currently being investigated as a treatment for hyperphosphatemia in chronic kidney disease patients undergoing dialysis (NCT02081534 and NCT02675998).[A185489]
DB01217AnastrozoleAnastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]
DB12808TrifaroteneTrifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.[L9013]
DrugDrug NameTargetType
DB00188BortezomibCytochrome P450 3A4enzyme
DB00188BortezomibCytochrome P450 2C19enzyme
DB00188BortezomibCytochrome P450 1A2enzyme
DB00188BortezomibCytochrome P450 2D6enzyme
DB00188BortezomibCytochrome P450 2C9enzyme
DB00188BortezomibProteasome subunit beta type-5target
DB00188BortezomibProteasome subunit beta type-1target
DB00201CaffeineAdenosine receptor A1target
DB00201CaffeinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00201CaffeineAdenosine receptor A2atarget
DB00201CaffeineCytochrome P450 1A2enzyme
DB00201CaffeineRyanodine receptor 1target
DB00201CaffeineCytochrome P450 3A4enzyme
DB00201CaffeineCytochrome P450 3A5enzyme
DB00201CaffeineCytochrome P450 3A7enzyme
DB00201CaffeineCytochrome P450 2E1enzyme
DB00201CaffeineCytochrome P450 2C8enzyme
DB00201CaffeineCytochrome P450 2C9enzyme
DB00201CaffeineCytochrome P450 1A1enzyme
DB00201CaffeineCytochrome P450 1B1enzyme
DB00201CaffeineCytochrome P450 2D6enzyme
DB00201CaffeineCyclic nucleotide phosphodiesterasetarget
DB00201CaffeineDNA-dependent protein kinase catalytic subunittarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformtarget
DB00201CaffeineInositol 1,4,5-trisphosphate receptortarget
DB00201CaffeineSerine-protein kinase ATMtarget
DB00201CaffeineATP-binding cassette sub-family G member 2transporter
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00261AnagrelideCytochrome P450 1A2enzyme
DB00268RopiniroleDopamine D2 receptortarget
DB00268RopiniroleDopamine D3 receptortarget
DB00268RopiniroleDopamine D4 receptortarget
DB00268RopiniroleCytochrome P450 1A2enzyme
DB00268RopiniroleAlpha adrenergic receptortarget
DB00277TheophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00277TheophyllineAdenosine receptor A2btarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00277TheophyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00277TheophyllineAdenosine receptor A1target
DB00277TheophyllineAdenosine receptor A2atarget
DB00277TheophyllineCytochrome P450 1A2enzyme
DB00277TheophyllineAdenosine deaminaseenzyme
DB00277TheophyllineCytochrome P450 2E1enzyme
DB00277TheophyllineCytochrome P450 3A4enzyme
DB00277TheophyllineSolute carrier family 22 member 7transporter
DB00277TheophyllineCytochrome P450 1A1enzyme
DB00277TheophyllineCytochrome P450 1B1enzyme
DB00277TheophyllineCytochrome P450 2D6enzyme
DB00277TheophyllineHistone deacetylase 2target
DB00277TheophyllineCopine-1target
DB00277TheophyllineMinor histocompatibility antigen H13target
DB00277TheophyllineNodal modulator 1target
DB00277TheophyllinePoly [ADP-ribose] polymerase 1target
DB00277TheophyllineProtein RIC-3target
DB00277TheophyllineTubulin monoglycylase TTLL3target
DB00281LidocaineSodium channel protein type 5 subunit alphatarget
DB00281LidocaineSodium channel protein type 10 subunit alphatarget
DB00281LidocaineEpidermal growth factor receptortarget
DB00281LidocaineSodium channel protein type 9 subunit alphatarget
DB00281LidocaineCytochrome P450 1A2enzyme
DB00281LidocaineCytochrome P450 2D6enzyme
DB00281LidocaineCytochrome P450 3A4enzyme
DB00281LidocaineCytochrome P450 3A5enzyme
DB00281LidocaineCytochrome P450 3A7enzyme
DB00281LidocaineSolute carrier family 22 member 5transporter
DB00281LidocaineP-glycoprotein 1transporter
DB00281LidocaineCytochrome P450 2A6enzyme
DB00281LidocaineCytochrome P450 2B6enzyme
DB00281LidocaineCytochrome P450 2C8enzyme
DB00281LidocaineCytochrome P450 2C9enzyme
DB00281LidocaineSodium channel protein type 4 subunit alphatarget
DB00281LidocaineAlpha-1-acid glycoprotein 1target
DB00281LidocaineAlpha-1-acid glycoprotein 2target
DB00286Conjugated estrogensEstrogen receptor alphatarget
DB00286Conjugated estrogensCytochrome P450 3A4enzyme
DB00286Conjugated estrogensCytochrome P450 1A2enzyme
DB00286Conjugated estrogensCatechol O-methyltransferaseenzyme
DB00286Conjugated estrogensCanalicular multispecific organic anion transporter 2transporter
DB00286Conjugated estrogensMultidrug resistance-associated protein 4transporter
DB00286Conjugated estrogensMultidrug resistance-associated protein 1transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 1A2transporter
DB00286Conjugated estrogensSodium/bile acid cotransportertransporter
DB00286Conjugated estrogensSolute carrier family 22 member 10transporter
DB00286Conjugated estrogensSolute carrier family 22 member 8transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 1C1transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 1B1transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 2B1transporter
DB00286Conjugated estrogensP-glycoprotein 1transporter
DB00286Conjugated estrogensSolute carrier family 22 member 6transporter
DB00286Conjugated estrogensOrganic solute transporter subunit alphatransporter
DB00286Conjugated estrogensOrganic solute transporter subunit betatransporter
DB00286Conjugated estrogensCanalicular multispecific organic anion transporter 1transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 4A1transporter
DB00286Conjugated estrogensATP-binding cassette sub-family C member 11transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 1B3transporter
DB00286Conjugated estrogensSolute carrier family 22 member 11transporter
DB00286Conjugated estrogensSolute carrier organic anion transporter family member 3A1transporter
DB00286Conjugated estrogensATP-binding cassette sub-family G member 2transporter
DB00286Conjugated estrogensThyroxine-binding globulincarrier
DB00286Conjugated estrogensSex hormone-binding globulincarrier
DB00286Conjugated estrogensSerum albumincarrier
DB00286Conjugated estrogensEstrogen receptor betatarget
DB00296RopivacaineSodium channel protein type 10 subunit alphatarget
DB00296RopivacaineCytochrome P450 1A2enzyme
DB00296RopivacaineCytochrome P450 2B6enzyme
DB00296RopivacaineCytochrome P450 3A4enzyme
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Dtarget
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Btarget
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Ftarget
DB00315ZolmitriptanCytochrome P450 1A2enzyme
DB00315ZolmitriptanAmine oxidase [flavin-containing] Aenzyme
DB00315Zolmitriptan5-hydroxytryptamine receptor 1Atarget
DB00321AmitriptylineSodium-dependent serotonin transportertarget
DB00321AmitriptylineSodium-dependent noradrenaline transportertarget
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 2target
DB00321AmitriptylineAlpha-2A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 1A2enzyme
DB00321AmitriptylineCytochrome P450 2C19enzyme
DB00321AmitriptylineCytochrome P450 2D6enzyme
DB00321AmitriptylineSerum albumincarrier
DB00321AmitriptylineAlpha-1-acid glycoprotein 1carrier
DB00321AmitriptylineHistamine H1 receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 2Atarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Atarget
DB00321AmitriptylineAlpha-1A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 3A4enzyme
DB00321AmitriptylineCytochrome P450 3A5enzyme
DB00321AmitriptylinePotassium voltage-gated channel subfamily A member 1target
DB00321AmitriptylineAlpha-1D adrenergic receptortarget
DB00321AmitriptylineDelta-type opioid receptortarget
DB00321AmitriptylineKappa-type opioid receptortarget
DB00321AmitriptylineHigh affinity nerve growth factor receptortarget
DB00321AmitriptylineBDNF/NT-3 growth factors receptortarget
DB00321AmitriptylineCytochrome P450 2C9enzyme
DB00321AmitriptylineCytochrome P450 2B6enzyme
DB00321AmitriptylineCytochrome P450 2C8enzyme
DB00321AmitriptylineHistamine H2 receptortarget
DB00321AmitriptylineHistamine H4 receptortarget
DB00321AmitriptylineSigma non-opioid intracellular receptor 1target
DB00321Amitriptyline5-hydroxytryptamine receptor 2Ctarget
DB00321AmitriptylineAlpha-1B adrenergic receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 7target
DB00321Amitriptyline5-hydroxytryptamine receptor 1Dtarget
DB00321AmitriptylineMu-type opioid receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Btarget
DB00321Amitriptyline5-hydroxytryptamine receptor 6target
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 3target
DB00321AmitriptylineUDP-glucuronosyltransferase 1-1enzyme
DB00321Amitriptyline5-hydroxytryptamine receptor 1Ctarget
DB00321AmitriptylineMuscarinic acetylcholine receptortarget
DB00321AmitriptylineHERG human cardiac K+ channeltarget
DB00321AmitriptylineP-glycoprotein 1transporter
DB00334OlanzapineDopamine D1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineDopamine D4 receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineDopamine D2 receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineDopamine D3 receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineDopamine D5 receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineP-glycoprotein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineBeta adrenergic receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 1target
DB00334OlanzapineGABA-A receptor (benzodiazepine site)target
DB00334OlanzapineCytochrome P450 2C9enzyme
DB00334OlanzapineUDP-glucuronosyltransferase 1-4enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334OlanzapineCYP3Aenzyme
DB00363ClozapineDopamine D4 receptortarget
DB00363ClozapineHistamine H1 receptortarget
DB00363ClozapineDopamine D2 receptortarget
DB00363ClozapineNeuron-specific vesicular protein calcyontarget
DB00363ClozapineHistamine H4 receptortarget
DB00363Clozapine5-hydroxytryptamine receptor 2Atarget
DB00363Clozapine5-hydroxytryptamine receptor 1Atarget
DB00363Clozapine5-hydroxytryptamine receptor 2Ctarget
DB00363ClozapineDopamine D1 receptortarget
DB00363ClozapineCytochrome P450 1A2enzyme
DB00363ClozapineCytochrome P450 2D6enzyme
DB00363ClozapineDopamine D3 receptortarget
DB00363ClozapineMuscarinic acetylcholine receptor M1target
DB00363ClozapineMuscarinic acetylcholine receptor M2target
DB00363ClozapineMuscarinic acetylcholine receptor M3target
DB00363ClozapineMuscarinic acetylcholine receptor M4target
DB00363ClozapineMuscarinic acetylcholine receptor M5target
DB00363Clozapine5-hydroxytryptamine receptor 1Btarget
DB00363Clozapine5-hydroxytryptamine receptor 1Dtarget
DB00363Clozapine5-hydroxytryptamine receptor 1Etarget
DB00363Clozapine5-hydroxytryptamine receptor 3Atarget
DB00363Clozapine5-hydroxytryptamine receptor 6target
DB00363Clozapine5-hydroxytryptamine receptor 7target
DB00363ClozapineAlpha-1A adrenergic receptortarget
DB00363ClozapineAlpha-1B adrenergic receptortarget
DB00363ClozapineAlpha-2A adrenergic receptortarget
DB00363ClozapineAlpha-2B adrenergic receptortarget
DB00363ClozapineAlpha-2C adrenergic receptortarget
DB00363ClozapineCytochrome P450 2C9enzyme
DB00363ClozapineP-glycoprotein 1transporter
DB00363ClozapineCytochrome P450 3A4enzyme
DB00363ClozapineCytochrome P450 2C19enzyme
DB00363ClozapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00363ClozapineUDP-glucuronosyltransferase 1-4enzyme
DB00363ClozapineCytochrome P450 1A1enzyme
DB00363ClozapineCytochrome P450 2A6enzyme
DB00363ClozapineCytochrome P450 2C8enzyme
DB00363ClozapineGlutathione S-transferase Ptarget
DB00365GrepafloxacinDNA gyrase subunit Atarget
DB00365GrepafloxacinDNA topoisomerase 4 subunit Atarget
DB00365GrepafloxacinCytochrome P450 3A4enzyme
DB00365GrepafloxacinCytochrome P450 1A2enzyme
DB00365GrepafloxacinSolute carrier family 22 member 2transporter
DB00365GrepafloxacinSolute carrier family 22 member 5transporter
DB00365GrepafloxacinCanalicular multispecific organic anion transporter 1transporter
DB00365GrepafloxacinP-glycoprotein 1transporter
DB00365GrepafloxacinMultidrug resistance-associated protein 1transporter
DB00365GrepafloxacinSolute carrier family 22 member 6transporter
DB00370Mirtazapine5-hydroxytryptamine receptor 2Atarget
DB00370Mirtazapine5HT3 serotonin receptortarget
DB00370MirtazapineAlpha-2A adrenergic receptortarget
DB00370Mirtazapine5-hydroxytryptamine receptor 2Ctarget
DB00370MirtazapineKappa-type opioid receptortarget
DB00370MirtazapineHistamine H1 receptortarget
DB00370MirtazapineCytochrome P450 1A2enzyme
DB00370MirtazapineCytochrome P450 3A4enzyme
DB00370MirtazapineCytochrome P450 2D6enzyme
DB00370MirtazapineAlpha-1 adrenergic receptorstarget
DB00370MirtazapineSodium-dependent serotonin transportertransporter
DB00379MexiletineSodium channel protein type 5 subunit alphatarget
DB00379MexiletineCytochrome P450 1A2enzyme
DB00379MexiletineCytochrome P450 2D6enzyme
DB00379MexiletineCytochrome P450 2B6enzyme
DB00379MexiletineCytochrome P450 2E1enzyme
DB00379MexiletineCytochrome P450 3A4enzyme
DB00379MexiletineAryl hydrocarbon receptortarget
DB00382TacrineAcetylcholinesterasetarget
DB00382TacrineCytochrome P450 1A2enzyme
DB00382TacrineCholinesterasetarget
DB00382TacrineP-glycoprotein 1transporter
DB00382TacrineLiver carboxylesterase 1target
DB00458ImipramineSodium-dependent noradrenaline transportertarget
DB00458ImipramineSodium-dependent serotonin transportertarget
DB00458ImipramineCytochrome P450 1A2enzyme
DB00458ImipramineCytochrome P450 2C19enzyme
DB00458ImipramineCytochrome P450 2D6enzyme
DB00458ImipramineHistamine H1 receptortarget
DB00458ImipramineAlpha-1A adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 2Atarget
DB00458ImipramineMuscarinic acetylcholine receptor M1target
DB00458ImipramineMuscarinic acetylcholine receptor M2target
DB00458ImipramineMuscarinic acetylcholine receptor M3target
DB00458ImipramineMuscarinic acetylcholine receptor M4target
DB00458ImipramineMuscarinic acetylcholine receptor M5target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 2target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 3target
DB00458ImipramineAlpha-1D adrenergic receptortarget
DB00458ImipramineAlpha-1-acid glycoprotein 1carrier
DB00458ImipramineSolute carrier family 22 member 2transporter
DB00458ImipramineSolute carrier family 22 member 3transporter
DB00458ImipramineP-glycoprotein 1transporter
DB00458ImipramineSolute carrier family 22 member 4transporter
DB00458ImipramineCytochrome P450 3A4enzyme
DB00458ImipramineCytochrome P450 2B6enzyme
DB00458ImipramineCytochrome P450 2C18enzyme
DB00458ImipramineCytochrome P450 2E1enzyme
DB00458ImipramineCytochrome P450 3A7enzyme
DB00458Imipramine5-hydroxytryptamine receptor 2Ctarget
DB00458ImipramineAlpha-1B adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 7target
DB00458ImipramineD(1) dopamine receptortarget
DB00458ImipramineDopamine D2 receptortarget
DB00458ImipraminePotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent dopamine transportertarget
DB00458Imipramine5-hydroxytryptamine receptor 1Atarget
DB00458Imipramine5-hydroxytryptamine receptor 6target
DB00458ImipraminePotassium voltage-gated channel subfamily H member 1target
DB00458ImipramineSerum albumincarrier
DB00458ImipramineAlpha-1-acid glycoprotein 2target
DB00476DuloxetineSodium-dependent serotonin transportertarget
DB00476DuloxetineSodium-dependent dopamine transportertarget
DB00476DuloxetineSodium-dependent noradrenaline transportertarget
DB00476DuloxetineCytochrome P450 1A2enzyme
DB00476DuloxetineCytochrome P450 2D6enzyme
DB00476DuloxetineCytochrome P450 2C9enzyme
DB00476DuloxetineSerum albumincarrier
DB00476Duloxetinealpha1-acid glycoproteincarrier
DB00476DuloxetineP-glycoprotein 1transporter
DB00499FlutamideAndrogen receptortarget
DB00499FlutamideCytochrome P450 1A2enzyme
DB00499FlutamideCytochrome P450 3A4enzyme
DB00499FlutamideCytochrome P450 1A1enzyme
DB00499FlutamideCytochrome P450 1B1enzyme
DB00499FlutamideCytochrome P450 2C19enzyme
DB00499FlutamideCytochrome P450 3A5enzyme
DB00499FlutamideAryl hydrocarbon receptortarget
DB00499FlutamideNuclear receptor subfamily 1 group I member 2target
DB00502HaloperidolDopamine D2 receptortarget
DB00502HaloperidolGlutamate receptor ionotropic, NMDA 2Btarget
DB00502HaloperidolDopamine D1 receptortarget
DB00502HaloperidolCytochrome P450 1A2enzyme
DB00502HaloperidolCytochrome P450 2D6enzyme
DB00502Haloperidol5-hydroxytryptamine receptor 2Atarget
DB00502HaloperidolDopamine D3 receptortarget
DB00502HaloperidolCytochrome P450 3A4enzyme
DB00502HaloperidolCytochrome P450 3A5enzyme
DB00502HaloperidolCytochrome P450 3A7enzyme
DB00502HaloperidolP-glycoprotein 1transporter
DB00502HaloperidolCarbonyl reductase [NADPH] 1enzyme
DB00502HaloperidolUDP-glucuronosyltransferase 1-9enzyme
DB00502HaloperidolCytochrome P450 2C19enzyme
DB00502HaloperidolCytochrome P450 2C9enzyme
DB00502HaloperidolMelanin-concentrating hormone receptor 1target
DB00502HaloperidolSynaptic vesicular amine transportertarget
DB00502Haloperidol5-hydroxytryptamine receptor 2Ctarget
DB00502HaloperidolSigma non-opioid intracellular receptor 1target
DB00502HaloperidolHistamine H1 receptortarget
DB00502HaloperidolMuscarinic acetylcholine receptor M3target
DB00502HaloperidolAlpha-1A adrenergic receptortarget
DB00502HaloperidolAlpha-2A adrenergic receptortarget
DB00502HaloperidolAlpha-2B adrenergic receptortarget
DB00502HaloperidolAlpha-2C adrenergic receptortarget
DB00502Haloperidol5-hydroxytryptamine receptor 1Atarget
DB00502Haloperidol5-hydroxytryptamine receptor 6target
DB00502Haloperidol5-hydroxytryptamine receptor 7target
DB00502HaloperidolCytochrome P450 1A1enzyme
DB00540NortriptylineSodium-dependent serotonin transportertarget
DB00540NortriptylineSodium-dependent noradrenaline transportertarget
DB00540NortriptylineCytochrome P450 1A2enzyme
DB00540NortriptylineCytochrome P450 2D6enzyme
DB00540NortriptylineSerum albumincarrier
DB00540NortriptylineAlpha-1-acid glycoprotein 1carrier
DB00540NortriptylineHistamine H1 receptortarget
DB00540NortriptylineMuscarinic acetylcholine receptor M1target
DB00540NortriptylineMuscarinic acetylcholine receptor M2target
DB00540NortriptylineMuscarinic acetylcholine receptor M3target
DB00540NortriptylineMuscarinic acetylcholine receptor M4target
DB00540NortriptylineMuscarinic acetylcholine receptor M5target
DB00540Nortriptyline5-hydroxytryptamine receptor 2Atarget
DB00540NortriptylineAlpha-1A adrenergic receptortarget
DB00540Nortriptyline5-hydroxytryptamine receptor 1Atarget
DB00540NortriptylineCytochrome P450 3A4enzyme
DB00540NortriptylineCytochrome P450 3A5enzyme
DB00540NortriptylineAlpha-1D adrenergic receptortarget
DB00540NortriptylineCytochrome P450 2C19enzyme
DB00540NortriptylineProstaglandin G/H synthase 1enzyme
DB00540NortriptylineCytochrome P450 2E1enzyme
DB00540Nortriptyline5-hydroxytryptamine receptor 2Ctarget
DB00540Nortriptyline5-hydroxytryptamine receptor 6target
DB00540NortriptylineAlpha-1B adrenergic receptortarget
DB00540NortriptylineAlpha-2 adrenergic receptorstarget
DB00540NortriptylineBeta adrenergic receptortarget
DB00540NortriptylineDopamine D2 receptortarget
DB00540NortriptylineSigma receptortarget
DB00540Nortriptyline5-hydroxytryptamine receptor 1Ctarget
DB00544FluorouracilThymidylate synthasetarget
DB00544FluorouracilCytochrome P450 1A2enzyme
DB00544FluorouracilThymidine phosphorylaseenzyme
DB00544FluorouracilSerum albumincarrier
DB00544FluorouracilCytochrome P450 2C9enzyme
DB00544FluorouracilDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB00544FluorouracilUridine phosphorylase 1enzyme
DB00544FluorouracilUridine phosphorylase 2enzyme
DB00544FluorouracilDNAtarget
DB00544FluorouracilRNAtarget
DB00544FluorouracilCytochrome P450 2A6enzyme
DB00544FluorouracilCytochrome P450 2C8enzyme
DB00544FluorouracilMethylenetetrahydrofolate reductaseenzyme
DB00544FluorouracilThymidylate synthaseenzyme
DB00544FluorouracilUridine 5'-monophosphate synthaseenzyme
DB00544FluorouracilAmidophosphoribosyltransferaseenzyme
DB00544FluorouracilSolute carrier family 22 member 7transporter
DB00544FluorouracilEquilibrative nucleoside transporter 1transporter
DB00544FluorouracilATP-binding cassette sub-family G member 2transporter
DB00544FluorouracilCanalicular multispecific organic anion transporter 2transporter
DB00544FluorouracilMultidrug resistance-associated protein 4transporter
DB00544FluorouracilMultidrug resistance-associated protein 5transporter
DB00544FluorouracilThyroxine-binding globulincarrier
DB00571PropranololBeta-1 adrenergic receptortarget
DB00571PropranololBeta-2 adrenergic receptortarget
DB00571PropranololBeta-3 adrenergic receptortarget
DB00571Propranolol5-hydroxytryptamine receptor 1Atarget
DB00571Propranolol5-hydroxytryptamine receptor 1Btarget
DB00571PropranololCytochrome P450 1A2enzyme
DB00571PropranololCytochrome P450 2D6enzyme
DB00571PropranololAlpha-1-acid glycoprotein 1carrier
DB00571PropranololCytochrome P450 2C19enzyme
DB00571PropranololCytochrome P450 3A4enzyme
DB00571PropranololCytochrome P450 3A5enzyme
DB00571PropranololCytochrome P450 3A7enzyme
DB00571PropranololSolute carrier family 22 member 2transporter
DB00571PropranololP-glycoprotein 1transporter
DB00571PropranololCytochrome P450 1A1enzyme
DB00571PropranololAmine oxidase [flavin-containing] Aenzyme
DB00571PropranololSerum albumincarrier
DB00655EstroneEstrogen receptor alphatarget
DB00655EstroneCytochrome P450 1A2enzyme
DB00655EstroneCytochrome P450 1A1enzyme
DB00655EstroneSerum albumincarrier
DB00655EstroneSolute carrier organic anion transporter family member 2B1transporter
DB00655EstroneP-glycoprotein 1transporter
DB00655EstroneSolute carrier organic anion transporter family member 1A2transporter
DB00655EstroneATP-binding cassette sub-family G member 2transporter
DB00655EstroneSolute carrier organic anion transporter family member 1B1transporter
DB00655EstroneCytochrome P450 3A4enzyme
DB00655EstroneCytochrome P450 1B1enzyme
DB00655EstroneCytochrome P450 2B6enzyme
DB00655EstroneCytochrome P450 2C9enzyme
DB00655EstroneCytochrome P450 2E1enzyme
DB00655EstroneCytochrome P450 3A5enzyme
DB00655EstroneEstrogen receptor betatarget
DB00655EstroneAndrogen receptortarget
DB00655EstroneCytochrome P450 19A1target
DB00655EstroneSex hormone-binding globulintarget
DB00655EstroneSolute carrier family 22 member 8transporter
DB00661VerapamilSodium channel protein type 5 subunit alphatarget
DB00661VerapamilATP-sensitive inward rectifier potassium channel 11target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-4target
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ftarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-3target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-1target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-2target
DB00661VerapamilPotassium voltage-gated channel subfamily H member 2target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB00661VerapamilCytochrome P450 1A2enzyme
DB00661VerapamilCytochrome P450 3A5enzyme
DB00661VerapamilVoltage-dependent N-type calcium channel subunit alpha-1Btarget
DB00661VerapamilVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
DB00661VerapamilSodium-dependent serotonin transportertarget
DB00661VerapamilCytochrome P450 3A4enzyme
DB00661VerapamilP-glycoprotein 1transporter
DB00661VerapamilSolute carrier family 22 member 1transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 2transporter
DB00661VerapamilMultidrug resistance-associated protein 4transporter
DB00661VerapamilSolute carrier family 22 member 5transporter
DB00661VerapamilMultidrug resistance-associated protein 1transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1A2transporter
DB00661VerapamilMultidrug resistance-associated protein 7transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 1transporter
DB00661VerapamilSolute carrier family 22 member 4transporter
DB00661VerapamilATP-binding cassette sub-family G member 2transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1B1transporter
DB00661VerapamilCytochrome P450 2C8enzyme
DB00661VerapamilCytochrome P450 2C9enzyme
DB00661VerapamilCytochrome P450 2B6enzyme
DB00661VerapamilCytochrome P450 2C19enzyme
DB00661VerapamilCytochrome P450 2D6enzyme
DB00661VerapamilAlpha-1A adrenergic receptortarget
DB00661VerapamilAlpha-1B adrenergic receptortarget
DB00661VerapamilAlpha-1D adrenergic receptortarget
DB00661VerapamilBile salt export pumptransporter
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DB00697TizanidineAlpha-2 adrenergic receptorstarget
DB00697TizanidineCytochrome P450 1A2enzyme
DB00697TizanidineNischarintarget
DB00697TizanidineAlpha-1 adrenergic receptorstarget
DB00740RiluzoleSodium channel protein type 5 subunit alphatarget
DB00740RiluzoleCytochrome P450 1A2enzyme
DB00740RiluzoleCystine/glutamate transportertarget
DB00740RiluzoleATP-binding cassette sub-family G member 2transporter
DB00740RiluzoleCytochrome P450 1A1enzyme
DB00744ZileutonArachidonate 5-lipoxygenasetarget
DB00744ZileutonCytochrome P450 2C9enzyme
DB00744ZileutonCytochrome P450 1A2enzyme
DB00744ZileutonCytochrome P450 3A4enzyme
DB00744ZileutonProstaglandin G/H synthase 1enzyme
DB00744ZileutonUDP-glucuronosyltransferase 1-9enzyme
DB00744ZileutonSerum albumincarrier
DB00783EstradiolEstrogen receptor alphatarget
DB00783EstradiolNuclear receptor subfamily 1 group I member 2target
DB00783EstradiolSex hormone-binding globulincarrier
DB00783EstradiolEstrogen receptor betatarget
DB00783EstradiolCytochrome P450 1A2enzyme
DB00783EstradiolUDP-glucuronosyltransferase 1-1enzyme
DB00783EstradiolSerum albumincarrier
DB00783EstradiolFatty acid-binding protein, intestinalcarrier
DB00783EstradiolCytochrome P450 3A4enzyme
DB00783EstradiolCytochrome P450 3A5enzyme
DB00783EstradiolCytochrome P450 3A7enzyme
DB00783EstradiolSolute carrier family 22 member 2transporter
DB00783EstradiolSolute carrier family 22 member 1transporter
DB00783EstradiolSolute carrier family 22 member 3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 2B1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1A2transporter
DB00783EstradiolMultidrug resistance-associated protein 7transporter
DB00783EstradiolSolute carrier family 22 member 11transporter
DB00783EstradiolATP-binding cassette sub-family G member 2transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B1transporter
DB00783EstradiolP-glycoprotein 1transporter
DB00783EstradiolCytochrome P450 1A1enzyme
DB00783EstradiolCytochrome P450 1B1enzyme
DB00783EstradiolCytochrome P450 2C19enzyme
DB00783EstradiolCytochrome P450 2C8enzyme
DB00783EstradiolCytochrome P450 2C9enzyme
DB00783EstradiolSolute carrier family 22 member 8transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1C1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 4A1transporter
DB00783EstradiolNeuronal acetylcholine receptor subunit alpha-4target
DB00783EstradiolNuclear receptor coactivator 2target
DB00783EstradiolG-protein coupled estrogen receptor 1target
DB00783EstradiolATP synthase subunit atarget
DB00783EstradiolBeclin-1target
DB00783EstradiolEstradiol 17-beta-dehydrogenase 2target
DB00783EstradiolEstrogen-related receptor gammatarget
DB00851DacarbazineDNA polymerase alpha subunit Btarget
DB00851DacarbazineCytochrome P450 1A1enzyme
DB00851DacarbazineCytochrome P450 1A2enzyme
DB00851DacarbazineCytochrome P450 2E1enzyme
DB00851Dacarbazine6-phosphogluconate dehydrogenase, decarboxylatingtarget
DB00851DacarbazineDNAtarget
DB00904Ondansetron5-hydroxytryptamine receptor 3Atarget
DB00904OndansetronCytochrome P450 3A4enzyme
DB00904OndansetronCytochrome P450 1A2enzyme
DB00904OndansetronCytochrome P450 2D6enzyme
DB00904OndansetronCytochrome P450 3A5enzyme
DB00904OndansetronCytochrome P450 3A7enzyme
DB00904Ondansetron5-hydroxytryptamine receptor 4target
DB00904Ondansetron5-hydroxytryptamine receptor 1Atarget
DB00904Ondansetron5-hydroxytryptamine receptor 1Btarget
DB00904OndansetronMu-type opioid receptortarget
DB00904OndansetronCytochrome P450 2C9enzyme
DB00904OndansetronCytochrome P450 2E1enzyme
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 2Atarget
DB00924CyclobenzaprineCytochrome P450 1A2enzyme
DB00924CyclobenzaprineCytochrome P450 3A4enzyme
DB00924CyclobenzaprineCytochrome P450 2D6enzyme
DB00924CyclobenzaprineSerum albumincarrier
DB00924CyclobenzaprineUDP-glucuronosyltransferase 1-4enzyme
DB00924CyclobenzaprineUDP-glucuronosyltransferase 2B10enzyme
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 2Btarget
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 2Ctarget
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 7target
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 6target
DB00924CyclobenzaprineSodium-dependent serotonin transportertarget
DB00924CyclobenzaprineSodium-dependent noradrenaline transportertarget
DB00924CyclobenzaprineToll-like receptor 4target
DB00924CyclobenzaprineAldehyde oxidasetarget
DB00980RamelteonMelatonin receptor type 1Btarget
DB00980RamelteonMelatonin receptor type 1Atarget
DB00980RamelteonCytochrome P450 1A2enzyme
DB00980RamelteonCytochrome P450 2C19enzyme
DB00980RamelteonCytochrome P450 3A4enzyme
DB00980RamelteonCytochrome P450 2C9enzyme
DB00998Frovatriptan5-hydroxytryptamine receptor 1Dtarget
DB00998Frovatriptan5-hydroxytryptamine receptor 1Btarget
DB00998FrovatriptanCytochrome P450 1A2enzyme
DB01002LevobupivacaineSodium channel protein type 10 subunit alphatarget
DB01002LevobupivacaineCytochrome P450 3A4enzyme
DB01002LevobupivacaineCytochrome P450 1A2enzyme
DB01012CinacalcetExtracellular calcium-sensing receptortarget
DB01012CinacalcetCytochrome P450 3A4enzyme
DB01012CinacalcetCytochrome P450 2D6enzyme
DB01012CinacalcetCytochrome P450 1A2enzyme
DB01100PimozideDopamine D2 receptortarget
DB01100PimozideCalmodulintarget
DB01100PimozidePotassium voltage-gated channel subfamily H member 2target
DB01100PimozideCytochrome P450 3A4enzyme
DB01100PimozideCytochrome P450 1A2enzyme
DB01100PimozideCytochrome P450 3A5enzyme
DB01100PimozideCytochrome P450 3A7enzyme
DB01100PimozideP-glycoprotein 1transporter
DB01100PimozideDopamine D3 receptortarget
DB01100PimozideCytochrome P450 2D6enzyme
DB01182PropafenoneSodium channel protein type 5 subunit alphatarget
DB01182PropafenonePotassium voltage-gated channel subfamily H member 2target
DB01182PropafenoneCytochrome P450 1A2enzyme
DB01182PropafenoneCytochrome P450 2D6enzyme
DB01182PropafenoneCytochrome P450 3A4enzyme
DB01182PropafenoneP-glycoprotein 1transporter
DB01182PropafenoneBeta-1 adrenergic receptortarget
DB01182PropafenoneBeta-2 adrenergic receptortarget
DB01242ClomipramineSodium-dependent serotonin transportertarget
DB01242ClomipramineSodium-dependent noradrenaline transportertarget
DB01242ClomipramineGlutathione S-transferase Ptarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Atarget
DB01242ClomipramineCytochrome P450 1A2enzyme
DB01242ClomipramineCytochrome P450 2D6enzyme
DB01242ClomipramineCytochrome P450 2C19enzyme
DB01242ClomipramineP-glycoprotein 1transporter
DB01242ClomipramineCytochrome P450 3A4enzyme
DB01242Clomipramine5-hydroxytryptamine receptor 2Btarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Ctarget
DB01242ClomipramineSerum albumincarrier
DB01367RasagilineApoptosis regulator Bcl-2target
DB01367RasagilineAmine oxidase [flavin-containing] Btarget
DB01367RasagilineCytochrome P450 1A2enzyme
DB00356ChlorzoxazoneCalcium-activated potassium channel subunit alpha-1target
DB00356ChlorzoxazoneCytochrome P450 2E1enzyme
DB00356ChlorzoxazoneCytochrome P450 1A2enzyme
DB00356ChlorzoxazoneCytochrome P450 2A6enzyme
DB00356ChlorzoxazoneCytochrome P450 1A1enzyme
DB00356ChlorzoxazoneCytochrome P450 2D6enzyme
DB00356ChlorzoxazoneCytochrome P450 3A4enzyme
DB00477ChlorpromazineDopamine D2 receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 2Atarget
DB00477ChlorpromazineCytochrome P450 2D6enzyme
DB00477ChlorpromazineCholinesteraseenzyme
DB00477ChlorpromazineCytochrome P450 1A2enzyme
DB00477ChlorpromazineSerum albumincarrier
DB00477ChlorpromazineP-glycoprotein 1transporter
DB00477ChlorpromazineDopamine D1 receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 1Atarget
DB00477ChlorpromazineAlpha-1A adrenergic receptortarget
DB00477ChlorpromazineAlpha-1B adrenergic receptortarget
DB00477ChlorpromazineCytochrome P450 2E1enzyme
DB00477ChlorpromazineCytochrome P450 3A4enzyme
DB00477ChlorpromazineHistamine H1 receptortarget
DB00477ChlorpromazinePotassium voltage-gated channel subfamily H member 2target
DB00477ChlorpromazineD(1) dopamine receptortarget
DB00477ChlorpromazineDopamine D3 receptortarget
DB00477ChlorpromazineDopamine D4 receptortarget
DB00477ChlorpromazineDopamine D5 receptortarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 2Ctarget
DB00477Chlorpromazine5-hydroxytryptamine 2 receptortarget
DB00477ChlorpromazineAlpha-1 adrenergic receptorstarget
DB00477ChlorpromazineAlpha-2 adrenergic receptorstarget
DB00477ChlorpromazineMuscarinic acetylcholine receptor M1target
DB00477ChlorpromazineMuscarinic acetylcholine receptor M3target
DB00477ChlorpromazineSphingomyelin phosphodiesterasetarget
DB00477ChlorpromazineCalmodulintarget
DB00477Chlorpromazinealpha1-acid glycoproteintarget
DB00477Chlorpromazine5-hydroxytryptamine receptor 6target
DB00477Chlorpromazine5-hydroxytryptamine receptor 7target
DB00477ChlorpromazineHistamine H4 receptortarget
DB00477ChlorpromazineBile salt export pumptransporter
DB00532MephenytoinSodium channel protein type 5 subunit alphatarget
DB00532MephenytoinCytochrome P450 2B6enzyme
DB00532MephenytoinCytochrome P450 2C9enzyme
DB00532MephenytoinCytochrome P450 2C19enzyme
DB00532MephenytoinCytochrome P450 1A2enzyme
DB00532MephenytoinCytochrome P450 2D6enzyme
DB00532MephenytoinCytochrome P450 2C8enzyme
DB00532MephenytoinNuclear receptor subfamily 1 group I member 2target
DB00532MephenytoinThyroxine-binding globulincarrier
DB00586DiclofenacProstaglandin G/H synthase 1target
DB00586DiclofenacProstaglandin G/H synthase 2target
DB00586DiclofenacTransthyretincarrier
DB00586DiclofenacCytochrome P450 2C9enzyme
DB00586DiclofenacCytochrome P450 2C19enzyme
DB00586DiclofenacCytochrome P450 1A2enzyme
DB00586DiclofenacCytochrome P450 2C8enzyme
DB00586DiclofenacSerum albumincarrier
DB00586DiclofenacMultidrug resistance-associated protein 4transporter
DB00586DiclofenacMultidrug resistance-associated protein 1transporter
DB00586DiclofenacSolute carrier family 22 member 6transporter
DB00586DiclofenacSolute carrier family 22 member 8transporter
DB00586DiclofenacSolute carrier organic anion transporter family member 1C1transporter
DB00586DiclofenacSolute carrier family 22 member 11transporter
DB00586DiclofenacUDP-glucuronosyltransferase 2B7enzyme
DB00586DiclofenacCytochrome P450 3A4enzyme
DB00586DiclofenacCytochrome P450 2B6enzyme
DB00586DiclofenacCytochrome P450 2C18enzyme
DB00586DiclofenacCytochrome P450 2E1enzyme
DB00586DiclofenacSolute carrier organic anion transporter family member 1B1transporter
DB00586DiclofenacBile salt export pumptransporter
DB00586DiclofenacUDP-glucuronosyltransferase 1-3enzyme
DB00586DiclofenacUDP-glucuronosyltransferase 1-9enzyme
DB00586DiclofenacUDP-glucuronosyltransferase 2B4enzyme
DB00586DiclofenacArachidonate 5-lipoxygenaseenzyme
DB00586DiclofenacSodium channel protein type 4 subunit alphatransporter
DB00586DiclofenacAcid-sensing ion channel 1transporter
DB00586DiclofenacPotassium voltage-gated channel subfamily KQT member 2transporter
DB00586DiclofenacPotassium voltage-gated channel subfamily KQT member 3transporter
DB00586DiclofenacPhospholipase A2, membrane associatedenzyme
DB00972AzelastineHistamine H1 receptortarget
DB00972AzelastineCytochrome P450 1A2enzyme
DB00972AzelastineCytochrome P450 2D6enzyme
DB00972AzelastineCytochrome P450 3A4enzyme
DB00972AzelastineCytochrome P450 2C19enzyme
DB00972AzelastineCytochrome P450 1A1enzyme
DB00972AzelastineCytochrome P450 3A5enzyme
DB00972AzelastineCytochrome P450 2C9enzyme
DB00972AzelastineCytochrome P450 2C8enzyme
DB00972AzelastineP-glycoprotein 1transporter
DB00972AzelastineCytochrome P450 2A6enzyme
DB00972AzelastineCytochrome P450 2E1enzyme
DB00972AzelastineHistamine H2 receptortarget
DB00972AzelastinePhospholipase A2target
DB00972AzelastineLeukotriene C4 synthasetarget
DB00972AzelastineCytochrome P450 2B6enzyme
DB01418AcenocoumarolVitamin K epoxide reductase complex subunit 1target
DB01418AcenocoumarolCytochrome P450 2C9enzyme
DB01418AcenocoumarolCytochrome P450 1A2enzyme
DB01418AcenocoumarolSerum albumincarrier
DB01418AcenocoumarolAlpha-1-acid glycoprotein 1carrier
DB01418AcenocoumarolCytochrome P450 2C19enzyme
DB01418AcenocoumarolCytochrome P450 3A4enzyme
DB01418AcenocoumarolP-glycoprotein 1transporter
DB01424AminophenazoneCytochrome P450 2C19enzyme
DB01424AminophenazoneCytochrome P450 1A2enzyme
DB01424AminophenazoneCytochrome P450 2C8enzyme
DB01424AminophenazoneSolute carrier family 22 member 6transporter
DB01424AminophenazoneCytochrome P450 2C9enzyme
DB01424AminophenazoneCytochrome P450 2D6enzyme
DB01424AminophenazoneCytochrome P450 3A4enzyme
DB01424AminophenazoneCytochrome P450 2C18enzyme
DB01424AminophenazoneSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB00377Palonosetron5-hydroxytryptamine receptor 3Atarget
DB00377PalonosetronCytochrome P450 2D6enzyme
DB00377PalonosetronCytochrome P450 3A4enzyme
DB00377PalonosetronCytochrome P450 1A2enzyme
DB01065MelatoninAcetylserotonin O-methyltransferasetarget
DB01065MelatoninMelatonin receptor type 1Atarget
DB01065MelatoninMelatonin receptor type 1Btarget
DB01065MelatoninNuclear receptor ROR-betatarget
DB01065MelatoninCalmodulintarget
DB01065MelatoninCalreticulintarget
DB01065MelatoninRibosyldihydronicotinamide dehydrogenase [quinone]target
DB01065MelatoninMyeloperoxidasetarget
DB01065MelatoninEstrogen receptor alphatarget
DB01065MelatoninEosinophil peroxidasetarget
DB01065MelatoninCytochrome P450 1A1enzyme
DB01065MelatoninCytochrome P450 1A2enzyme
DB01065MelatoninCytochrome P450 2C19enzyme
DB01065MelatoninCytochrome P450 2C9enzyme
DB01065MelatoninAcetylserotonin O-methyltransferaseenzyme
DB01065MelatoninIndoleamine 2,3-dioxygenase 1enzyme
DB01065MelatoninMyeloperoxidaseenzyme
DB01065MelatoninCytochrome P450 1B1enzyme
DB01065MelatoninSolute carrier family 22 member 8transporter
DB01065MelatoninCytochrome P450 19A1enzyme
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibP-glycoprotein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00619ImatinibBile salt export pumptransporter
DB00619ImatinibCytochrome P450 2C8enzyme
DB00468QuininePlatelet glycoprotein IXtarget
DB00468QuinineIntermediate conductance calcium-activated potassium channel protein 4target
DB00468QuinineCytochrome P450 3A4enzyme
DB00468QuinineCytochrome P450 3A5enzyme
DB00468QuinineCytochrome P450 1A1enzyme
DB00468QuinineCytochrome P450 2D6enzyme
DB00468QuinineCytochrome P450 1A2enzyme
DB00468QuinineCytochrome P450 2C8enzyme
DB00468QuinineCytochrome P450 2C9enzyme
DB00468QuinineCytochrome P450 2C19enzyme
DB00468QuinineCytochrome P450 2E1enzyme
DB00468QuinineCytochrome P450 3A7enzyme
DB00468QuinineSolute carrier family 22 member 2transporter
DB00468QuinineSolute carrier family 22 member 1transporter
DB00468QuinineSolute carrier family 22 member 5transporter
DB00468QuinineP-glycoprotein 1transporter
DB00468QuinineSolute carrier organic anion transporter family member 1A2transporter
DB00468QuinineSolute carrier family 22 member 4transporter
DB00468QuinineFe(II)-protoporphyrin IXtarget
DB00468QuinineSolute carrier organic anion transporter family member 1B1transporter
DB01142DoxepinSodium-dependent serotonin transportertarget
DB01142DoxepinSodium-dependent noradrenaline transportertarget
DB01142DoxepinHistamine H1 receptortarget
DB01142DoxepinHistamine H2 receptortarget
DB01142DoxepinCytochrome P450 2D6enzyme
DB01142DoxepinMuscarinic acetylcholine receptor M1target
DB01142DoxepinMuscarinic acetylcholine receptor M2target
DB01142DoxepinMuscarinic acetylcholine receptor M3target
DB01142DoxepinMuscarinic acetylcholine receptor M4target
DB01142DoxepinMuscarinic acetylcholine receptor M5target
DB01142DoxepinAlpha-1A adrenergic receptortarget
DB01142Doxepin5-hydroxytryptamine receptor 1Atarget
DB01142Doxepin5-hydroxytryptamine receptor 2Atarget
DB01142DoxepinCytochrome P450 2C19enzyme
DB01142DoxepinCytochrome P450 2C9enzyme
DB01142DoxepinCytochrome P450 1A2enzyme
DB01142DoxepinP-glycoprotein 1transporter
DB01142Doxepin5-hydroxytryptamine receptor 2Btarget
DB01142Doxepin5-hydroxytryptamine receptor 2Ctarget
DB01142DoxepinAlpha-1B adrenergic receptortarget
DB01142DoxepinAlpha-1D adrenergic receptortarget
DB01142DoxepinCytochrome P450 3A4enzyme
DB01142Doxepin5-hydroxytryptamine receptor 6target
DB01142DoxepinHistamine H4 receptortarget
DB01142DoxepinPotassium voltage-gated channel subfamily H member 2target
DB01142DoxepinSerum albumincarrier
DB01142DoxepinAlpha-1-acid glycoprotein 1carrier
DB00564CarbamazepineVoltage-gated sodium channel alpha subunittarget
DB00564CarbamazepineCytochrome P450 2C8enzyme
DB00564CarbamazepineCytochrome P450 2B6enzyme
DB00564CarbamazepineCytochrome P450 3A4enzyme
DB00564CarbamazepineCytochrome P450 1A2enzyme
DB00564CarbamazepineCytochrome P450 2C19enzyme
DB00564CarbamazepineCytochrome P450 2C9enzyme
DB00564CarbamazepineP-glycoprotein 1transporter
DB00564CarbamazepineCytochrome P450 3A5enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 2B7enzyme
DB00564CarbamazepineRalA-binding protein 1transporter
DB00564CarbamazepineCanalicular multispecific organic anion transporter 1transporter
DB00564CarbamazepineNeuronal acetylcholine receptor subunit alpha-4target
DB00564CarbamazepineNuclear receptor subfamily 1 group I member 2target
DB00564CarbamazepineUDP-glucuronosyltransferase 1-1enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 1-6enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 1-7enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-1target
DB00425ZolpidemCytochrome P450 3A4enzyme
DB00425ZolpidemCytochrome P450 1A2enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-2target
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-3target
DB00425ZolpidemCytochrome P450 2C9enzyme
DB00425ZolpidemCytochrome P450 2C19enzyme
DB00425ZolpidemCytochrome P450 2D6enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit gamma-2target
DB00472FluoxetineSodium-dependent serotonin transportertarget
DB00472FluoxetineCytochrome P450 2C9enzyme
DB00472FluoxetineCytochrome P450 2D6enzyme
DB00472FluoxetineCYP2B proteinenzyme
DB00472FluoxetineCytochrome P450 1A2enzyme
DB00472FluoxetineCytochrome P450 3A4enzyme
DB00472FluoxetineCytochrome P450 2C19enzyme
DB00472FluoxetineP-glycoprotein 1transporter
DB00472FluoxetineCytochrome P450 2B6enzyme
DB00472FluoxetineCytochrome P450 3A5enzyme
DB00472FluoxetineSerum albumincarrier
DB00472FluoxetineAlpha-1-acid glycoprotein 1carrier
DB00472FluoxetinePotassium voltage-gated channel subfamily H member 2target
DB00472Fluoxetine5-hydroxytryptamine receptor 2Ctarget
DB00472FluoxetineCyclin-dependent kinases regulatory subunit 1target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-2target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-3target
DB00472FluoxetineNeuronal acetylcholine receptor subunit beta-4target
DB01435AntipyrineCytochrome P450 2C8enzyme
DB01435AntipyrineCytochrome P450 2C9enzyme
DB01435AntipyrineCytochrome P450 1A2enzyme
DB01435AntipyrineCytochrome P450 2C19enzyme
DB01435AntipyrineCytochrome P450 3A4enzyme
DB01435AntipyrineSolute carrier family 22 member 6transporter
DB01435AntipyrineCytochrome P450 2A6enzyme
DB01435AntipyrineCytochrome P450 2B6enzyme
DB01435AntipyrineCytochrome P450 2C18enzyme
DB01435AntipyrineCytochrome P450 2D6enzyme
DB01435AntipyrineCytochrome P450 2E1enzyme
DB01435AntipyrineProstaglandin G/H synthase 2target
DB01435AntipyrineProstaglandin G/H synthase 1target
DB00857TerbinafineSqualene monooxygenasetarget
DB00857TerbinafineCytochrome P450 2D6enzyme
DB00857TerbinafineCytochrome P450 2C9enzyme
DB00857TerbinafineCytochrome P450 1A2enzyme
DB00857TerbinafineCytochrome P450 3A4enzyme
DB00857TerbinafineCytochrome P450 2C8enzyme
DB00857TerbinafineCytochrome P450 2C19enzyme
DB00857TerbinafineProstaglandin G/H synthase 1enzyme
DB00568CinnarizineHistamine H1 receptortarget
DB00568CinnarizineDopamine D2 receptortarget
DB00568CinnarizineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB00568CinnarizineCytochrome P450 2D6enzyme
DB00568CinnarizineCytochrome P450 2B6enzyme
DB00568CinnarizineCytochrome P450 2C9enzyme
DB00568CinnarizineCytochrome P450 1A1enzyme
DB00568CinnarizineCytochrome P450 1A2enzyme
DB00568CinnarizineCytochrome P450 2A6enzyme
DB00568CinnarizineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00568CinnarizineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00568CinnarizineVoltage-dependent L-type calcium channel subunit alpha-1Ftarget
DB00568CinnarizineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00568CinnarizineVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB00568CinnarizineVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB00568CinnarizineD(1) dopamine receptortarget
DB00568CinnarizineMuscarinic acetylcholine receptortarget
DB00568CinnarizineCytochrome P450 3A4enzyme
DB04841FlunarizineHistamine H1 receptortarget
DB04841FlunarizineVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB04841FlunarizineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB04841FlunarizineVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB04841FlunarizineCalmodulintarget
DB04841FlunarizineCytochrome P450 2D6enzyme
DB04841FlunarizineCytochrome P450 2C9enzyme
DB04841FlunarizineCytochrome P450 1A1enzyme
DB04841FlunarizineCytochrome P450 1A2enzyme
DB04841FlunarizineCytochrome P450 2A6enzyme
DB04841FlunarizineCytochrome P450 3A4enzyme
DB00788NaproxenProstaglandin G/H synthase 1target
DB00788NaproxenProstaglandin G/H synthase 2target
DB00788NaproxenSerum albumincarrier
DB00788NaproxenCytochrome P450 2C9enzyme
DB00788NaproxenCytochrome P450 1A2enzyme
DB00788NaproxenSolute carrier organic anion transporter family member 1A2transporter
DB00788NaproxenSolute carrier family 22 member 6transporter
DB00788NaproxenCytochrome P450 2C8enzyme
DB00788NaproxenUDP-glucuronosyltransferase 2B7enzyme
DB00788NaproxenPeptostreptococcal albumin-binding proteintarget
DB00788NaproxenBile salt export pumptransporter
DB00788NaproxenP-glycoprotein 1transporter
DB00788NaproxenUDP-glucuronosyltransferase 1-3enzyme
DB00788NaproxenUDP-glucuronosyltransferase 1-6enzyme
DB00788NaproxenUDP-glucuronosyltransferase 1-7enzyme
DB00788NaproxenUDP-glucuronosyltransferase 1-8enzyme
DB00788NaproxenUDP-glucuronosyltransferase 1-9enzyme
DB00788NaproxenUDP-glucuronosyltransferase 1-10enzyme
DB00788NaproxenSolute carrier family 22 member 8transporter
DB03783PhenacetinProstaglandin G/H synthase 1target
DB03783PhenacetinCytochrome P450 1A2enzyme
DB03783PhenacetinCytochrome P450 2D6enzyme
DB03783PhenacetinSolute carrier family 22 member 6transporter
DB03783PhenacetinCytochrome P450 1A1enzyme
DB03783PhenacetinCytochrome P450 2A13enzyme
DB03783PhenacetinCytochrome P450 2A6enzyme
DB03783PhenacetinCytochrome P450 2C19enzyme
DB03783PhenacetinCytochrome P450 2C9enzyme
DB03783PhenacetinCytochrome P450 2E1enzyme
DB03783PhenacetinCytochrome P450 3A4enzyme
DB01223AminophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01223AminophyllineAdenosine receptor A3target
DB01223AminophyllineAdenosine receptor A1target
DB01223AminophyllineCytochrome P450 1A2enzyme
DB01223AminophyllineCytochrome P450 2E1enzyme
DB01223AminophyllineCytochrome P450 3A4enzyme
DB01223AminophyllineHistone deacetylase 2target
DB06216Asenapine5-hydroxytryptamine receptor 1Atarget
DB06216Asenapine5-hydroxytryptamine receptor 1Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Atarget
DB06216Asenapine5-hydroxytryptamine receptor 2Btarget
DB06216Asenapine5-hydroxytryptamine receptor 2Ctarget
DB06216Asenapine5-hydroxytryptamine receptor 6target
DB06216Asenapine5-hydroxytryptamine receptor 7target
DB06216AsenapineAlpha-2A adrenergic receptortarget
DB06216AsenapineAlpha-2B adrenergic receptortarget
DB06216AsenapineAlpha-2C adrenergic receptortarget
DB06216AsenapineAlpha-1A adrenergic receptortarget
DB06216AsenapineDopamine D1 receptortarget
DB06216AsenapineDopamine D2 receptortarget
DB06216AsenapineDopamine D3 receptortarget
DB06216AsenapineDopamine D4 receptortarget
DB06216AsenapineHistamine H1 receptortarget
DB06216AsenapineHistamine H2 receptortarget
DB06216AsenapineCytochrome P450 1A2enzyme
DB06216AsenapineCytochrome P450 2D6enzyme
DB06216Asenapine5-hydroxytryptamine receptor 5Atarget
DB06216AsenapineUDP-glucuronosyltransferase 1-4enzyme
DB06216AsenapineCytochrome P450 3A4enzyme
DB06216AsenapineBeta-1 adrenergic receptortarget
DB06216AsenapineBeta-2 adrenergic receptortarget
DB00195BetaxololBeta-1 adrenergic receptortarget
DB00195BetaxololBeta-2 adrenergic receptortarget
DB00195BetaxololCytochrome P450 1A2enzyme
DB00195BetaxololCytochrome P450 2D6enzyme
DB04574Estrone sulfateCytochrome P450 1A2enzyme
DB04574Estrone sulfateCytochrome P450 3A4enzyme
DB04574Estrone sulfateEstrogen receptor alphatarget
DB04574Estrone sulfateEstrogen receptor betatarget
DB04574Estrone sulfateSex hormone-binding globulincarrier
DB04574Estrone sulfateSerum albumincarrier
DB04574Estrone sulfateCytochrome P450 2C9enzyme
DB04574Estrone sulfateMultidrug and toxin extrusion protein 1transporter
DB04574Estrone sulfateMultidrug and toxin extrusion protein 2transporter
DB00629GuanabenzAlpha-2A adrenergic receptortarget
DB00629GuanabenzCytochrome P450 1A2enzyme
DB00629GuanabenzAlpha-2B adrenergic receptortarget
DB01623ThiothixeneCytochrome P450 1A2enzyme
DB01623ThiothixeneCytochrome P450 2D6enzyme
DB01623ThiothixeneDopamine D2 receptortarget
DB01623ThiothixeneDopamine D1 receptortarget
DB01623Thiothixene5-hydroxytryptamine receptor 2Atarget
DB01623ThiothixeneSolute carrier family 22 member 1transporter
DB01623ThiothixeneSerum albumincarrier
DB00831TrifluoperazineDopamine D2 receptortarget
DB00831TrifluoperazineAlpha-1A adrenergic receptortarget
DB00831TrifluoperazineNeuron-specific vesicular protein calcyontarget
DB00831TrifluoperazineXanthine dehydrogenase/oxidaseenzyme
DB00831TrifluoperazineUDP-glucuronosyltransferase 1-4enzyme
DB00831TrifluoperazineCytochrome P450 1A2enzyme
DB00831TrifluoperazineP-glycoprotein 1transporter
DB00831TrifluoperazineCalmodulintarget
DB00831TrifluoperazineTroponin C, slow skeletal and cardiac musclestarget
DB00831TrifluoperazineProtein S100-A4target
DB00420PromazineDopamine D2 receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M4target
DB00420PromazineMuscarinic acetylcholine receptor M2target
DB00420PromazineMuscarinic acetylcholine receptor M3target
DB00420PromazineAlpha-1B adrenergic receptortarget
DB00420PromazineDopamine D1 receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M5target
DB00420Promazine5-hydroxytryptamine receptor 2Atarget
DB00420Promazine5-hydroxytryptamine receptor 2Ctarget
DB00420PromazineAlpha-1A adrenergic receptortarget
DB00420PromazineMuscarinic acetylcholine receptor M1target
DB00420PromazineDopamine D4 receptortarget
DB00420PromazineHistamine H1 receptortarget
DB00420PromazineAlpha-1D adrenergic receptortarget
DB00420PromazineCytochrome P450 2C19enzyme
DB00420PromazineCytochrome P450 1A2enzyme
DB00420PromazineCytochrome P450 3A4enzyme
DB00420PromazineCytochrome P450 2C9enzyme
DB00420PromazineCytochrome P450 2D6enzyme
DB01136CarvedilolAlpha-1A adrenergic receptortarget
DB01136CarvedilolBeta-1 adrenergic receptortarget
DB01136CarvedilolNADH dehydrogenase [ubiquinone] 1 subunit C2target
DB01136CarvedilolBeta-2 adrenergic receptortarget
DB01136CarvedilolVascular endothelial growth factor Atarget
DB01136CarvedilolNatriuretic peptides Btarget
DB01136CarvedilolGap junction alpha-1 proteintarget
DB01136CarvedilolPotassium voltage-gated channel subfamily H member 2target
DB01136CarvedilolVascular cell adhesion protein 1target
DB01136CarvedilolCytochrome P450 2C9enzyme
DB01136CarvedilolCytochrome P450 2D6enzyme
DB01136CarvedilolXanthine dehydrogenase/oxidaseenzyme
DB01136CarvedilolP-glycoprotein 1transporter
DB01136CarvedilolCytochrome P450 1A2enzyme
DB01136CarvedilolCytochrome P450 3A4enzyme
DB01136CarvedilolCytochrome P450 1A1enzyme
DB01136CarvedilolCytochrome P450 2E1enzyme
DB01136CarvedilolAlpha-1D adrenergic receptortarget
DB01136CarvedilolAlpha-1B adrenergic receptortarget
DB01136CarvedilolAlpha-2C adrenergic receptortarget
DB01136CarvedilolAlpha-2B adrenergic receptortarget
DB01136CarvedilolAlpha-2A adrenergic receptortarget
DB01136CarvedilolE-selectintarget
DB01136CarvedilolHypoxia-inducible factor 1-alphatarget
DB01136CarvedilolInward rectifier potassium channel 4target
DB01136CarvedilolUDP-glucuronosyltransferase 1-1enzyme
DB01136CarvedilolSerum albumincarrier
DB01136CarvedilolUDP-glucuronosyltransferase 2B4enzyme
DB01136CarvedilolUDP-glucuronosyltransferase 2B7enzyme
DB01136CarvedilolInward rectifier potassium channel 2target
DB01645GenisteinEstrogen receptor betatarget
DB01645GenisteinDNA topoisomerase 2-alphatarget
DB01645GenisteinProtein-tyrosine kinase 2-betatarget
DB01645GenisteinP-glycoprotein 1transporter
DB01645GenisteinMultidrug resistance-associated protein 1transporter
DB01645GenisteinATP-binding cassette sub-family G member 2transporter
DB01645GenisteinCytochrome P450 1A2enzyme
DB01645GenisteinNuclear receptor coactivator 1target
DB01645GenisteinEstrogen receptor alphatarget
DB01645GenisteinNuclear receptor coactivator 2target
DB01645GenisteinTransthyretincarrier
DB01645GenisteinSteroid hormone receptor ERR2target
DB01645GenisteinSteroid hormone receptor ERR1target
DB01645GenisteinNuclear receptor subfamily 1 group I member 2target
DB01645GenisteinRAC-alpha serine/threonine-protein kinasetarget
DB01645GenisteinG-protein coupled estrogen receptor 1target
DB01645GenisteinCytochrome P450 1B1target
DB01645GenisteinSex hormone-binding globulintarget
DB01645GenisteinCytochrome P450 1A1enzyme
DB01645GenisteinSolute carrier organic anion transporter family member 1B1transporter
DB01645GenisteinSolute carrier organic anion transporter family member 2B1transporter
DB01645GenisteinCytochrome P450 2C8enzyme
DB01645GenisteinCytochrome P450 2C9enzyme
DB01645GenisteinCytochrome P450 3A1enzyme
DB01645GenisteinCytochrome P450 3A2enzyme
DB01645GenisteinCytochrome P450 3A4enzyme
DB02709ResveratrolTransthyretincarrier
DB02709ResveratrolRibosyldihydronicotinamide dehydrogenase [quinone]target
DB02709ResveratrolProstaglandin G/H synthase 1target
DB02709ResveratrolCasein kinase II subunit alphatarget
DB02709ResveratrolProstaglandin G/H synthase 2target
DB02709ResveratrolCytochrome P450 1A1enzyme
DB02709ResveratrolCytochrome P450 3A4enzyme
DB02709ResveratrolCytochrome P450 1A2enzyme
DB02709ResveratrolCytochrome P450 1B1enzyme
DB02709ResveratrolArachidonate 15-lipoxygenasetarget
DB02709ResveratrolArachidonate 5-lipoxygenasetarget
DB02709ResveratrolAryl hydrocarbon receptortarget
DB02709ResveratrolPhosphatidylinositol 4-kinase type 2-betatarget
DB02709ResveratrolIntegrin alpha-5target
DB02709ResveratrolIntegrin beta-3target
DB02709ResveratrolSerum albumincarrier
DB02709ResveratrolAmyloid beta A4 proteintarget
DB02709ResveratrolAlpha-synucleintarget
DB02709ResveratrolEstrogen receptor alphatarget
DB02709ResveratrolMelatonin receptor type 1Atarget
DB02709ResveratrolMelatonin receptor type 1Btarget
DB02709ResveratrolC-type lectin domain family 14 member Atarget
DB02709ResveratrolNuclear receptor subfamily 1 group I member 2target
DB02709ResveratrolNuclear receptor subfamily 1 group I member 3target
DB02709ResveratrolSolute carrier family 2, facilitated glucose transporter member 1target
DB02709ResveratrolCarbonyl reductase [NADPH] 1target
DB02709ResveratrolPeroxisome proliferator-activated receptor alphatarget
DB02709ResveratrolPeroxisome proliferator-activated receptor gammatarget
DB02709ResveratrolRAC-alpha serine/threonine-protein kinasetarget
DB02709ResveratrolFar upstream element-binding protein 2target
DB02709ResveratrolTyrosine--tRNA ligase, cytoplasmictarget
DB00518AlbendazoleTubulin alpha-1A chaintarget
DB00518AlbendazoleTubulin beta-4B chaintarget
DB00518AlbendazoleCytochrome P450 3A4enzyme
DB00518AlbendazoleFumarate reductase flavoprotein subunittarget
DB00518AlbendazoleP-glycoprotein 1transporter
DB00518AlbendazoleCytochrome P450 1A1enzyme
DB00518AlbendazoleCytochrome P450 1A2enzyme
DB00518AlbendazoleTubulin beta-2 chaintarget
DB00518AlbendazoleCytochrome P450 2C19enzyme
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-4target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB01558BromazepamGamma-aminobutyric acid receptor subunit alpha-6target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit beta-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB01558BromazepamGamma-aminobutyric acid receptor subunit deltatarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit pitarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-1target
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-2target
DB01558BromazepamGamma-aminobutyric acid receptor subunit thetatarget
DB01558BromazepamGamma-aminobutyric acid receptor subunit rho-3target
DB01558BromazepamCytochrome P450 1A2enzyme
DB01558BromazepamCytochrome P450 2C19enzyme
DB01558BromazepamCytochrome P450 2E1enzyme
DB01151DesipramineMuscarinic acetylcholine receptor M1target
DB01151DesipramineSodium-dependent noradrenaline transportertarget
DB01151DesipramineBeta-2 adrenergic receptortarget
DB01151DesipramineMuscarinic acetylcholine receptor M2target
DB01151DesipramineSodium-dependent serotonin transportertarget
DB01151DesipramineHistamine H1 receptortarget
DB01151DesipramineBeta-1 adrenergic receptortarget
DB01151DesipramineCytochrome P450 2D6enzyme
DB01151DesipramineMuscarinic acetylcholine receptor M3target
DB01151DesipramineMuscarinic acetylcholine receptor M4target
DB01151DesipramineMuscarinic acetylcholine receptor M5target
DB01151DesipramineAlpha-1 adrenergic receptorstarget
DB01151Desipramine5-hydroxytryptamine receptor 2Atarget
DB01151DesipramineAlpha-1-acid glycoprotein 1carrier
DB01151DesipramineCytochrome P450 2B6enzyme
DB01151DesipramineCytochrome P450 3A4enzyme
DB01151DesipramineSolute carrier family 22 member 2transporter
DB01151DesipramineSolute carrier family 22 member 1transporter
DB01151DesipramineSolute carrier family 22 member 3transporter
DB01151DesipramineSolute carrier family 22 member 5transporter
DB01151DesipramineP-glycoprotein 1transporter
DB01151DesipramineSolute carrier family 22 member 4transporter
DB01151DesipramineCytochrome P450 1A2enzyme
DB01151DesipramineCytochrome P450 2E1enzyme
DB01151DesipramineSphingomyelin phosphodiesterasetarget
DB01151Desipramine5-hydroxytryptamine receptor 1Atarget
DB01151Desipramine5-hydroxytryptamine receptor 2Ctarget
DB01151DesipramineDopamine D2 receptortarget
DB01151DesipramineAlpha-2 adrenergic receptorstarget
DB01191DexfenfluramineSodium-dependent serotonin transportertarget
DB01191Dexfenfluramine5-hydroxytryptamine receptor 2Ctarget
DB01191DexfenfluramineCytochrome P450 2D6enzyme
DB01191DexfenfluramineCytochrome P450 1A2enzyme
DB01191DexfenfluramineCytochrome P450 2E1enzyme
DB01184DomperidoneDopamine D2 receptortarget
DB01184DomperidoneCytochrome P450 3A4enzyme
DB01184DomperidoneCytochrome P450 3A5enzyme
DB01184DomperidoneCytochrome P450 3A7enzyme
DB01184DomperidoneP-glycoprotein 1transporter
DB01184DomperidoneCytochrome P450 1A2enzyme
DB01184DomperidoneCytochrome P450 2B6enzyme
DB01184DomperidoneCytochrome P450 2C8enzyme
DB01184DomperidoneCytochrome P450 2D6enzyme
DB01184DomperidoneDopamine D3 receptortarget
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-1target
DB00898EthanolGlutamate receptor ionotropic, NMDA 3Atarget
DB00898EthanolGlycine receptor subunit alpha-1target
DB00898EthanolGlycine receptor subunit alpha-2target
DB00898EthanolCytochrome P450 2E1enzyme
DB00898EthanolCytochrome P450 1A1enzyme
DB00898EthanolCytochrome P450 1A2enzyme
DB00898EthanolCytochrome P450 2B6enzyme
DB00898EthanolCytochrome P450 2C19enzyme
DB00898EthanolCytochrome P450 2C9enzyme
DB00898EthanolCytochrome P450 3A4enzyme
DB00898EthanolCytochrome P450 4A11enzyme
DB00898EthanolAlcohol dehydrogenase 1Aenzyme
DB00898EthanolAlcohol dehydrogenase 1Benzyme
DB00898EthanolAlcohol dehydrogenase 1Cenzyme
DB00898EthanolAlcohol dehydrogenase class-3enzyme
DB00898EthanolVoltage-dependent L-type calcium channel subunit beta-1target
DB00898Ethanol5-hydroxytryptamine receptor 3Atarget
DB00898EthanolAlcohol dehydrogenase 4enzyme
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-2target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-10target
DB00898EthanolVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-5target
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-4target
DB00898EthanolAlcohol dehydrogenase class 4 mu/sigma chainenzyme
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-3target
DB00898EthanolGlutamate receptor 1target
DB00898EthanolVoltage-dependent calcium channel gamma-1 subunittarget
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-2target
DB00898EthanolGamma-aminobutyric acid receptor subunit alpha-6target
DB00898EthanolGlutamate receptor 2target
DB00898EthanolGlutamate receptor 4target
DB00898EthanolGlutamate receptor 3target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-4target
DB00898EthanolNeuronal acetylcholine receptor subunit beta-2target
DB00898EthanolG protein-activated inward rectifier potassium channel 1target
DB00898EthanolG protein-activated inward rectifier potassium channel 2target
DB00898EthanolVascular cell adhesion protein 1target
DB00898EthanolEquilibrative nucleoside transporter 1target
DB00898EthanolG protein-activated inward rectifier potassium channel 4target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-7target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-9target
DB00898EthanolGamma-aminobutyric acid receptor subunit beta-1target
DB00898EthanolGamma-aminobutyric acid receptor subunit beta-3target
DB00898EthanolGamma-aminobutyric acid receptor subunit beta-2target
DB00898EthanolVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00898EthanolVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00898EthanolAlcohol dehydrogenase 6enzyme
DB00898EthanolNeuronal acetylcholine receptor subunit beta-4target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-3target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-5target
DB00898EthanolNeuronal acetylcholine receptor subunit alpha-6target
DB00898EthanolNeuronal acetylcholine receptor subunit beta-3target
DB00898EthanolGamma-aminobutyric acid receptor subunit gamma-1target
DB00898EthanolGamma-aminobutyric acid receptor subunit gamma-3target
DB00898EthanolGamma-aminobutyric acid receptor subunit epsilontarget
DB00898EthanolGamma-aminobutyric acid receptor subunit pitarget
DB00898EthanolGamma-aminobutyric acid receptor subunit thetatarget
DB00898EthanolGamma-aminobutyric acid receptor subunit deltatarget
DB00898EthanolAlcohol dehydrogenase [NADP(+)]enzyme
DB00898EthanolEquilibrative nucleoside transporter 2target
DB00898Ethanol5-hydroxytryptamine receptor 3Etarget
DB00898Ethanol5-hydroxytryptamine receptor 3Btarget
DB00898Ethanol5-hydroxytryptamine receptor 3Dtarget
DB00898Ethanol5-hydroxytryptamine receptor 3Ctarget
DB00898EthanolVoltage-dependent calcium channel gamma-2 subunittarget
DB00898EthanolG protein-activated inward rectifier potassium channel 3target
DB00898EthanolNeural cell adhesion molecule L1target
DB00773EtoposideDNA topoisomerase 2-alphatarget
DB00773EtoposideCytochrome P450 3A4enzyme
DB00773EtoposideCanalicular multispecific organic anion transporter 2transporter
DB00773EtoposideMultidrug resistance-associated protein 6transporter
DB00773EtoposideP-glycoprotein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 1transporter
DB00773EtoposideMultidrug resistance-associated protein 7transporter
DB00773EtoposideCanalicular multispecific organic anion transporter 1transporter
DB00773EtoposideATP-binding cassette sub-family G member 2transporter
DB00773EtoposideCytochrome P450 1A2enzyme
DB00773EtoposideCytochrome P450 2E1enzyme
DB00773EtoposideCytochrome P450 3A5enzyme
DB00773EtoposideUDP-glucuronosyltransferase 1-1enzyme
DB00773EtoposideDNA topoisomerase 2-betatarget
DB00773EtoposideGlutathione S-transferase theta-1enzyme
DB00773EtoposideGlutathione S-transferase Penzyme
DB00773EtoposideProstaglandin G/H synthase 2enzyme
DB00773EtoposideProstaglandin G/H synthase 1enzyme
DB01283LumiracoxibProstaglandin G/H synthase 2target
DB01283LumiracoxibProstaglandin G/H synthase 1target
DB01283LumiracoxibCytochrome P450 2C9enzyme
DB01283LumiracoxibCytochrome P450 2C19enzyme
DB01283LumiracoxibUDP-glucuronosyltransferase 1-9enzyme
DB01283LumiracoxibCytochrome P450 1A2enzyme
DB00772MalathionCholinesterasetarget
DB00772MalathionCytochrome P450 1A2enzyme
DB00772MalathionCytochrome P450 2B6enzyme
DB00934MaprotilineHistamine H1 receptortarget
DB00934MaprotilineSodium-dependent noradrenaline transportertarget
DB00934MaprotilineAlpha-1 adrenergic receptorstarget
DB00934MaprotilineCytochrome P450 2D6enzyme
DB00934MaprotilineAlpha-1-acid glycoprotein 1carrier
DB00934MaprotilineMuscarinic acetylcholine receptor M1target
DB00934MaprotilineMuscarinic acetylcholine receptor M2target
DB00934MaprotilineMuscarinic acetylcholine receptor M3target
DB00934MaprotilineMuscarinic acetylcholine receptor M4target
DB00934MaprotilineMuscarinic acetylcholine receptor M5target
DB00934MaprotilineCytochrome P450 1A2enzyme
DB00934Maprotiline5-hydroxytryptamine receptor 2Atarget
DB00934Maprotiline5-hydroxytryptamine receptor 2Ctarget
DB00934Maprotiline5-hydroxytryptamine receptor 7target
DB00934MaprotilineDopamine D2 receptortarget
DB00934MaprotilineAlpha-2 adrenergic receptorstarget
DB00333MethadoneNMDA receptortarget
DB00333MethadoneMu-type opioid receptortarget
DB00333MethadoneCytochrome P450 2B6enzyme
DB00333MethadoneCytochrome P450 3A4enzyme
DB00333MethadoneCytochrome P450 2C19enzyme
DB00333MethadoneDelta-type opioid receptortarget
DB00333MethadoneCytochrome P450 3A7enzyme
DB00333MethadoneCytochrome P450 2D6enzyme
DB00333MethadoneP-glycoprotein 1transporter
DB00333MethadoneCytochrome P450 2C8enzyme
DB00333MethadoneCytochrome P450 19A1enzyme
DB00333MethadoneCytochrome P450 1A2enzyme
DB00333MethadoneCytochrome P450 2C18enzyme
DB00333MethadoneCytochrome P450 2C9enzyme
DB00333Methadone5-hydroxytryptamine receptor 3Atarget
DB00333MethadoneAlpha-1-acid glycoprotein 1carrier
DB00333MethadoneSerum albumincarrier
DB00333MethadoneNeuronal acetylcholine receptor subunit alpha-7target
DB00333MethadoneNeuronal acetylcholine receptor subunit alpha-3target
DB00333MethadoneNeuronal acetylcholine receptor subunit alpha-4target
DB00333MethadoneNeuronal acetylcholine receptor subunit beta-2target
DB01028MethoxyfluraneCalcium-transporting ATPase type 2C member 1target
DB01028MethoxyfluraneATP synthase subunit delta, mitochondrialtarget
DB01028MethoxyfluraneNADH-ubiquinone oxidoreductase chain 1target
DB01028MethoxyfluraneGamma-aminobutyric acid receptor subunit alpha-1target
DB01028MethoxyfluranePotassium voltage-gated channel subfamily A member 1target
DB01028MethoxyfluraneGlutamate receptor 1target
DB01028MethoxyfluraneGlycine receptor subunit alpha-1target
DB01028MethoxyfluraneCytochrome P450 2E1enzyme
DB01028MethoxyfluraneCytochrome P450 1A2enzyme
DB01028MethoxyfluraneCytochrome P450 2A6enzyme
DB01028MethoxyfluraneCytochrome P450 2B6enzyme
DB01028MethoxyfluraneCytochrome P450 2C9enzyme
DB01028MethoxyfluraneCytochrome P450 2D6enzyme
DB01028MethoxyfluraneCytochrome P450 3A4enzyme
DB01028MethoxyfluraneGABA-A receptor (anion channel)target
DB06148MianserinHistamine H1 receptortarget
DB06148MianserinAlpha-2A adrenergic receptortarget
DB06148Mianserin5-hydroxytryptamine receptor 2Atarget
DB06148Mianserin5-hydroxytryptamine receptor 2Ctarget
DB06148MianserinCytochrome P450 2D6enzyme
DB06148MianserinSodium-dependent serotonin transportertarget
DB06148MianserinCytochrome P450 3A4enzyme
DB06148MianserinCytochrome P450 1A2enzyme
DB06148MianserinCytochrome P450 2B6enzyme
DB06148MianserinSodium-dependent noradrenaline transportertarget
DB06148MianserinHistamine H4 receptortarget
DB06148Mianserin5-hydroxytryptamine receptor 1Atarget
DB06148MianserinAlpha-2C adrenergic receptortarget
DB06148Mianserin5-hydroxytryptamine receptor 2Btarget
DB06148Mianserin5-hydroxytryptamine receptor 1Ftarget
DB06148MianserinAlpha-2B adrenergic receptortarget
DB06148MianserinDopamine D3 receptortarget
DB06148MianserinKappa-type opioid receptortarget
DB06148MianserinSodium-dependent dopamine transportertarget
DB06148Mianserin5-hydroxytryptamine receptor 7target
DB06148MianserinDopamine D2 receptortarget
DB06148Mianserin5-hydroxytryptamine receptor 6target
DB06148MianserinAlpha-1 adrenergic receptorstarget
DB06148MianserinD(1) dopamine receptortarget
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00806Pentoxifylline5'-nucleotidasetarget
DB00806PentoxifyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00806PentoxifyllineAdenosine receptor A1target
DB00806PentoxifyllineAdenosine receptor A2atarget
DB00806PentoxifyllineCytochrome P450 1A2enzyme
DB00850PerphenazineDopamine D1 receptortarget
DB00850PerphenazineDopamine D2 receptortarget
DB00850PerphenazineCalmodulintarget
DB00850PerphenazineCytochrome P450 2D6enzyme
DB00850PerphenazineCytochrome P450 1A2enzyme
DB00850PerphenazineCytochrome P450 2C18enzyme
DB00850PerphenazineCytochrome P450 2C19enzyme
DB00850PerphenazineCytochrome P450 2C8enzyme
DB00850PerphenazineCytochrome P450 2C9enzyme
DB00850PerphenazineCytochrome P450 3A4enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Btarget
DB01037SelegilineCytochrome P450 2B6enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Atarget
DB01037SelegilineCytochrome P450 2A6enzyme
DB01037SelegilineCytochrome P450 3A4enzyme
DB01037SelegilineP-glycoprotein 1transporter
DB01037SelegilineCytochrome P450 1A2enzyme
DB01037SelegilineCytochrome P450 2C19enzyme
DB01037SelegilineCytochrome P450 2C8enzyme
DB01037SelegilineCytochrome P450 2C9enzyme
DB01037SelegilineCytochrome P450 2D6enzyme
DB01037SelegilineCytochrome P450 2E1enzyme
DB01412TheobromineCytochrome P450 1A2enzyme
DB01412TheobromineCytochrome P450 2E1enzyme
DB01412TheobromineAdenosine receptor A1target
DB01412TheobromineAdenosine receptor A2atarget
DB01412TheobrominecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB06264TolperisoneCytochrome P450 1A2enzyme
DB00246ZiprasidoneAlpha-1A adrenergic receptortarget
DB00246ZiprasidoneDopamine D2 receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 2Ctarget
DB00246ZiprasidoneDopamine D3 receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Atarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Dtarget
DB00246ZiprasidoneHistamine H1 receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 2Atarget
DB00246ZiprasidoneDopamine D4 receptortarget
DB00246Ziprasidone5-hydroxytryptamine receptor 7target
DB00246ZiprasidoneCytochrome P450 3A4enzyme
DB00246ZiprasidoneAlpha-2A adrenergic receptortarget
DB00246ZiprasidoneAlpha-1B adrenergic receptortarget
DB00246ZiprasidoneAlpha-2B adrenergic receptortarget
DB00246ZiprasidoneAlpha-2C adrenergic receptortarget
DB00246ZiprasidoneDopamine D1 receptortarget
DB00246ZiprasidoneDopamine D5 receptortarget
DB00246ZiprasidoneMuscarinic acetylcholine receptor M1target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M2target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M3target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M4target
DB00246ZiprasidoneMuscarinic acetylcholine receptor M5target
DB00246Ziprasidone5-hydroxytryptamine receptor 1Btarget
DB00246Ziprasidone5-hydroxytryptamine receptor 1Etarget
DB00246Ziprasidone5-hydroxytryptamine receptor 3Atarget
DB00246Ziprasidone5-hydroxytryptamine receptor 6target
DB00246ZiprasidoneAldehyde oxidaseenzyme
DB00530ErlotinibEpidermal growth factor receptortarget
DB00530ErlotinibCytochrome P450 3A4enzyme
DB00530ErlotinibATP-binding cassette sub-family G member 2transporter
DB00530ErlotinibP-glycoprotein 1transporter
DB00530ErlotinibNuclear receptor subfamily 1 group I member 2target
DB00530ErlotinibCytochrome P450 3A5enzyme
DB00530ErlotinibCytochrome P450 1A1enzyme
DB00530ErlotinibCytochrome P450 1A2enzyme
DB00530ErlotinibCytochrome P450 1B1enzyme
DB00530ErlotinibCytochrome P450 2D6enzyme
DB00530ErlotinibCytochrome P450 2C8enzyme
DB00530ErlotinibUDP-glucuronosyltransferase 1-1enzyme
DB00530ErlotinibSerum albumincarrier
DB00530ErlotinibAlpha-1-acid glycoprotein 1carrier
DB00530ErlotinibSolute carrier organic anion transporter family member 2B1transporter
DB01166CilostazolcGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01166CilostazolCytochrome P450 2C19enzyme
DB01166CilostazolCytochrome P450 3A4enzyme
DB01166CilostazolCytochrome P450 3A5enzyme
DB01166CilostazolCytochrome P450 3A7enzyme
DB01166CilostazolCytochrome P450 1A2enzyme
DB01166CilostazolCytochrome P450 2D6enzyme
DB06210EltrombopagThrombopoietin receptortarget
DB06210EltrombopagCytochrome P450 2C8enzyme
DB06210EltrombopagCytochrome P450 1A2enzyme
DB06210EltrombopagUDP-glucuronosyltransferase 1-1enzyme
DB06210EltrombopagUDP-glucuronosyltransferase 1-3enzyme
DB06210EltrombopagSolute carrier organic anion transporter family member 1B1transporter
DB06210EltrombopagATP-binding cassette sub-family G member 2transporter
DB06210EltrombopagUDP-glucuronosyltransferase 1-9enzyme
DB00575ClonidineAlpha-2A adrenergic receptortarget
DB00575ClonidineCytochrome P450 2D6enzyme
DB00575ClonidineAlpha-2B adrenergic receptortarget
DB00575ClonidineAlpha-2C adrenergic receptortarget
DB00575ClonidineSolute carrier family 22 member 3transporter
DB00575ClonidineSolute carrier family 22 member 5transporter
DB00575ClonidineSolute carrier family 22 member 4transporter
DB00575ClonidineP-glycoprotein 1transporter
DB00575ClonidineCytochrome P450 1A2enzyme
DB00575ClonidineCytochrome P450 3A4enzyme
DB00575ClonidineCytochrome P450 1A1enzyme
DB00575ClonidineCytochrome P450 3A5enzyme
DB00575ClonidineAlpha-1A adrenergic receptortarget
DB00575ClonidineAlpha-1B adrenergic receptortarget
DB00575ClonidineAlpha-1D adrenergic receptortarget
DB00575ClonidineSerum albumincarrier
DB06510MuraglitazarPeroxisome proliferator-activated receptor alphatarget
DB06510MuraglitazarPeroxisome proliferator-activated receptor gammatarget
DB06510MuraglitazarCytochrome P450 1A2enzyme
DB06510MuraglitazarUDP-glucuronosyltransferase 1-3enzyme
DB06510MuraglitazarUDP-glucuronosyltransferase 1-1enzyme
DB06510MuraglitazarCytochrome P450 2C8enzyme
DB06235VadimezanUDP-glucuronosyltransferase 1-9enzyme
DB06235VadimezanUDP-glucuronosyltransferase 2B7enzyme
DB06235VadimezanCytochrome P450 1A2enzyme
DB00461NabumetoneProstaglandin G/H synthase 1target
DB00461NabumetoneProstaglandin G/H synthase 2target
DB00461NabumetoneMyeloperoxidaseenzyme
DB00461NabumetoneCytochrome P450 1A2enzyme
DB00461NabumetoneCytochrome P450 2C9enzyme
DB00461NabumetoneCorticosteroid 11-beta-dehydrogenase isozyme 1enzyme
DB00461NabumetoneAldo-keto reductase family 1 member C1enzyme
DB00461NabumetoneAldo-keto reductase family 1 member C2enzyme
DB00461NabumetoneAldo-keto reductase family 1 member C4enzyme
DB00461NabumetoneSerum albumincarrier
DB06589PazopanibVascular endothelial growth factor receptor 1target
DB06589PazopanibVascular endothelial growth factor receptor 2target
DB06589PazopanibVascular endothelial growth factor receptor 3target
DB06589PazopanibPlatelet-derived growth factor receptor alphatarget
DB06589PazopanibPlatelet-derived growth factor receptor betatarget
DB06589PazopanibMast/stem cell growth factor receptor Kittarget
DB06589PazopanibCytochrome P450 3A4enzyme
DB06589PazopanibCytochrome P450 2D6enzyme
DB06589PazopanibCytochrome P450 2C8enzyme
DB06589PazopanibCytochrome P450 1A2enzyme
DB06589PazopanibP-glycoprotein 1transporter
DB06589PazopanibATP-binding cassette sub-family G member 2transporter
DB06589PazopanibSolute carrier organic anion transporter family member 1B1transporter
DB06589PazopanibUDP-glucuronosyltransferase 1-1transporter
DB06589PazopanibFibroblast growth factor receptor 3target
DB06589PazopanibTyrosine-protein kinase ITK/TSKtarget
DB06589PazopanibFibroblast growth factor 1target
DB06589PazopanibSH2B adapter protein 3target
DB08867UlipristalProgesterone receptortarget
DB08867UlipristalGlucocorticoid receptortarget
DB08867UlipristalAndrogen receptortarget
DB08867UlipristalCytochrome P450 3A4enzyme
DB08867UlipristalCytochrome P450 1A2enzyme
DB08867UlipristalSerum albumincarrier
DB08867UlipristalAlpha-1-acid glycoprotein 1carrier
DB04871Lorcaserin5-hydroxytryptamine receptor 2Ctarget
DB04871LorcaserinCytochrome P450 1A2enzyme
DB04871LorcaserinCytochrome P450 2A6enzyme
DB04871LorcaserinCytochrome P450 2B6enzyme
DB04871LorcaserinCytochrome P450 2C19enzyme
DB04871LorcaserinCytochrome P450 2D6enzyme
DB04871LorcaserinCytochrome P450 3A4enzyme
DB04871LorcaserinDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB04871LorcaserinCytochrome P450 1A1enzyme
DB06605ApixabanCoagulation factor Xtarget
DB06605ApixabanCytochrome P450 3A4enzyme
DB06605ApixabanCytochrome P450 1A2enzyme
DB06605ApixabanCytochrome P450 2C8enzyme
DB06605ApixabanCytochrome P450 2C9enzyme
DB06605ApixabanCytochrome P450 2C19enzyme
DB06605ApixabanCytochrome P450 2J2enzyme
DB06605ApixabanP-glycoprotein 1transporter
DB06605ApixabanATP-binding cassette sub-family G member 2transporter
DB06605ApixabanCytochrome P450 3A5enzyme
DB06626AxitinibVascular endothelial growth factor receptor 1target
DB06626AxitinibVascular endothelial growth factor receptor 2target
DB06626AxitinibVascular endothelial growth factor receptor 3target
DB06626AxitinibCytochrome P450 3A4enzyme
DB06626AxitinibCytochrome P450 3A5enzyme
DB06626AxitinibCytochrome P450 1A2enzyme
DB06626AxitinibCytochrome P450 2C19enzyme
DB06626AxitinibUDP-glucuronosyltransferase 1-1enzyme
DB06626AxitinibP-glycoprotein 1transporter
DB06626AxitinibSolute carrier organic anion transporter family member 1B1transporter
DB08910PomalidomideCytochrome P450 1A2enzyme
DB08910PomalidomideCytochrome P450 3A4enzyme
DB08910PomalidomideP-glycoprotein 1transporter
DB08910PomalidomideProtein cereblontarget
DB08910PomalidomideTumor necrosis factortarget
DB08910PomalidomideProstaglandin G/H synthase 2target
DB09570IxazomibCytochrome P450 3A4enzyme
DB09570IxazomibCytochrome P450 1A2enzyme
DB09570IxazomibCytochrome P450 2B6enzyme
DB09570IxazomibCytochrome P450 2C8enzyme
DB09570IxazomibCytochrome P450 2D6enzyme
DB09570IxazomibCytochrome P450 2C19enzyme
DB09570IxazomibCytochrome P450 2C9enzyme
DB06769BendamustineCytochrome P450 1A2enzyme
DB12332RucaparibPoly [ADP-ribose] polymerase 1target
DB12332RucaparibPoly [ADP-ribose] polymerase 2target
DB12332RucaparibPoly [ADP-ribose] polymerase 3target
DB12332RucaparibCytochrome P450 2D6enzyme
DB12332RucaparibCytochrome P450 1A2enzyme
DB12332RucaparibCytochrome P450 3A4enzyme
DB12332RucaparibP-glycoprotein 1transporter
DB12332RucaparibATP-binding cassette sub-family G member 2transporter
DB12332RucaparibMultidrug and toxin extrusion protein 1transporter
DB12332RucaparibMultidrug and toxin extrusion protein 2transporter
DB12332RucaparibSolute carrier family 22 member 1transporter
DB12332RucaparibMultidrug resistance-associated protein 4transporter
DB12332RucaparibSolute carrier organic anion transporter family member 1B1transporter
DB12332RucaparibSolute carrier organic anion transporter family member 1B3transporter
DB12332RucaparibSolute carrier family 22 member 6transporter
DB12332RucaparibSolute carrier family 22 member 8transporter
DB12332RucaparibCytochrome P450 3A5enzyme
DB12332RucaparibCytochrome P450 3A7enzyme
DB12332RucaparibCytochrome P450 3A43enzyme
DB12332RucaparibCytochrome P450 2C19enzyme
DB12332RucaparibCytochrome P450 2C9enzyme
DB12332RucaparibCytochrome P450 2C8enzyme
DB12332RucaparibUDP-glucuronosyltransferase 1-1enzyme
DB11737IcotinibEpidermal growth factor receptortarget
DB11737IcotinibCytochrome P450 3A4enzyme
DB11737IcotinibCytochrome P450 1A2enzyme
DB11737IcotinibCytochrome P450 3A5enzyme
DB12161DeutetrabenazineSynaptic vesicular amine transportertarget
DB12161DeutetrabenazineCarbonyl reductase [NADPH] 1enzyme
DB12161DeutetrabenazineCarbonyl reductase [NADPH] 3enzyme
DB12161DeutetrabenazineCytochrome P450 2D6enzyme
DB12161DeutetrabenazineCytochrome P450 1A2enzyme
DB12161DeutetrabenazineCytochrome P450 3A5enzyme
DB12161DeutetrabenazineCytochrome P450 3A4enzyme
DB09118StiripentolCytochrome P450 2C19enzyme
DB09118StiripentolCytochrome P450 2D6enzyme
DB09118StiripentolCytochrome P450 3A4enzyme
DB09118StiripentolCytochrome P450 1A2enzyme
DB09118StiripentolCytochrome P450 2C9enzyme
DB09118StiripentolGABA-A receptor (anion channel)target
DB09118StiripentolL-lactate dehydrogenase A chaintarget
DB09118StiripentolL-lactate dehydrogenase B chaintarget
DB12026VoxilaprevirCytochrome P450 3A4enzyme
DB12026VoxilaprevirCytochrome P450 1A2enzyme
DB12026VoxilaprevirCytochrome P450 2C8enzyme
DB12026VoxilaprevirNS3/4A proteintarget
DB12026VoxilaprevirP-glycoprotein 1transporter
DB12026VoxilaprevirATP-binding cassette sub-family G member 2transporter
DB12026VoxilaprevirSolute carrier organic anion transporter family member 1B1transporter
DB12026VoxilaprevirSolute carrier organic anion transporter family member 1B3transporter
DB13874EnasidenibCytochrome P450 1A2enzyme
DB13874EnasidenibCytochrome P450 2B6enzyme
DB13874EnasidenibIsocitrate dehydrogenase [NADP], mitochondrialtarget
DB13874EnasidenibCytochrome P450 2C8enzyme
DB13874EnasidenibCytochrome P450 2C9enzyme
DB13874EnasidenibCytochrome P450 2C19enzyme
DB13874EnasidenibCytochrome P450 2D6enzyme
DB13874EnasidenibCytochrome P450 3A4enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 1-1enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 1-3enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 1-4enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 1-9enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 2B7enzyme
DB13874EnasidenibUDP-glucuronosyltransferase 2B15enzyme
DB13874EnasidenibP-glycoprotein 1transporter
DB13874EnasidenibATP-binding cassette sub-family G member 2transporter
DB13874EnasidenibSolute carrier family 22 member 6transporter
DB13874EnasidenibSolute carrier organic anion transporter family member 1B1transporter
DB13874EnasidenibSolute carrier family 22 member 2transporter
DB13874EnasidenibSolute carrier organic anion transporter family member 1B3transporter
DB13874EnasidenibSolute carrier family 22 member 8transporter
DB13952Estradiol acetateEstrogen receptor alphatarget
DB13952Estradiol acetateNuclear receptor subfamily 1 group I member 2target
DB13952Estradiol acetateSex hormone-binding globulincarrier
DB13952Estradiol acetateEstrogen receptor betatarget
DB13952Estradiol acetateCytochrome P450 1A2enzyme
DB13952Estradiol acetateUDP-glucuronosyltransferase 1-1enzyme
DB13952Estradiol acetateSerum albumincarrier
DB13952Estradiol acetateFatty acid-binding protein, intestinalcarrier
DB13952Estradiol acetateCytochrome P450 3A4enzyme
DB13952Estradiol acetateCytochrome P450 3A5enzyme
DB13952Estradiol acetateCytochrome P450 3A7enzyme
DB13952Estradiol acetateSolute carrier family 22 member 2transporter
DB13952Estradiol acetateSolute carrier family 22 member 1transporter
DB13952Estradiol acetateSolute carrier family 22 member 3transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 2B1transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 1A2transporter
DB13952Estradiol acetateMultidrug resistance-associated protein 7transporter
DB13952Estradiol acetateSolute carrier family 22 member 11transporter
DB13952Estradiol acetateATP-binding cassette sub-family G member 2transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 1B1transporter
DB13952Estradiol acetateP-glycoprotein 1transporter
DB13952Estradiol acetateCytochrome P450 1A1enzyme
DB13952Estradiol acetateCytochrome P450 1B1enzyme
DB13952Estradiol acetateCytochrome P450 2C19enzyme
DB13952Estradiol acetateCytochrome P450 2C8enzyme
DB13952Estradiol acetateCytochrome P450 2C9enzyme
DB13952Estradiol acetateSolute carrier family 22 member 8transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 1B3transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 1C1transporter
DB13952Estradiol acetateSolute carrier organic anion transporter family member 4A1transporter
DB13952Estradiol acetateNeuronal acetylcholine receptor subunit alpha-4target
DB13952Estradiol acetateNuclear receptor coactivator 2target
DB13952Estradiol acetateG-protein coupled estrogen receptor 1target
DB13952Estradiol acetateATP synthase subunit atarget
DB13952Estradiol acetateBeclin-1target
DB13952Estradiol acetateEstradiol 17-beta-dehydrogenase 2target
DB13952Estradiol acetateEstrogen-related receptor gammatarget
DB13953Estradiol benzoateEstrogen receptor alphatarget
DB13953Estradiol benzoateNuclear receptor subfamily 1 group I member 2target
DB13953Estradiol benzoateSex hormone-binding globulincarrier
DB13953Estradiol benzoateEstrogen receptor betatarget
DB13953Estradiol benzoateCytochrome P450 1A2enzyme
DB13953Estradiol benzoateUDP-glucuronosyltransferase 1-1enzyme
DB13953Estradiol benzoateSerum albumincarrier
DB13953Estradiol benzoateFatty acid-binding protein, intestinalcarrier
DB13953Estradiol benzoateCytochrome P450 3A4enzyme
DB13953Estradiol benzoateCytochrome P450 3A5enzyme
DB13953Estradiol benzoateCytochrome P450 3A7enzyme
DB13953Estradiol benzoateSolute carrier family 22 member 2transporter
DB13953Estradiol benzoateSolute carrier family 22 member 1transporter
DB13953Estradiol benzoateSolute carrier family 22 member 3transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 2B1transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 1A2transporter
DB13953Estradiol benzoateMultidrug resistance-associated protein 7transporter
DB13953Estradiol benzoateSolute carrier family 22 member 11transporter
DB13953Estradiol benzoateATP-binding cassette sub-family G member 2transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 1B1transporter
DB13953Estradiol benzoateP-glycoprotein 1transporter
DB13953Estradiol benzoateCytochrome P450 1A1enzyme
DB13953Estradiol benzoateCytochrome P450 1B1enzyme
DB13953Estradiol benzoateCytochrome P450 2C19enzyme
DB13953Estradiol benzoateCytochrome P450 2C8enzyme
DB13953Estradiol benzoateCytochrome P450 2C9enzyme
DB13953Estradiol benzoateSolute carrier family 22 member 8transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 1B3transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 1C1transporter
DB13953Estradiol benzoateSolute carrier organic anion transporter family member 4A1transporter
DB13953Estradiol benzoateNeuronal acetylcholine receptor subunit alpha-4target
DB13953Estradiol benzoateNuclear receptor coactivator 2target
DB13953Estradiol benzoateG-protein coupled estrogen receptor 1target
DB13953Estradiol benzoateATP synthase subunit atarget
DB13953Estradiol benzoateBeclin-1target
DB13953Estradiol benzoateEstradiol 17-beta-dehydrogenase 2target
DB13953Estradiol benzoateEstrogen-related receptor gammatarget
DB13954Estradiol cypionateEstrogen receptor alphatarget
DB13954Estradiol cypionateNuclear receptor subfamily 1 group I member 2target
DB13954Estradiol cypionateSex hormone-binding globulincarrier
DB13954Estradiol cypionateEstrogen receptor betatarget
DB13954Estradiol cypionateCytochrome P450 1A2enzyme
DB13954Estradiol cypionateUDP-glucuronosyltransferase 1-1enzyme
DB13954Estradiol cypionateSerum albumincarrier
DB13954Estradiol cypionateFatty acid-binding protein, intestinalcarrier
DB13954Estradiol cypionateCytochrome P450 3A4enzyme
DB13954Estradiol cypionateCytochrome P450 3A5enzyme
DB13954Estradiol cypionateCytochrome P450 3A7enzyme
DB13954Estradiol cypionateSolute carrier family 22 member 2transporter
DB13954Estradiol cypionateSolute carrier family 22 member 1transporter
DB13954Estradiol cypionateSolute carrier family 22 member 3transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 2B1transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1A2transporter
DB13954Estradiol cypionateMultidrug resistance-associated protein 7transporter
DB13954Estradiol cypionateSolute carrier family 22 member 11transporter
DB13954Estradiol cypionateATP-binding cassette sub-family G member 2transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1B1transporter
DB13954Estradiol cypionateP-glycoprotein 1transporter
DB13954Estradiol cypionateCytochrome P450 1A1enzyme
DB13954Estradiol cypionateCytochrome P450 1B1enzyme
DB13954Estradiol cypionateCytochrome P450 2C19enzyme
DB13954Estradiol cypionateCytochrome P450 2C8enzyme
DB13954Estradiol cypionateCytochrome P450 2C9enzyme
DB13954Estradiol cypionateSolute carrier family 22 member 8transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1B3transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1C1transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 4A1transporter
DB13954Estradiol cypionateNeuronal acetylcholine receptor subunit alpha-4target
DB13954Estradiol cypionateNuclear receptor coactivator 2target
DB13954Estradiol cypionateG-protein coupled estrogen receptor 1target
DB13954Estradiol cypionateATP synthase subunit atarget
DB13954Estradiol cypionateBeclin-1target
DB13954Estradiol cypionateEstradiol 17-beta-dehydrogenase 2target
DB13954Estradiol cypionateEstrogen-related receptor gammatarget
DB13955Estradiol dienanthateEstrogen receptor alphatarget
DB13955Estradiol dienanthateNuclear receptor subfamily 1 group I member 2target
DB13955Estradiol dienanthateSex hormone-binding globulincarrier
DB13955Estradiol dienanthateEstrogen receptor betatarget
DB13955Estradiol dienanthateCytochrome P450 1A2enzyme
DB13955Estradiol dienanthateUDP-glucuronosyltransferase 1-1enzyme
DB13955Estradiol dienanthateSerum albumincarrier
DB13955Estradiol dienanthateFatty acid-binding protein, intestinalcarrier
DB13955Estradiol dienanthateCytochrome P450 3A4enzyme
DB13955Estradiol dienanthateCytochrome P450 3A5enzyme
DB13955Estradiol dienanthateCytochrome P450 3A7enzyme
DB13955Estradiol dienanthateSolute carrier family 22 member 2transporter
DB13955Estradiol dienanthateSolute carrier family 22 member 1transporter
DB13955Estradiol dienanthateSolute carrier family 22 member 3transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 2B1transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 1A2transporter
DB13955Estradiol dienanthateMultidrug resistance-associated protein 7transporter
DB13955Estradiol dienanthateSolute carrier family 22 member 11transporter
DB13955Estradiol dienanthateATP-binding cassette sub-family G member 2transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 1B1transporter
DB13955Estradiol dienanthateP-glycoprotein 1transporter
DB13955Estradiol dienanthateCytochrome P450 1A1enzyme
DB13955Estradiol dienanthateCytochrome P450 1B1enzyme
DB13955Estradiol dienanthateCytochrome P450 2C19enzyme
DB13955Estradiol dienanthateCytochrome P450 2C8enzyme
DB13955Estradiol dienanthateCytochrome P450 2C9enzyme
DB13955Estradiol dienanthateSolute carrier family 22 member 8transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 1B3transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 1C1transporter
DB13955Estradiol dienanthateSolute carrier organic anion transporter family member 4A1transporter
DB13955Estradiol dienanthateNeuronal acetylcholine receptor subunit alpha-4target
DB13955Estradiol dienanthateNuclear receptor coactivator 2target
DB13955Estradiol dienanthateG-protein coupled estrogen receptor 1target
DB13955Estradiol dienanthateATP synthase subunit atarget
DB13955Estradiol dienanthateBeclin-1target
DB13955Estradiol dienanthateEstradiol 17-beta-dehydrogenase 2target
DB13955Estradiol dienanthateEstrogen-related receptor gammatarget
DB13956Estradiol valerateEstrogen receptor alphatarget
DB13956Estradiol valerateNuclear receptor subfamily 1 group I member 2target
DB13956Estradiol valerateSex hormone-binding globulincarrier
DB13956Estradiol valerateEstrogen receptor betatarget
DB13956Estradiol valerateCytochrome P450 1A2enzyme
DB13956Estradiol valerateUDP-glucuronosyltransferase 1-1enzyme
DB13956Estradiol valerateSerum albumincarrier
DB13956Estradiol valerateFatty acid-binding protein, intestinalcarrier
DB13956Estradiol valerateCytochrome P450 3A4enzyme
DB13956Estradiol valerateCytochrome P450 3A5enzyme
DB13956Estradiol valerateCytochrome P450 3A7enzyme
DB13956Estradiol valerateSolute carrier family 22 member 2transporter
DB13956Estradiol valerateSolute carrier family 22 member 1transporter
DB13956Estradiol valerateSolute carrier family 22 member 3transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 2B1transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1A2transporter
DB13956Estradiol valerateMultidrug resistance-associated protein 7transporter
DB13956Estradiol valerateSolute carrier family 22 member 11transporter
DB13956Estradiol valerateATP-binding cassette sub-family G member 2transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1B1transporter
DB13956Estradiol valerateP-glycoprotein 1transporter
DB13956Estradiol valerateCytochrome P450 1A1enzyme
DB13956Estradiol valerateCytochrome P450 1B1enzyme
DB13956Estradiol valerateCytochrome P450 2C19enzyme
DB13956Estradiol valerateCytochrome P450 2C8enzyme
DB13956Estradiol valerateCytochrome P450 2C9enzyme
DB13956Estradiol valerateSolute carrier family 22 member 8transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1B3transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1C1transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 4A1transporter
DB13956Estradiol valerateNeuronal acetylcholine receptor subunit alpha-4target
DB13956Estradiol valerateNuclear receptor coactivator 2target
DB13956Estradiol valerateG-protein coupled estrogen receptor 1target
DB13956Estradiol valerateATP synthase subunit atarget
DB13956Estradiol valerateBeclin-1target
DB13956Estradiol valerateEstradiol 17-beta-dehydrogenase 2target
DB13956Estradiol valerateEstrogen-related receptor gammatarget
DB09225ZotepineD(1) dopamine receptortarget
DB09225ZotepineDopamine D2 receptortarget
DB09225Zotepine5-hydroxytryptamine receptor 2Atarget
DB09225Zotepine5-hydroxytryptamine receptor 6target
DB09225Zotepine5-hydroxytryptamine receptor 7target
DB09225ZotepineSodium-dependent noradrenaline transportertarget
DB09225ZotepineSodium-dependent serotonin transportertarget
DB09225ZotepineCytochrome P450 1A2enzyme
DB09225ZotepineCytochrome P450 3A4enzyme
DB04948LofexidineAlpha-2A adrenergic receptortarget
DB04948LofexidineAlpha-1A adrenergic receptortarget
DB04948Lofexidine5-hydroxytryptamine receptor 1Atarget
DB04948Lofexidine5-hydroxytryptamine receptor 7target
DB04948Lofexidine5-hydroxytryptamine receptor 2Ctarget
DB04948Lofexidine5-hydroxytryptamine receptor 1Dtarget
DB04948LofexidineCytochrome P450 2D6enzyme
DB04948LofexidineCytochrome P450 1A2enzyme
DB04948LofexidineCytochrome P450 2C19enzyme
DB04948LofexidineATP-binding cassette sub-family B member 5transporter
DB04948LofexidineMultidrug and toxin extrusion protein 1transporter
DB09071TasimelteonMelatonin receptor type 1Atarget
DB09071TasimelteonMelatonin receptor type 1Btarget
DB09071TasimelteonCytochrome P450 3A4enzyme
DB09071TasimelteonCytochrome P450 1A2enzyme
DB04951PirfenidoneFurintarget
DB04951PirfenidoneCytochrome P450 1A2enzyme
DB09290Ramosetron5-hydroxytryptamine receptor 3Atarget
DB09290RamosetronCytochrome P450 1A2enzyme
DB00316AcetaminophenProstaglandin G/H synthase 1target
DB00316AcetaminophenProstaglandin G/H synthase 2target
DB00316AcetaminophenCytochrome P450 1A2enzyme
DB00316AcetaminophenCytochrome P450 2E1enzyme
DB00316AcetaminophenP-glycoprotein 1transporter
DB00316AcetaminophenCytochrome P450 2D6enzyme
DB00316AcetaminophenCytochrome P450 2A6enzyme
DB00316AcetaminophenCytochrome P450 3A4enzyme
DB00316AcetaminophenUDP-glucuronosyltransferase 1-1enzyme
DB00316AcetaminophenUDP-glucuronosyltransferase 1-6enzyme
DB00316AcetaminophenUDP-glucuronosyltransferase 1-9enzyme
DB00316AcetaminophenUDP-glucuronosyltransferase 2B15enzyme
DB00316AcetaminophenSulfotransferase 1A1enzyme
DB00316AcetaminophenSulfotransferase 1A3/1A4enzyme
DB00316AcetaminophenArylamine N-acetyltransferase 2enzyme
DB00316AcetaminophenProstaglandin E synthase 3target
DB00316AcetaminophenFatty-acid amide hydrolase 1target
DB00316AcetaminophenTransient receptor potential cation channel subfamily V member 1target
DB00316AcetaminophenGlutathione S-transferase Ptarget
DB00316AcetaminophenSerum albumincarrier
DB00758ClopidogrelP2Y purinoceptor 12target
DB00758ClopidogrelCytochrome P450 3A4enzyme
DB00758ClopidogrelCytochrome P450 2B6enzyme
DB00758ClopidogrelCytochrome P450 3A5enzyme
DB00758ClopidogrelCytochrome P450 2C19enzyme
DB00758ClopidogrelCytochrome P450 2C9enzyme
DB00758ClopidogrelCytochrome P450 1A2enzyme
DB00758ClopidogrelCytochrome P450 2C8enzyme
DB00758ClopidogrelLiver carboxylesterase 1enzyme
DB00758ClopidogrelP-glycoprotein 1transporter
DB00758ClopidogrelSolute carrier family 22 member 1transporter
DB00758ClopidogrelSolute carrier family 22 member 2transporter
DB00176FluvoxamineSodium-dependent serotonin transportertarget
DB00176FluvoxamineCytochrome P450 1A2enzyme
DB00176FluvoxamineCytochrome P450 2D6enzyme
DB00176FluvoxamineCytochrome P450 2C9enzyme
DB00176FluvoxamineCytochrome P450 2C19enzyme
DB00176FluvoxamineCytochrome P450 1A1enzyme
DB00176FluvoxamineCytochrome P450 3A4enzyme
DB00176FluvoxamineCYP3Aenzyme
DB00176FluvoxamineP-glycoprotein 1transporter
DB00176FluvoxamineCytochrome P450 2B6enzyme
DB00176FluvoxaminePotassium voltage-gated channel subfamily H member 2target
DB00176FluvoxamineBile salt export pumptransporter
DB09256TegafurCytochrome P450 2A6enzyme
DB09256TegafurThymidylate synthasetarget
DB09256TegafurCytochrome P450 1A2enzyme
DB09256TegafurCytochrome P450 2C8enzyme
DB09256TegafurCytochrome P450 2E1enzyme
DB09256TegafurCytochrome P450 3A5enzyme
DB09256TegafurThyroxine-binding globulincarrier
DB01118AmiodaroneBeta-1 adrenergic receptortarget
DB01118AmiodaronePotassium voltage-gated channel subfamily H member 2target
DB01118AmiodaroneCytochrome P450 2C8enzyme
DB01118AmiodaroneCytochrome P450 2C9enzyme
DB01118AmiodaroneCytochrome P450 2D6enzyme
DB01118AmiodaroneVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01118AmiodaroneVoltage-dependent calcium channel subunit alpha-2/delta-2target
DB01118AmiodaroneCytochrome P450 3A4enzyme
DB01118AmiodaroneCytochrome P450 1A2enzyme
DB01118AmiodaroneCytochrome P450 1A1enzyme
DB01118AmiodaroneP-glycoprotein 1transporter
DB01118AmiodaroneCytochrome P450 2C19enzyme
DB01118AmiodaroneCytochrome P450 2A6enzyme
DB01118AmiodaroneThyroid hormone receptor alphatarget
DB01118AmiodaroneThyroid hormone receptor betatarget
DB01118AmiodaronePeroxisome proliferator-activated receptor gammatarget
DB01118AmiodaroneBile salt export pumptransporter
DB01118AmiodaroneSolute carrier family 22 member 2transporter
DB01118AmiodaroneCytochrome P450 2J2enzyme
DB12945DihydralazineCytochrome P450 1A2enzyme
DB11450PimobendanCytochrome P450 1A2enzyme
DB00863RanitidineHistamine H2 receptortarget
DB00863RanitidineCytochrome P450 1A2enzyme
DB00863RanitidineCytochrome P450 2D6enzyme
DB00863RanitidineSolute carrier family 22 member 1transporter
DB00863RanitidineP-glycoprotein 1transporter
DB00863RanitidineSolute carrier family 22 member 8transporter
DB00863RanitidineCytochrome P450 3A4enzyme
DB00863RanitidineAcetylcholinesterasetarget
DB00863RanitidineSolute carrier family 22 member 2transporter
DB00863RanitidineCholinesterasetarget
DB00863RanitidineCholinesteraseenzyme
DB08883PerampanelGlutamate receptor 1target
DB08883PerampanelCytochrome P450 3A4enzyme
DB08883PerampanelCytochrome P450 3A5enzyme
DB08883PerampanelCytochrome P450 1A2enzyme
DB08883PerampanelCytochrome P450 2B6enzyme
DB08496(R)-warfarinSerum albumincarrier
DB08496(R)-warfarinCytochrome P450 2C8enzyme
DB08496(R)-warfarinCytochrome P450 2C9enzyme
DB08496(R)-warfarinCytochrome P450 2C18enzyme
DB08496(R)-warfarinCytochrome P450 2C19enzyme
DB08496(R)-warfarinCytochrome P450 1A2enzyme
DB08496(R)-warfarinCytochrome P450 1A1enzyme
DB08496(R)-warfarinCytochrome P450 3A4enzyme
DB119196-O-benzylguanineCytochrome P450 3A4enzyme
DB141328-chlorotheophyllineAdenosine receptor A2atarget
DB141328-chlorotheophyllineCytochrome P450 1A2enzyme
DB04076HypoxanthinePurine nucleoside phosphorylasetarget
DB04076HypoxanthineCytochrome P450 1A2enzyme
DB12406LisofyllineCytochrome P450 1A2enzyme
DB01303OxtriphyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01303OxtriphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01303OxtriphyllineAdenosine receptor A2atarget
DB01303OxtriphyllineAdenosine receptor A1target
DB01303OxtriphyllineCytochrome P450 1A2enzyme
DB01303OxtriphyllineSolute carrier family 22 member 7transporter
DB01303OxtriphyllineHistone deacetylase 2target
DB02134XanthinePurine nucleoside phosphorylase 2target
DB02134XanthineXanthine phosphoribosyltransferasetarget
DB02134XanthineCytochrome P450 1A2enzyme
DB01405TemafloxacinDNA gyrase subunit Atarget
DB01405TemafloxacinDNA topoisomerase 4 subunit Atarget
DB01405TemafloxacinCytochrome P450 1A2enzyme
DB13573AcefyllineCytochrome P450 1A2enzyme
DB00787AcyclovirDNA polymerase catalytic subunittarget
DB00787AcyclovirDNA polymerase catalytic subunittarget
DB00787AcyclovirThymidine kinasetarget
DB00787AcyclovirSolute carrier family 22 member 1transporter
DB00787AcyclovirSolute carrier family 22 member 6transporter
DB00787AcyclovirSolute carrier family 22 member 8transporter
DB00787AcyclovirIleal sodium/bile acid cotransportertransporter
DB00787AcyclovirMultidrug and toxin extrusion protein 1transporter
DB00787AcyclovirMultidrug and toxin extrusion protein 2transporter
DB00787AcyclovirThymidine kinaseenzyme
DB00787AcyclovirGuanylate kinaseenzyme
DB00787AcyclovirNucleoside diphosphokinaseenzyme
DB00787AcyclovirPyruvate Kinasesenzyme
DB00787AcyclovirCreatine Kinasesenzyme
DB00787AcyclovirPhosphoglycerate Kinasesenzyme
DB00787AcyclovirSuccinyl-CoA Synthetasesenzyme
DB00787AcyclovirPhosphoenolpyruvate Carboxykinasesenzyme
DB00787AcyclovirAdenylosuccinate Synthetasesenzyme
DB00787AcyclovirSerum albumincarrier
DB13203BamifyllineCytochrome P450 1A2enzyme
DB14018BromotheophyllineCytochrome P450 1A2enzyme
DB13812BufyllineCytochrome P450 1A2enzyme
DB09273DoxofyllinePhosphodiesterase 2A, cGMP-stimulatedtarget
DB09273DoxofyllineAdenosine receptor A2atarget
DB09273DoxofyllineBeta-2 adrenergic receptortarget
DB09273DoxofyllineCytochrome P450 1A2enzyme
DB00442EntecavirDNAtarget
DB13592EtamiphyllineCytochrome P450 1A2enzyme
DB01482FenethyllineCytochrome P450 1A2enzyme
DB02568PeldesinePurine nucleoside phosphorylasetarget
DB00642PemetrexedThymidylate synthasetarget
DB00642PemetrexedDihydrofolate reductasetarget
DB00642PemetrexedTrifunctional purine biosynthetic protein adenosine-3target
DB00642PemetrexedDeoxycytidine kinaseenzyme
DB00642PemetrexedBifunctional purine biosynthesis protein PURHtarget
DB00642PemetrexedEquilibrative nucleoside transporter 1enzyme
DB00642PemetrexedSolute carrier family 22 member 8transporter
DB00299PenciclovirDNA polymerase catalytic subunittarget
DB00299PenciclovirThymidine kinasetarget
DB13634PentifyllineCytochrome P450 1A2enzyme
DB06479PropentofyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB06479PropentofyllineCytochrome P450 1A2enzyme
DB13449ProxyphyllineCytochrome P450 1A2enzyme
DB09288PropacetamolCholinesteraseenzyme
DB09288PropacetamolProstaglandin G/H synthase 1target
DB09288PropacetamolProstaglandin G/H synthase 2target
DB09288Propacetamol